|Drug, bio-affecting and body treating compositions patents - Monitor Patents|
USPTO Class 424 | Browse by Industry: Previous - Next | All
08/2013 | Recent | 13: Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn | | 2008 | 2007 |
Drug, bio-affecting and body treating compositions August inventions list 08/13Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 08/29/2013 > 214 patent applications in 113 patent subcategories. inventions list
20130224107 - Heterocyclic derivates, preparation processes and medical uses thereof: Disclosed are heterocyclic derivatives, methods for making them, compositions containing the same and uses thereof. Particularly, their pharmaceutical use as inhibitors of PARP is disclosed.... Agent: Shanghai De Novo Pharmatech Co Ltd.
20130224109 - Compositions and methods featuring il-6 and il-21 antagonists: The present invention features compositions for inhibiting both the IL-6 and the IL-21 pathways and methods of making and using such compositions. Our work to date indicates the importance of the redundancy of IL-6 and IL-21 to perform certain crucial functions. The pathways can be inhibited by inhibiting the ligands... Agent: Beth Israel Deaconess Medical Center, Inc.
20130224111 - Inhibition of cd69 for treatment of inflammatory conditions: A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same.... Agent: National University Corporation Chiba University
20130224108 - Methods for the treatment of head and neck squamous cell carcinoma: This invention relates to the staging, diagnosis, and treatment of cancerous diseases, particularly to the use of monoclonal antibodies, antigen binding fragments thereof, and/or cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB, chemotherapeutic agents, and conjugates thereof, as a means for initiating a cytotoxic response... Agent: Hoffmann-la Roche Inc.
20130224110 - Use of adenosine receptor signaling to modulate permeability of blood-brain barrier: The present invention relates to a method of increasing blood brain barrier (“BBB”) permeability in a subject. This method involves administering to the subject an agent or agents which activate both of the A1 and A2A adenosine receptors. Also disclosed is a method to decrease BBB permeability in a subject.... Agent: Cornell University
20130224112 - Compositions and methods for surface abrasion with frozen particles: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least... Agent: Searete LLC
20130224113 - Imaging diagnostics by combining contrast agents: The present invention relates to the use of a combination of several contrast agents having different properties with respect to imaging representation.... Agent: Mivenion Gmbh
20130224114 - Translocator protein ligands: The present invention relates to compounds and methods for imaging translocator protein (18 kDa) (TSPO) expression in a subject. This invention also relates to compounds and methods for the treatment of neurodegenerative disorders, inflammation or anxiety in a subject.... Agent: The University Of Sydney
20130224116 - Markers of endothelial progenitor cells and uses thereof: The present invention provides markers of endothelial progenitor cells (EPCs) and use of those markers and reagents that bind thereto to detect EPC cells or diagnose, prognose, treat or prevent EPC-associated conditions.... Agent: Transbio Ltd.
20130224115 - Non-radioactive agents for neuroblastoma imaging: Multi-modal tumor imaging of neuroblastoma is essential for tumor staging, response evaluation and detection of relapsed diseased. The present invention provides a norepinephine analogue with a near-infrared (near-IR) dye, W765-BG, that efficiently and stably detects neuroblastoma in vivo using near-IR optical imaging. Confocal microscopy and optical imaging of neuroblastoma xenografts... Agent: Baylor College Of Medicine
20130224117 - Latent variable approach to the identification and/or diagnosis of cognitive disorders and/or behaviors and their endophenotypes: Certain embodiments are directed to methods of distinguish “target-relevant” variance in observed clinical and physiological measures from the variance in observed data that is unrelated to any target process.... Agent: The Board Of Regents Of The University Of Texas System
20130224119 - Omentum and use thereof: In some embodiments, mammalian omentum and methods of using the same for treating symptoms and/or conditions related to dementia are provided. In addition, a composition comprising the omentum tissue and/or the extract thereof is described in some embodiments. In some other embodiments, methods of formulating and administering the composition are... Agent:
20130224118 - Perhexiline for treating chronic heart failure: Disclosed are methods for the treatment of chronic heart failure, comprising administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure. The chronic heart failure maybe non-ischaemic or ischaemic. Also disclosed is the use of perhexiline... Agent: Heart Metabolics Limited
20130224122 - Magnetotatic bacteria mri positive contract enhancement agent and methods of use: Magnetic resonance imaging (MRI) is enhanced by contrast agents such as superparamagnetic iron-oxide (SPIO) particles that resemble magnetite particles produced by magnetotactic bacteria. Magnetospirillum magneticum AMB-1 produces positive MRI contrast when generating ultrasmall magnetite particles (10-40 nm diameter). Positive MRI contrast permits clearer distinction from image voids compared to negative... Agent: The Board Of Trustees Of The Leland Stanford Junior University
20130224123 - Nanoparticulate compositions having lysozyme as a surface stabilizer: The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.... Agent: Alkermes Pharma Ireland Limited
20130224120 - Multimodal diagnostic technology for early stage cancer lesions: Disclosed herein are compositions of a multimodal detection agent and methods of fabricating the same. The multimodal detection agent comprises a plurality of metallic nanoparticles attached to a surface of a polymeric carrier. The detection agent further comprising one or more target-specific binding agents attached to the metallic nanoparticles or... Agent: Northeastern University
20130224121 - Particle containing hydrophobic dye having cyanine structure, and contrast agent containing the particle: Provided is a particle which can stably hold a dye in itself even in an aqueous solution such as serum, in order to solve such a problem of a particle containing ICG, which has been conventionally used in a contrast agent or the like, that the ICG is a dye... Agent: Canon Kabushiki Kaisha
20130224124 - Liquid non-stick toothpaste: My tooth cream will not stick, this is what makes it different from other tooth pastes. It can be dispensed in any type container, but it is different in that this toothpaste contains NO thickeners, no carrageenan, no cellulose gum, no glycerin and no SLS (sodium lanyl sulfates). My tooth... Agent:
20130224125 - Alcohol-free slightly-alcoholic oral care composition and a process for preparing same: An aqueous, heat and cold stable, non-alcoholic or slightly-alcoholic microemulsion based antimicrobial mouthwash composition with improved antimicrobial efficacy. The composition comprises a unique water-soluble matrix composite, at least one water-immiscible or water-insoluble antimicrobial agent, and optionally, a preservative or preservative system, a weak carboxylic acid, a coloring agent and other... Agent:
20130224126 - Oral care product and methods of use and manufacture thereof: This invention relates to a mouthwash comprising an aqueous solution of an effective amount of a basic amino acid, in free or salt form together with an effective amount of a preservative selected from methylisothiazolinone (MIT), benzyl alcohol, phenoxyethanol, and combinations thereof; as well as to methods of using and... Agent: Colgate-palmolive Company
20130224127 - Compositions and related methods for oral wellness: The present invention provides for an oral serum made from natural ingredients that advantageously reduces oral bacteria. Further, toothpaste and oral rinse compositions are provided. A method for reducing oral bacteria using the oral serum of the present invention is additionally described herein.... Agent: Nowsystem, Inc.
20130224128 - Dental cleanser composition for improving adhesion to teeth: The present invention relates to a dental cleanser composition for improving adhesion to teeth, and more particularly to, a dental cleanser composition which functions to remove not only a smear layer from the dentin surface of an exposed tooth root, but also oral bacteria, and thus is effective in improving... Agent: Nano Intelligent Biomedical Engineering Co., Ltd.
20130224129 - Compositions and related methods for oral wellness: Disclosed are compositions, apparatus, and related methods and systems for oral health care.... Agent:
20130224131 - 4-amidino benzylamines for cosmetic and/or dermatological use: This invention relates to the use of 4-amidino benzylamine derivatives as cosmetic ingredients and to cosmetic compositions, as well as to non-therapeutic methods for the cosmetic treatment of the skin and the scalp. Said derivatives and compositions can be used as urokinase inhibitors to prevent and restore damage of the... Agent: DsmIPAssets B.v.
20130224132 - Colouring pre-mix for use in colouring of a cosmetic composition: The present invention provides a colouring pre-mix for use in colouring of a cosmetic composition and a coloured cosmetic composition including the same, wherein the colouring pre-mix includes 45-80 wt-% benzyl benzoate; 20-49 wt-% dipropylene glycol; 0.00001-5 wt-% colouring plant extracts; and optionally 0.00001-5 wt-% colorants; with the provision that... Agent: Coty Inc.
20130224130 - Cosmetic composition for long-wearing properties: Disclosed are cosmetic compositions comprising (1) at least one MQTPr siloxane resin; (2) at least one film former chosen from a silicone acrylate copolymer; (3) at least one film former chosen from a hydrogenated hydrocarbon copolymer; (4) at least one fatty phase; and (5) optionally at least one wax and/or... Agent: L'oreal S.a.
20130224133 - Surfactant-free oil-in-water type emulsion, process for preparation thereof and its uses: There is described an oil-in-water emulsion free of surfactant agents comprising: A) At least a cross-polymer acrylate/alkyl-acrylate or derivatives thereof, or mixtures thereof in the aqueous phase of the emulsion; b) At least a polyacrylate or derivatives thereof, or mixtures thereof in the oily phase of the emulsion, and c)... Agent: Natura Cosmeticos S.a.
20130224134 - Nitrocellulose-free nail polish compositions: The present invention relates to a nail polish composition comprising: at least one high gloss film forming agent chosen from a styrene maleic anhydride copolymer; at least one co-film forming agent chosen from an epoxy resin; at least one reactive agent chosen from a combination of a polyalkyleneamine and a... Agent: L'oreal
20130224136 - Chiral compounds, compositions, products and methods employing same: Compounds that function, alone or in combination, as inhibitors of pigmentation for the improvement of mammalian skin are described herein. Specifically, the compounds of the present disclosure, namely chiral, non-racemic compounds, function as pigment formation inhibitors thereof to beautify skin and discourage the production of melanins. One or more products,... Agent: Lasya, Inc.
20130224135 - Diarylalkanes as potent inhibitors of binuclear enzymes: The present invention implements a strategy that combines an enzyme inhibition assay with a chemical dereplication process to identify active plant extracts and the particular compounds—diarylalkanes and/or diarylalkanols within those extracts that specifically inhibit binuclear enzyme function. Included in the present invention are compositions of matter comprised of one or... Agent: Unigen, Inc.
20130224137 - Skin lightening compositions: Compositions and methods for lightening mammalian skin are described herein.... Agent: Lasya, Inc.
20130224139 - Bisurea gelling agents and compositions: Bisurea gelling agents that impart a number of unexpected benefits within various gelled formulations and exhibit great versatility in terms of gelling capabilities for many types of solvents are provided. Such gelling agents should include pendant groups, such as sterically hindering alkyl groups attached to polyoxyalkylenated moieties that allow the... Agent:
20130224140 - Aluminum salt containing high percentage of al30: A composition comprising an aluminum chlorohydrate salt, the aluminum chlorohydrate salt having at least 50 mole % Al30 polyhydroxyoxoaluminum cation of all polyhydroxyoxoaluminum cations detectable by quantitative27 Al NMR within the aluminum chlorohydrate salt, and a buffer. The composition can optionally include zirconium. Also disclosed are a method of making... Agent: Colgate-palmolive Company
20130224141 - Method for straightening hair: A method of straightening hair comprising the step of applying to the hair a composition comprising at least 2 wt % of the total composition of vitamin C and vitamin E.... Agent:
20130224142 - Mascara compositions containing a micronized wax and a nonionic polycondensate: The invention relates to a composition comprising at least one nonionic polycondensate and at least one micronized wax which, if desired, can be processed at room temperature.... Agent: L'oreal
20130224143 - Hair conditioning composition: The present invention is a hair conditioning composition includes approximately 40,000 IU of Vitamin E oil from 2 fl. oz., approximately 2 fl. oz. of 100% pure Australian tea tree oil, approximately 4 fl. oz. of Jojoba oil, approximately 32 oz. of pure extra virgin organic coconut oil with 62... Agent:
20130224145 - Complex having tumor vaccine effect, and use thereof: The present invention provides a tumor cell-soluble TNF family member molecule complex containing a tumor cell and an isolated soluble TNF family member molecule, wherein the soluble TNF family member molecule is bound on a surface of the tumor cell such that it binds to a receptor of the TNF... Agent: Riken
20130224144 - Sequential administration of a replication defective adenovirus vector in vaccination protocols: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.... Agent: Etubics Corporation
20130224148 - Activated leukocyte conditioned supernatant and uses for wound healing: Disclosed are therapeutic, activated leukocyte conditioned supernatants, methods of making them, and methods of using the conditioned supernatants to repair or promote healing of wounds.... Agent:
20130224146 - Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling: Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.... Agent:
20130224147 - Macrocyclic serine protease inhibitors: Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.... Agent: Idenix Pharmaceuticals, Inc.
20130224150 - Igg stimulated remyelination of peripheral nerves: The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral... Agent: Baxter International Inc.
20130224149 - Process for preparing antiviral compounds: This disclosure is directed to: (a) processes for preparing compounds and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compounds and salts; (c) pharmaceutical compositions comprising the compounds or salts; and (d) methods of use of such... Agent: Abbvie Inc.
20130224151 - Use of faah inhibitors for treating abdominal, visceral and pelvic pain: The present disclosure relates to methods of using fatty acid amide hydrolase (FAAH) inhibitors alone or in combination for the treatment or prevention of abdominal, visceral or pelvic pain. Also described herein are pharmaceutical compositions comprising a FAAH inhibitor, alone or in combination with an additional therapeutic agent for the... Agent: Ironwood Pharmaceuticals, Inc
20130224152 - Spiro[2.4]heptanes for treatment of flaviviridae infections: Compounds, methods, and compositions for the treatment of infections in or exposure to humans and other host animals of Flaviviridae viruses, including HCV, that includes the administration of an effective amount of a spiro[2.4]heptane as described herein or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable... Agent: University Of Georgia Research Foundation, Inc.
20130224153 - Recombinant lactobacillus with decreased lipoteichoic acid to reduce inflammatory responses: Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display... Agent: North Carolina State University
20130224154 - Retargeting of rat parvovirus h-1pv to cancer cells through genetic engineering of its capsid: Described is a parvovirus, in particular a H-IPV, that can be genetically retargeted through modification of its capsid, which is useful in cancer therapy.... Agent: Deutsches Krebsforschungszentrum
20130224162 - Human neural stem cells expressing human choline acetyltransferase, and use thereof: The present invention relates to human neural stem cells (NSCs) transfected with a vector comprising a polynucleotide encoding human choline acetyltransferase (ChAT) and thereby stably expressing the human ChAT, a composition for treating Alzheimer disease or for improving a cognitive disorder comprising the human NSCs expressing a human ChAT. The... Agent: Chungbuk National University Industry Academic Cooperation Foundation
20130224163 - Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord: The invention provides an expression system for producing Caveolin-1 in neuronal cells or neural stem cells comprising a neuron-specific regulatory element and a nucleic acid sequence encoding Caveolin-1.... Agent:
20130224155 - Compositions of microbiota and methods related thereto: Methods and compositions are generally provided for treating metabolic disorders, e.g., obesity. One aspect discloses methods and compositions for obtaining a biological sample from the subject, evaluating the sample for the presence or absence of a genetic indicator, wherein the genetic indicator is selected from a single nucleotide polymorphism and... Agent: Ethicon Endo-surgery, Inc.
20130224164 - Environmental clostridial bacteriotherapy and related formulations and methods of manufacture and use: Compositions and methods for inhibiting Clostridium associated diseases are disclosed.... Agent: Viropharma Incorporated
20130224165 - Drinking yoghurt preparations containing non-replicating probiotic micro-organisms: The present invention relates to the field of drinkable yoghurt compositions. In particular, the present invention provides drinkable yoghurt compositions comprising non-replicating probiotic micro-organisms. These non-replicating probiotic micro-organisms may be bioactive heat treated probiotic micro-organisms, for example. The present invention also relates to health benefits provided by these non-replicating probiotic... Agent: Single Buoy Moorings, Inc
20130224167 - Non-replicating probiotic bacteria and prevention or treatment of infections to reduce absence from school or daycare: The present invention relates to non-replicating probiotic micro-organisms and their health benefits. In particular, the present invention provides a means to help parents to protect their children from infections. The subject matter of the present inventions allows it to reduce absence from school or daycare. One embodiment of the present... Agent: Nestec S.a.
20130224166 - Powdered cereal compositions comprising non-replicating probiotic microorganisms: The present invention relates to the field of powdered cereal compositions to be reconstituted in milk, infant formula or water. In particular, the present invention relates to powdered cereal compositions to be administered to infants or young children. The powdered cereal compositions may be used to strengthen the immune system... Agent: Nestec S.a.
20130224168 - Lactobacillus rhamnosus and weight control: The present invention generally relates to the field of obesity. In particular the present invention relates to the use of probiotics to treat obesity. One embodiment of the present invention relates to the use of Lactobacillus rhamnosus CGMCC 1.3724 and/or Lactobacillus rhamnosus NCC 4007 for the preparation of a composition... Agent: Nestec S.a.
20130224156 - Method of producing human retinal pigment epithelial cells: The invention relates to a method of producing a retinal pigment epithelial cell from a human pluripotent stem cell, and a method of treating or preventing a retinal disease by using the produced cell. The retinal pigment epithelial cell is prepared by (a) inducing differentiation of a human pluripotent stem... Agent: Riken
20130224161 - Methods for organ regeneration: A method of enhancing or initiating regeneration of an organ in a subject in need thereof comprising the administration of endothelial cells specific to said organ, or inductive endothelial cells specific to said organ, into the area of the body in which organ regeneration is desired in said subject.... Agent: Cornell University
20130224159 - Placental tissue grafts and improved methods of preparing and using the same: Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more... Agent: Mimedx Group, Inc.
20130224157 - Stem cells for treating lung diseases: The invention is compositions and methods for treating lung diseases and conditions using mesenchymal stem cells. The preferred stem cells are those derived from a human umbilical cord, or from bone marrow.... Agent:
20130224158 - Tissue repair using allogeneic dermal fibroblasts: e
20130224160 - Treatment of vocal cords with autologous dermal fibroblast formulation: Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated for augmentation or regeneration of vocal cords. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and... Agent: Fibrocell Technologies, Inc.
20130224169 - Composition and method for recovery from mild traumatic brain injury: A method and composition for reducing the recovery time for a human suffering from mild traumatic brain injury are provided. The composition is a mixture of component supplements that synergistically address the symptoms of the condition and the damage done by the injury.... Agent:
20130224170 - Method of ameliorating oxidative stress and supplementing the diet: wherein R1 is an aromatic backbone and R2 is a sulfur containing ligand. Through formation of disulfide linkages other moieties can be attached to R2 converting the hydrophobic base into a water soluble entity, for ease of delivery, which can be reconverted back to the original compound by biochemical reduction... Agent: The University Of Kentucky Research Foundation
20130224171 - Agent for use in the case of fructose intolerance: 5-D-fructose dehydrogenase, optionally in combination with invertase and/or maltase and/or glucose isomerase, may be used to treat fructose intolerance. Other embodiments are also disclosed.... Agent: Pro Natura Gesellschaft Fur Gesunde Ernahrung Mbh
20130224172 - Methods of treating behavioral symptoms of neurological and mental disorders: Disclosed herein are methods of using coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations for treatment of subjects having behavioral disorders, neurological disorders or mental health disorders. Disclosed herein are methods of treating core and non-core symptoms of behavioral disorders, neurological disorders or mental... Agent: Curemark, LLC
20130224173 - Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-trna synthetases: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.... Agent: Atyr Pharma, Inc.
20130224174 - Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.... Agent: Atyr Pharma, Inc.
20130224176 - Method of restoring the incretin effect: The present invention relates to methods of treating metabolic syndrome, Type 2 diabetes mellitus, atherogenic dyslipidemia and/or obesity. The present invention also relates to methods of restoring the incretin effect, to restoring physiologic control of glucagon levels, to restoring first-phase insulin secretion, and to restoring the physiologic glucose-dependent insulin secretion.... Agent: Neurendo Pharma, LLC
20130224175 - Recombinant therapeutic glycine n-acyltransferase: This invention relates to a method of producing a recombinant enzyme, more particularly, this invention relates to a method of producing water soluble enzymatically active recombinant glycine N-acyltransferase (GLYAT (E.G. 18.104.22.168)), including the steps of providing a suitable expression host; preparing a vector including a gene for expressing GLYAT in... Agent: North-west University
20130224177 - Method of regulating fertilizing ability using cyclic adp-ribose and cd38: The present invention relates to a pharmaceutical composition for promoting fertilization comprising cyclic ADP-ribose or its derivative, CD38 and to a method of promoting fertilization by promoting the synthesis of cyclic ADP-ribose to increase sperm motility. Also, the present invention relates to a pharmaceutical composition for contraception and a method... Agent: Industrial Cooperation Foundation Chonbuk National University
20130224178 - Methods of treating cancer using glucagon-like hormone retargeted endopepidases: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.... Agent: Allergan, Inc.
20130224179 - Plasma protein effective for suppressing cough: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide... Agent:
20130224180 - Injection paradigm for administration of botulinum toxins: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin... Agent: Allergan, Inc.
20130224181 - Composition for preventing or treating atopic dermatitis including galenical extract or lactobacillus fermentation thereof: The present invention relates to a pharmaceutical composition and health supplement for preventing or treating atopic dermatitis, the composition and supplement having as active ingredients extract of a galenical mixture including sophora root, licorice, lonicer aflower, Korean angelica root, Korean aralia root, saussurea root, seselos radix, zizyphus spinosi, Houttuynia cordata,... Agent: Korea Institute Of Oriental Medicine
20130224182 - Bcl-g polypeptides, encoding nucleic acids and methods of use: The invention provides Bcl-G polypeptides and encoding nucleic acids. Bcl-G polypeptides include Bcl-GL and Bcl-GS. The invention also provides mouse Bcl-G. The invention also provides vectors containing Bcl-G nucleic acids, host cells containing such vectors, Bcl-G anti-sense nucleic acids and related compositions. The invention additionally provides Bcl-G oligonucleotides that can... Agent: Sanford-burnham Medical Research Institute
20130224183 - Fraction i-iv-1 precipitation of immunoglobins from plasma: Among other aspects, the present invention provides methods for the manufacture of blood protein compositions from pooled plasma. In one embodiment, the invention provides an alcohol fractionation scheme that allows for significant increases in the yield of blood proteins purified from the starting plasma sample. In a specific embodiment, a... Agent: Baxter International Inc.
20130224184 - Method to produce an immunoglobulin preparation with improved yield: The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In... Agent: Baxter International Inc.
20130224187 - Anti-c5a antibodies and methods for using the antibodies: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid... Agent: Alexion Pharmaceuticals, Inc.
20130224190 - Anti-cd19 antibody having adcc and cdc functions and improved glycosylation profile: The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a... Agent: International - Drug - Development - Biotech
20130224188 - Cd47 antibodies and methods of use thereof: This invention relates generally to monoclonal antibodies that recognize CD47, more specifically to CD47 antibodies that do not cause a significant level of agglutination of cells, to methods of generating these antibodies, and to methods of using these monoclonal antibodies as therapeutics.... Agent: Inhibrx LLC
20130224192 - Method for the prognosis of the progression of cancer: The present invention relates to methods for the prognosis of the progression of cancer in a patient, and more particularly methods for the prediction of the occurrence of metastasis in one or more tissue or organ of patients affected with a cancer, in particular with a breast cancer, a lung... Agent: Institut National De La Sante Et De La Recherche Medicale (inserm)
20130224193 - Methods and compositions for diagnostic use in cancer patients: Disclosed herein are methods and compositions useful for identifying therapies likely to confer optimal clinical benefit for patients with cancer.... Agent: Genentech, Inc.
20130224194 - Methods and compositions for diagnostic use in cancer patients: Disclosed herein are methods and compositions useful for identifying therapies likely to confer optimal clinical benefit for patients with cancer.... Agent: Genentech, Inc.
20130224191 - Notum protein modulators and methods of use: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.... Agent:
20130224186 - Oxazole and thiazole compounds as ksp inhibitors: Disclosed are new substituted oxazole and thiazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses thereof:... Agent:
20130224185 - Protein formulation: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The... Agent:
20130224195 - Substituted benzazoles and methods of their use as inhibitors of raf kinase: New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as... Agent:
20130224189 - Tweak receptor: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac... Agent: Immunex Corporation
20130224196 - Methods and compositions using kloto-fgf fusion polypeptides: The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such... Agent:
20130224197 - Methods for treatment of brain injury utilizing biologics: A method of using biologics to treat chronic brain injury or spasticity due to stroke, trauma and other causes. Preferred embodiments include perispinal, parenteral, transepidermal or intranasal use of TNF antagonists. The TNF antagonists include TNF receptor fusion proteins, TNF monoclonal antibodies (mAbs), humanized TNF mAbs, fully human TNF mAbs,... Agent: TactIPLLC
20130224198 - Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo: A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo compared to naturally occurring or recombinant native human erythropoietin. In one embodiment, the protein has a half-life in vivo at least three-fold higher... Agent: Novagen Holding Corporation
20130224199 - Viral chemokine-antigen fusion proteins: The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides... Agent: The United States Of America, As Represented By The Secretary, Department Of Health And Human
20130224201 - Antibodies to il-6 and use thereof: The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise... Agent: Alderbio Holdings LLC
20130224204 - Method of treatment based on atad2 inhibitors: A method of treating autoimmune and inflammatory diseases or conditions in a mammal, such as a human, which comprises the administration of a inhibitor of the bromodomain-containing protein: ATAD2.... Agent: Glaxo Group Limited
20130224203 - Pharmaceutical composition of recombinant polyclonal immunoglobulins: There is disclosed a recombinant pharmaceutical composition comprising a large plurality of recombinant immunoglobulins made by expression of a wide diversity of antibodies from a recombinant antibody library, preferably obtained from a wide diversity of human sources, synthetic or semi-synthetic germline immunoglobulin sequences, or a combination thereof, and then purified.... Agent: Sorrento Therapeutics, Inc.
20130224200 - Product and process for inhibition of biofilm development: Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing... Agent: National Jewish Health
20130224202 - Single-chain variable fragment anti-cd133 antibodies and uses thereof: Disclosed herein are a monoclonal antibody that specifically binds to human CD 133 and single-chain variable fragments thereof. Also disclosed herein is a hybridoma that produces the monoclonal antibody that specifically binds to human CD133.... Agent: Regents Of The University Of Minnesota
20130224206 - Compositions and methods for stem cell delivery: This invention provides compositions of matter, articles of manufacture and methods for delivering and/or affixing a stem cell to a target tissue. This invention also provides related nucleic acids, vectors, cells, methods of production, and kits.... Agent: Trans Target Inc.
20130224207 - Identification of antibodies specific for lyssaviruses and methods of their use: Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that... Agent: The Government Of The United States Of America As Represented By The Secretary Of The
20130224205 - Multispecific deimmunized cd3-binders: The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an Ig-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct of the invention is provided. Further aspects of the invention are vectors and... Agent: Micromet Ag
20130224208 - Glioma treatment method, glioma testing method, method for delivering desired substance to glioma, and drugs used in these methods: An object is to provide glioma treatment and testing methods, and a method for delivering a desired substance to a glioma, all of which target a molecule specifically expressed in a glioma, as well as drugs and so forth used in these methods. It has been found out that targeting... Agent: Riken
20130224210 - Antibodies to matrix metalloproteinase 9: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an... Agent: Gilead Biologics, Inc.
20130224211 - Glycated cd59 peptides, their preparation, and uses thereof: The present invention provides glycated Amadori products of the CD59 peptide and fragments thereof to be used as tools and among methods for the diagnosis and prognosis of pre-diabetes and diabetes. Certain aspects of the invention include glycated Amadori products of CD59 and fragments thereof to be used for the... Agent: President And Fellows Of Harvard College
20130224212 - Methods and products relating to gsk3ss regulation: The invention relates to methods and compositions for regulation of GSK3β activity. The invention provides phosphorylated GSK3β polypeptides and antibodies that recognize such polypeptides. The invention further includes methods for treating disorders that are associated with elevated or reduced GSK3β activity.... Agent: University Of Vermont And State Agricultural College
20130224209 - Methods for diagnosing and treating prostate and lung cancer: Methods for detecting and treating prostate and lung cancer are disclosed In practicing the method, a subject sample is assayed for GPR110 protein or its RNA transcript, and the GPR110 or transcript level observed is used in determining whether the subject has an elevated GPR110 level associated with prostate or... Agent: Picobella, LLC
20130224213 - Compositions and methods for stabilizing protein-containing formulations: The present invention relates to use of certain alkylglycoside compositions for the prevention of aggregation and oxidation of antibodies and other proteins in therapeutically useful formulations thereof.... Agent: Genetech, Inc.
20130224214 - Compositions and methods for therapy and diagnosis of cancer and cancer metastasis: The present invention relates to methods which make possible to assess and/or prognose a cancer disease, the metastatic behaviour of a cancer disease and/or the occurrence of a relapse of cancer. In particular, the methods of the invention make possible to assess and/or prognose the occurrence of cancer metastasis, in... Agent:
20130224215 - A b cell depleting agent for the treatment of atherosclerosis: The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.... Agent:
20130224216 - Anti-lps enriched immunoglobulin for use in treatment and/or prophylaxis of a pathologic disorder: Methods and compositions for treating conditions including liver dysfunction, e.g., associated with fatty liver; glucose intolerance; and others, by administering compositions comprising anti-LPS immunoglobulin enriched colostrum preparations.... Agent:
20130224219 - Drug and method for the prophylaxis of hiv infection and for the prophylaxis and treatment of diseases caused by or associated with hiv, including aids: The drug for the prophylaxis of HIV infection and for the prophylaxis and treatment of diseases caused by or associated with HIV, including AIDS, comprises an activated, potentiated form of antibodies to a protein or peptide of the immune system which interacts with the HIV or has a content and/or... Agent:
20130224220 - Erbb3 binding antibody: The present invention relates to an antibody, particularly a monoclonal antibody, which binds to the ErbB3 receptor, compositions comprising such an antibody as well as methods using such an antibody.... Agent: Mediapharma S.r.l.
20130224218 - Methods and compositions for the inhibition of fructokinase: The invention relates to the use of isoform-specific fructokinase (ketohexokinase) (KHK) inhibitors alone or in combination with various agents to both prevent and treat a wide variety of diseases including, but not limited to, sugar craving, obesity, features of metabolic syndrome (including insulin resistance, hypertriglyceridemia, hypertension, and fatty liver), polyuria,... Agent: The Regents Of The University Of Colorado, A Body
20130224217 - Methods of treating complications and disorders associated with g-csf administration: The present embodiments relate to novel uses of MPO inhibitors and inhibitors of MPO and E-selectin binding. In some embodiments, methods are provided for treating G-CSF-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits E-selectin receptor/ligand interaction or inhibits MPO... Agent:
20130224221 - Biomarkers for schizophrenia: The invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorder.... Agent: Psynova Neurotech Ltd.
20130224223 - Compositions and methods for treating neurological disorders: Methods and compositions for modulating GABA release in a subject are provided. A preferred embodiment provides a composition containing an effective amount of an ErbB4 ligand to enhance or promote GABA release, i.e., GABAergic transmission. The ErbB4 ligand can be an agonist ligand or an antagonist ligand depending on the... Agent: Georgia Regents University
20130224222 - Methods and assays for treating or preventing obesity and/or diabetes or increasing insulin sensitivity: The present invention provides methods for determining a putative agent that treats or prevents obesity and/or diabetes or increasing insulin sensitivity, the method comprising contacting cells with the putative agent and measuring thioredoxin-interacting protein (TXNIP) or thioredoxin expression or activity in the cells. The present invention also provides the agent,... Agent:
20130224224 - Cx3cr1-binding polypeptides: The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such... Agent: Boehringer Ingelheim International Gmbh
20130224225 - Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins: An antibody comprising an antigen recognition region which comprises CDR amino acid sequences set forth in SEQ ID NO: 7, 8, 9, 10, 11 and 12.... Agent: Yeda Research And Development Co., Ltd.
20130224226 - Insect binding antibodies: Described is a binding domain, preferably an antigen binding domain, more preferably an antigen binding domain that specifically binds a binding site on an insect. More specifically, described are antigen binding domains comprising an amino acid sequence that comprises 4 framework regions and 3 complementary determining regions, whereby the antigen... Agent: Agrosavfe N.v.
20130224228 - Antibody-drug conjugates and related compounds, compositions, and methods: Antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, tubulysin analogs, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.... Agent: Igenica, Inc.
20130224227 - Novel conjugates of cc-1065 analogs and bifunctional linkers: This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span... Agent:
20130224229 - Novel curcumin-antibody conjugates as anti-cancer agents: The invention relates to curcumin derivatives having the formula I: wherein: Z represents: H3CO A represents —CH2—CH2— or —CH═CH—; L represents —C(O)—(NH)n1—R—(NH)n2—C(O)—; R represents a saturated or unsaturated, branched or unbranched hydrocarbyl chain having a minimum of 3 carbon atoms in the chain; wherein the maximum number of carbon atoms... Agent: Research Foundation Of The City University Of New York
20130224230 - Therapeutic uses of glandular kallikrein: The present invention relates to pharmaceutical compositions comprising glandular kallikrein in combination with myelin basic protein or copaxone for use in the treatment of multiple sclerosis. The present invention further relates to a method of suppressing autoimmune responses in a patient afflicted with or suffering at least one clinical sign... Agent: Diamedica Inc.
20130224232 - Cyclic tetrapeptides and therapeutic applications thereof: There are provided compounds of formula I wherein k, m, n, p, R, R′, R″, R′″, R3 and R4 are as defined in the application. Other embodiments are also disclosed.... Agent:
20130224233 - Immunotherapeutic method for treating prostate cancer: The invention relates to treatment of prostate cancer and metastases thereof. More specifically, the invention relates to immunogenic polypeptides comprising at least a portion of a prostatic tumor cell-associated protein or immunologically active variants thereof and to nucleic acids encoding such polypeptides and to the use thereof in immunotherapeutic methods... Agent: Pantarhei Bioscience B.v.
20130224231 - Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity: In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject and/or for the treatment of an immune-related disorder, including treating and preventing infection by modulating innate immunity. Also provided are an agent reactive with the peptide, a pharmaceutical composition... Agent: Inimex Pharmaceuticals, Inc.
20130224234 - Ttll4 peptides and vaccines containing the same: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTLL4 gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical... Agent: Onco Therapy Science, Inc.
20130224236 - Hsv-1 epitopes and methods for using same: The invention provides HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic... Agent: University Of Washington
20130224235 - Potato virus a coat protein-based vaccines for melanoma: A vaccine for treating melanoma, comprising at least one melanoma antigen and a viral-like particle comprising potato virus A coat protein. Use of vaccine for treating melanoma, including protein and DNA vaccines, based on potato virus A coat protein.... Agent: Tallinn University Of Technology
20130224238 - Gpcr as vaccines or for removing/inhibiting autoantibodies, toxins or ligands binding to the gpcr: There is provided a G protein coupled receptor (GPCR) or a polynucleotide encoding said GPCR for use as a vaccine. There is also provided methods of antagonising or agonising A GPCR in vivo comprising the administration of a GPCR or a polynucleotide encoding a GPCR to a subject. The invention... Agent: Heptares Therapeutics Limited
20130224237 - Inhibition of nonsense mediated decay pathways: Compositions for inducing or enhancing antigenicity of a target cell by modulating the nonsense mediated decay pathway in the target cell. The compositions comprise one or more cell binding ligands providing specificity and delivery of an oligonucleotide or other molecule to the target. These compositions have broad applicability in the... Agent: University Of Miami
20130224239 - Alcoholic extract of fungi of genus cunninghamella and use thereof: The present invention relates to an alcoholic extract of fungi of the genus Cunninghamella; a method for its preparation and use thereof.... Agent: King Saud University
20130224240 - Method of reducing weight using composition containing fucoxanthin extract: A method of reducing a weight of a subject includes administering to the subject in need thereof a composition comprised of fucoxanthin extract and at least one selected from the group consisting of tocotrienol, fucoidan and a combination thereof, wherein the subject is a mammal.... Agent: Beijing Gingko Group Biological Technology Co., Ltd.
20130224241 - Multivalent meningococcal polysaccharide-protein conjugate vaccine: The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and... Agent:
20130224242 - Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type i interferon response: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.... Agent: Aeras Global Tb Vaccine Foundation
20130224243 - Use of herpes vectors for tumor therapy: Eliciting a systemic antitumor immune response can be efficacious for a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type. To this end a pharmaceutical composition is employed that comprises a defective HSV vector, preferably containing an expressible nucleotide sequence... Agent:
20130224244 - Vaccine composition for vaccinating dogs against canine infectious respiratory disease (cird): A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against Streptococcus equi sub species zooepidemicus in a dog, (b) an agent capable of raising an immune response against Mycoplasma cynos in a dog, and (c) an agent capable... Agent: The Royal Veterinary College
20130224245 - Concentration of vaccine antigens without lyophilization: An antigen concentration procedure does not involve lyophilisation of a bulk antigen before its final formulation and/or delivery. Thus a process for preparing a vaccine comprises steps of (i) increasing the concentration of an antigen in a liquid composition including that antigen, to provide a concentrated antigen, and (ii) formulating... Agent: Novartis Ag
20130224246 - Modified hepatitis c virus proteins: A composition comprising a hepatitis C virus (HCV) Envelope 2 (E2) polypeptide including a receptor binding variant, wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597; and wherein the polypeptide forms substantially fewer... Agent:
20130224247 - Vaccine against ehrlichia canis: Vaccine and/or immunogenic compositions that comprise an effective immunizing amount of an E. canis bacterin are described. In addition, methods of immunizing a subject against E. canis by providing the vaccine and/or immunogenic compositions are also disclosed.... Agent:
20130224248 - Formulation suitable for stabilizing proteins, which is free of mammalian excipients: A formulation free of protein which stabilizes pharmaceutical active proteins, peptides, or mixtures thereof in large scale production processes comprising a mixture of a hydrophilic polymer and a non-ionic detergent, and a mixture of a polyalcohol and a sugar. In some embodiments the polyalcohol is absent.... Agent: Merz Pharma Gmbh & Co. Kgaa
20130224249 - Recombinant trypanosoma cruzi cells useful as anti-cancer immune agents: Recombinant, attenuated parasites are transformed or transfected with nucleic acid molecules which provoke an immunostimulatory and protective response in subjects. Preferably, the parasite is Trypanosoma cruzi, especially strain CL-14, and the transforming nucleic acid molecule encodes for a cancer testis antigen, such as NY-ESO-1.... Agent: Ludwig Institute For Cancer Research Ltd.
20130224250 - Purified plasmodium and vaccine composition: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.... Agent: Sanaria Inc.
20130224251 - Variants of group 6 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues: The present invention relates to the preparation and use of recombinant variants of group 6 allergens of the Poaceae (true grasses), which are characterised by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung
20130224252 - Intestine immunomodulator: The purpose of the present invention is to provide a better intestine immunomodulator. The intestine immunomodulator of the present invention comprises bacterial cells or a bacterial component of a Lactobacillus paracasei K71 strain having an international deposit No.: FERM BP-11098 as an active ingredient. Preferably, the intestine immunomodulator is used... Agent: Niigata University
20130224253 - Non-replicating probiotic micro-organisms protect against upper respiratory tract infections: The present invention relates to non-replicating probiotic micro-organisms and their health benefits. For example, the present invention relates to compositions comprising non-replicating probiotic micro-organisms for use in the treatment of prevention of upper respiratory tract infections and/or their symptoms. Embodiments of the present invention provide means to help parents to... Agent: Nestec S.a.
20130224254 - Non-replicating probiotic micro-organisms protect children against gastrointestinal infections: The present invention relates to non-replicating probiotic micro-organisms and their health benefits. In particular, the present invention provides a means to help parents to protect their children from gastro-intestinal infections, in particular diarrhea. One embodiment of the present invention relates to a composition comprising non-replicating probiotic micro-organisms for use in... Agent: Nestec S.a.
20130224258 - Bismuth-thiols as antiseptics for agricultural, industrial and other uses: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural and artificial surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds... Agent: Microbion Corporation
20130224263 - Calcium phosphate composition and process for production thereof: A calcium phosphate composition comprising calcium phosphate particles (A) and a sulfonic acid salt (B), wherein the calcium phosphate composition contains 0.5 to 20 parts by weight of the sulfonic acid salt (B) based on 100 parts by weight of the calcium phosphate particles (A). This provides a calcium phosphate... Agent:
20130224259 - Dimethylarginine dimethylaminohydrolase inhibitors and methods of use thereof: The present disclosure provides DDAH modulators. Thus, the present disclosure provides a method of treating a patient suffering from a disorder characterized by excessive NO production and/or elevated DDAH activity, the method comprising administering to said patient an effective amount of a compound of one of formulae I-X. The present... Agent: The Board Of Trustees Of The Leland Stanford Junior University
20130224265 - Dosage forms for tamper prone therapeutic agents: A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap... Agent: Atlantic Pharmaceuticals, Inc.
20130224261 - Environmentally-responsive nanocomposites and methods of their use: Environmentally-responsive composites useful for intracellular delivery of therapeutic agents.... Agent: University Of Washington Through Its Center For Commercialization
20130224264 - High-loading, controlled-release magnesium oral dosage forms and methods for making and using same: Disclosed are high loading, controlled-release dosage forms for oral administration of magnesium salts. For example, an oral dosage form can comprise from about 80% to about 95% magnesium lactate and one or more components. As another example, an oral dosage form can comprise at least about 50% magnesium salt and... Agent: Pharmalyte Solutions, LLC
20130224256 - Hydrogel nanocomposite wound dressing and a method of synthesizing the same: The various embodiments herein provide hydrogel nanocomposite wound dressing comprising a polymeric basal matrix, a reinforcing agent, a biological sensor and an antibiotic for a slow release in a wound when applied. The polymeric basal matrix is made up of polyvinyl alcohol polymer with an amount of 1-15% by weight.... Agent:
20130224266 - Immunogenic composition: The present invention relates to the use of a immunogenic or immunostimulatory composition comprising a Shigella outer membrane protein (OMP) and Shigella LPS molecule in medicine and methods for preparing the composition.... Agent: Glaxosmithkline Biologicals S.a.
20130224257 - Method for preparing microspheres and microspheres produced thereby: The present invention relates to a method for preparing microsphere and microspheres produced thereby. The method comprises: mixing a water-insoluble organic solvent with a dispersion solvent; mixing a polymer compound, a drug and a water-insoluble organic solvent to prepare a dispersed phase; mixing the dispersed phase with the dispersion solvent... Agent: Sk Chemicals Co., Ltd.
20130224260 - Tissue scaffolds derived from forestomach extracellular matrix: The present invention pertains to the development of Extracellular Matrix (ECM) scaffolds derived from the forestomach of a ruminant. Such scaffolds are useful in many clinical and therapeutic applications, including wound repair, tissue regeneration, and breast reconstruction. In addition, the present invention features methods of isolating ECM scaffolds from mammalian... Agent: Mesynthes Ltd.
20130224262 - Transdermal preparation: The invention provides a transdermal absorption preparation showing sufficient adhesiveness on adhesion to the skin, causing low skin irritation, and capable of well controlling releaseability of lidocaine. The transdermal absorption preparation contains a support and an adhesive layer formed on the support. The adhesive layer contains a drug, as well... Agent: Km Transderm
20130224255 - Treatment of diabetic patients with a drug eluting stent and adjunctive therapy: Embodiments of the present invention include methods for the treatment, prevention, or amelioration of vascular disease in diabetic patients. The methods include both implantation of a stent including a first drug. Some embodiments include additional therapy, such as the co-administration of another drug. Some embodiments involve different stent selection for... Agent: Abbott Cardiovascular Systems Inc.
20130224269 - Biofunctional anchored extended-wear cosmetics: An extended wear cosmetic composition for application to a keratinous surface comprising a cosmetic particle coated with a biofunctional polymer wherein said coated particle adheres to the keratinous surface for an extended time period. A delivery system for conjugating a biofunctional polymer and cosmetic particle to specific cells on a... Agent: Avon Products, Inc.
20130224267 - Emulsion containing organosilicon-based portions of hollow spheres: The present invention relates to a composition in the form of an emulsion containing portions of hollow spheres of organosilicon-based material, the portions of hollow spheres having a mean diameter ranging from 0.05 to 10 μm. The invention also relates to physiologically acceptable emulsion compositions comprising hollow spheres, and to... Agent: L'oreal
20130224270 - Oral care composition comprising arginine and calcium carbonate: This invention relates to oral care compositions comprising a basic amino acid or salt thereof, and an abrasive system comprising natural calcium carbonate and precipitated calcium carbonate; and to methods of using and of making these compositions.... Agent: Colgate-palmolive Company
20130224271 - Oral compositions containing microaggregates: The invention relates to a composite and oral care compositions for use in the mouth to retard the accumulation of dental plaque and/or calculus. The composite is a microaggregate comprising polymer coated, surfactant stabilized particles of a substantially insoluble metal, metal salt or metal oxide, for example zinc oxide. Also... Agent: Colgate-palmolive Company
20130224268 - Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same: The present invention relates to methods for treating, preventing, minimizing, and/or diminishing signs of aging in the skin comprising topically administering to the subject in need thereof a hormonal nano formulation.... Agent: Newgen Biopharma Corp.
20130224272 - Compositions and methods for treating demodex infestations: Compositions containing about 0.6% to about 20% of tea tree oil are described. Some compositions are in the form of solutions, suspensions, spray, lotions, gels, pastes, medicated sticks, balms, cleansers (including shampoos and soaps), creams, or ointments. Also described are compositions and methods for use in treating ocular Demodex infestations... Agent: Tissuetech, Inc.
20130224273 - Topical sanitizer and method of use with gloves: Topical sanitizer includes avenanthramides, which is an active component of oats that is beneficial to the skin. The topical sanitizer is used preferably in conjunction with gloves that have an inner coating that includes avenanthramides. By using topical sanitizer that includes avenanthramides before and after wearing gloves, the skin of... Agent: The Idea Folder LLC
20130224274 - Antibacterial medicinal product and method for producing same: The present invention relates to a medical product, comprising an antibacterial hard material coating, which is applied to a main body and which comprises biocide. Said hard material coating includes at least one inner layer and one outer layer, wherein the biocide concentration in the outer layer is substantially constant... Agent: Oerlikon Trading Ag, Trubbach
20130224275 - Delivery of compositions to arthropods: A method of delivering a biologically active chemical agent to an arthropod pest of a bee, comprising exposing a surface of the said bee to carnauba wax particles having a volume mean diameter of at least 10 μm comprising at least one biologically active chemical agent, wherein the bee delivers... Agent: Exosect Limited
20130224276 - Compositions and methods for coating medical implants: Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant.... Agent: Angiotech International Ag
20130224277 - Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation: The present invention relate to three dimensional porous polysaccharide matrices able to induce mineralisation of a tissue in osseous site, as well as in non-osseous site, in the absence of stem cells or growth factors.... Agent: Institut National De La Sante Et De La Recherche Medicale (inserm)
20130224278 - Resorbable cellulose based biomaterial and implant: The present disclosure describes an implant for tissue replacement or augmentation including a resorbable non-pyrogenic porous body of irradiated oxidized cellulose, formed from a precurosr reactive mixture of irradiated cellulose and an oxidizing agent, where the body forms a heterogeneous three-dimensional fibrillar network. Also disclosed is a method for producing... Agent:
20130224279 - Process for the preparation of calcium salt suspensions: The current invention is related to a novel process for the production of aqueous suspensions of micro and nanoparticles of calcium salts smaller than 10 μm particle size, along with a method to enrich nutritional, nutraceutical, and pharmaceutical beverages with calcium salts. In the process, an aqueous suspension of calcium... Agent: Universidad Del Valle
20130224280 - Transdermal compositions and methods for treating stretch marks: A transdermal delivery device for treating or preventing scars, such as stretch marks, comprising a composition comprising vitamin E, hyaluronan, biotin, Rosmarinus officinalis, collagen, and a heat generating ingredient, and methods therefor.... Agent:
20130224283 - Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery: A biphasic lipid vesicle composition for treating cervical displasia by intravaginal delivery. The composition includes a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and L-methionine, the composition having an interferon alpha-2b specific activity of between about 1-10 MIU (million international units) per gram composition,... Agent: Helix Biopharma Corp.
20130224285 - Estrogen receptor alpha polypeptide sequence, diagnostic and therapeutic applications thereof: The present invention presents new insights in the mechanism of action of the estrogen receptor alpha in breast cancer cells and provides means and tools for modulating said mechanisms of action, thereby influencing the proliferation of estrogen-positive cells such as cancer cells.... Agent: University Of Crete - School Of Medicine
20130224284 - Geodate delivery vehicles: The present invention provides geodate delivery vehicles and methods of manufacture and administration. A vehicle including a lipid monolayer disposed about a hydrophobic domain is disclosed, that can be part of an emulsion or other mixture, or further disposed in a lipid strata. A vehicle including a lipid strata disposed... Agent:
20130224287 - Liposome-based construct comprising a peptide modified through hydrophobic moieties: The present invention relates to method for preparing liposome-based constructs comprising a peptide, particularly an antigenic peptide, of interest modified through hydrophobic moieties reconstituted in liposomes and to the antigenic constructs obtained with said method. The invention further relates to the use of said constructs for the therapeutic and diagnostic... Agent: Ac Immune S.a.
20130224281 - Method and composition for ameliorating the effects for a subject exposed to radiation or other sources of oxidative stress: Radiation-oxidative exposure treatment compositions may include a mixture of micronutrient multivitamin and trace elements, a mixture of antioxidants and chemopreventative agents, and optionally a mixture of fatty acids. Methods of treatment of a subject exposed to a radiation source or an oxidative stress with the radiation-oxidative exposure treatment composition may... Agent: Amerisciences, Lp
20130224286 - Methods and compositions for treating pox virus infections: Human viral infections can cause lesions of the skin and/or mucous membranes. Provided herein are 1,4-naphthoquinone family compounds which are useful in the treatment of these lesions. Further provided herein are pharmaceutical compositions comprising a 1,4-naphthoquinone family compound and methods of using such compositions in the treatment of these lesions.... Agent:
20130224282 - Multistage nanoparticles: Multistage nanostructures, e.g., for delivery of agents such as imaging agents and therapeutic agents to tumor vasculature.... Agent: The General Hospital Corporation
20130224288 - F, g, h, i and k crystal forms of imatinib mesylate: The invention relates to the F-crystal form, G-crystal form, H-crystal form, I-crystal form and K-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, certain processes for their preparation, pharmaceutical compositions containing these crystal forms, their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their... Agent:
20130224289 - Gastric retained gabapentin dosage form: A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.... Agent: Depomed, Inc.
20130224290 - Oral pharmaceutical composition of duloxetine: The present invention relates to an oral pharmaceutical composition of duloxetine or pharmaceutically acceptable salts thereof. Preferably, the invention relates to a delayed release composition of duloxetine comprising a core containing duloxetine, an optional separating layer, an enteric layer and an optional finishing layer.... Agent: Hetero Research Foundation
20130224292 - Acamprosate formulations, methods of using the same, and combinations comprising the same: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.... Agent: Synchroneuron Inc.
20130224291 - Delayed-release formulation for reducing the frequency of urination and method of use thereof: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount... Agent: Wellesley Pharmaceuticals, LLC
20130224294 - Dry processing of atazanavir: The invention relates to dry processes for producing oral dosage forms, more specifically tablets, comprising atazanavir and adhesion enhancers. The invention further relates to compacted intermediates comprising atazanavir and adhesion enhancers.... Agent: Ratiopharm Gmbh
20130224293 - Pharmaceutical composition and administrations thereof: The present invention relates to pharmaceutical compositions containing a solid dispersion of N—[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.... Agent: Vertex Pharmaceuticals Incorporated
20130224296 - Drug formulations using water soluble antioxidants: The present invention relates to solid, semisolid, or liquid formulations comprising water soluble antioxidants that prevent or reduce formic acid and/or formyl species generation in the dosage form during the manufacturing process and/or during shelf-life storage. The formulations of the present invention prevent or reduce formation of N-formyl impurities (and... Agent: Bristol-myers Squibb Company
20130224297 - Pharmaceutical composition comprising krebs cycle precursor salt, in particular citrate salt, and use thereof as a medicament: A solid oral pharmaceutical composition in the form of a tablet consisting of a core including a Krebs cycle precursor salt as active ingredient, and of a coating including a coating agent, the composition including from 40% to 80% by weight of this precursor salt on the basis of the... Agent: Advicenne
20130224299 - Novel process for the preparation of roflumilast: A method for the treatment of chronic obstructive pulmonary disease (COPD), including administering to a patient suffering from COPD, a therapeutically effective amount of roflumilast having a purity of greater than or equal to 99% by weight, and N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide present (relative to roflumilast) in an amount greater than zero and... Agent: Nycomed Gmbh
20130224298 - Two-phase preparation and use thereof for the treatment of herpes: The invention relates to a novel two-phase preparation for use as a food supplement, dietary substance, and/or medicament. The medical use thereof for helping the immune system fight against viral diseases, especially herpes, is particularly preferred. Said preparation may have two different phases which may be used in a chronologically... Agent: Nutriteam Gmbh
20130224300 - Compositions and methods thereof for oral administration of drugs: The present invention provides therapeutic compositions including a therapeutic agent in a non-aqueous matrix having an absorption enhancer and therapeutic agent, as well as methods for administering such compositions and providing enhanced oral bioavailability.... Agent:
20130224302 - Porous photonic crystals for drug delivery to the eye: A minimally invasive controlled drug delivery system for delivering a particular drug or drugs to a particular location of the eye, the system including a porous film template having pores configured and dimensioned to at least partially receive at least one drug therein, and wherein the template is dimensioned to... Agent: The Regents Of The University Of California
20130224301 - Solid pharmaceutical dispersions with enhanced bioavailability: Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or bioavailability in a use environment.... Agent: Bend Research, Inc.
20130224303 - Process of producing shelf stable probiotic food: The invention provides an ingredient containing shelf-stable probiotic microorganisms for use in preparing probiotic food products requiring long shelf-life. The ingredient is prepared by coating particles or an agglomeration thereof with a suspension of osmotically shocked probiotic microorganisms and drying the product.... Agent: Massey University
20130224304 - Effervescent nutritional and/or dietary supplement composition: An effervescent composition is provided comprising a dry, free-flowing powder comprising (a) microcapsules comprising a hollow, solid, water soluble outer shell comprising a starch, a sugar or mixtures thereof and an inner core comprising a liquid, water immiscible oil comprising at least one polyunsaturated fatty acid, at least one derivative... Agent: Nordic Naturals, Inc.
20130224305 - Methods of identifying insect-trpa1 modulators: The invention provides a screening method for identifying an insect-specific TRPA1 modulator by comparing modulation of an insect TRPA1 and a mammalian TRPA1. The invention further provides method of insect control by applying to an insect a insect-specific TRPA1 modulator identified by the screening method.... Agent: Brandeis University
20130224306 - Method for treating a pulmonary hypertension condition without companion diagnosis: There is provided a method for treating pulmonary hypertension in a subject, comprising: administering to the subject in need thereof a daily dose of ambrisentan from 1 mg to about 15 mg, wherein the method is carried out without drug labeling instruction to monitor liver aminotransferase levels during ambrisentan treatment.... Agent: Gilead Sciences, Inc.
20130224307 - Alpha-keto peracids and methods for producing and using the same: The present invention provides α-keto peracids and methods for producing and using the same. In particular, α-keto peracids are useful as antimicrobial agents.... Agent: Chd Bioscience, Inc.
20130224308 - Gel comprising reactive oxidant release agent: Gel comprising reactive oxidant release agent The invention provides a gel composition comprising 5% to 75% w/w of an inorganic gelling agent other than silica based gelling agents, 0.5-60% w/w, preferably 0.5 to 30% w/w, of an inorganic oxidant release agent and at least 20% w/w of water, and possibly... Agent: Biorem Engineering Sarl
20130224309 - Antimicrobial medical devices: The present invention provides methods for making an antimicrobial medical device, preferably an antimicrobial ophthalmic device, more preferably an antimicrobial extended-wear contact lens, which contains silver nano-particles distributed uniformly therein. The antimicrobial medical device can exhibit antimicrobial activity over an extended period of time.... Agent:
20130224310 - Noscapine analogs and their use in treating cancers: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are noscapine analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. While the antitussive plant alkaloid, noscapine, binds tubulin, displays anticancer... Agent: Emory University
20130224313 - Cancer therapy method: This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the... Agent: Centro De Ingenieria Genetica Y Biotecnologia
20130224311 - Methods and compositions for the treatment of cancer: Some embodiments of the present invention relate to methods and compositions for treating cancer. More embodiments include methods and compositions for modulating the activity of the Hedgehog pathway.... Agent: University Of South Alabama
20130224312 - Methods and materials for assessing responsiveness to parp inhibitors and platinating agents: This document provides methods and materials involved in assessing responsiveness to PARP inhibitors and platinating agents. For example, methods and materials for using levels of non-homologous end-joining pathway members (e.g., artemis mRNA or polypeptide levels, Ku80 mRNA or polypeptide levels, or DNA-PKcs mRNA or polypeptide levels) to determine if cancer... Agent: Mayo Foundation For Medical Education And Research
20130224314 - Medical uses of nanoclustered water: The present invention relates to methods of treating or preventing an infection or infectious disease in a mammal, or sanitizing mammalian tissue, or treating or preventing psoriasis in a mammal, comprising topically administering to said mammal an electrolytic acid water comprising free chlorine, wherein: a) from 90% to 99.9% of... Agent: Apr Nanotechnologies S.a.
20130224315 - Compositions of volatile organic compounds and methods of user thereof: The present invention provides compositions and methods for treating, inhibiting or preventing the developing of a plant pathogenic disease. The compositions comprise volatile organic compounds effective to inhibit the growth of, or kill pathogenic microbes, including Ganoderma boninense. Invention compositions are especially useful in preventing and treating basal stem rot... Agent: Synthetic Genomics, Inc.
20130224316 - Melt-blended protein composition: A melt-processed protein composition formed from a protein, plasticizer, and an electrophilic reagent is provided. The electrophilic reagent, for instance, may be selected to undergo a nucleophilic addition reaction with free sulfhydryl and/or thiyl radicals to help minimize the formation of disulfide crosslinking bonds that could otherwise lead to protein... Agent: Kimberly-clark Worldwide, Inc.
20130224317 - Methods and materials for reducing multiple risk factors associated with the metabolic syndrome: A composition containing nelumbo extract reduces and/or eliminates one or more risk factors associated with Metabolic syndrome. The composition also includes optionally one of more components selected from the group consisting of vitamins, cholesterol lowering agents, lipid lowering agents, and glucose lowering agent. Also described is a method of reducing... Agent: Fhg Corporation D/b/a Integrity Nutraceuticals
20130224319 - Compositions and methods to reduce hangover and reduce blood alcohol levels after alcohol consumption: Compositions and methods for preventing and/or reducing hangover, when consumed before, after or during drinking alcohol. Compositions of the inventions include fructose powder, prickly pear extract, N-acetyl cysteine; kudzu; lemon balm; Vitamin C; nopal; white willow bark extract; milk thistle; Vitamin B1; Vitamin B6; lemon juice; acacia fiber; and other... Agent:
20130224318 - Use of cpt-1 modulators and compositions thereof: The present invention describes methods for improving the appearance of skin, particularly, treating, ameliorating, preventing, delaying, and/or improving one or more signs of excess accumulation and/or production of subcutaneous fat, such as cellulite, and conditions related thereto, by topically applying compositions comprising Carnitine Palmitoyl Transferase-1 (CPT-1) modulators, optionally with other... Agent: Avon Products, Inc.
20130224320 - Process to improve feed efficiency and carcass characteristics of animals: This invention relates to a process to improve the feed efficiency and carcass characteristics of an animal. The process of this invention can be used to decrease the cost of animal diets, to improve performance of animals and to improve the percentage of carcass in animals.... Agent:08/22/2013 > 164 patent applications in 92 patent subcategories. inventions list
20130216474 - Nanocells for diagnosis and treatment of diseases and disorders: The present invention relates to novel nanocell compositions and their use in imaging, diagnostic and treatment methods. In one embodiment, nanocells tailored for imaging methods comprise a nanocore surrounded by a lipid matrix, and are modified to contain a radionuclide core or a nanocore with an emission spectra. The nanocells... Agent: Massachusetts Institute Of Technology
20130216475 - Methods and compositions for protein labelling: A modular platform is provided for rapid preparation of various water-soluble prosthetic groups capable to efficiently introduce 18F into proteins with 18F labelling reagents.... Agent: Genentech, Inc.
20130216476 - Use of an anti-cd71 antibody for preparing a medicament: The use of an anti-CD71 monoclonal antibody or a fragment of an abovementioned antibody capable of binding to the CD71 antigen for the preparation of a drug intended for the prevention or treatment of myelomas.... Agent: Lfb Biotechnologies
20130216478 - Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is... Agent:
20130216479 - Site-specific chemical modification of proteins at their n-termini, enabling the formation of homogeneous adducts: Site-specific modifications of proteins at their N-termini are provided. In particular, a chemical modification of proteins at their N-termini via a transamination reaction to form homogeneous adducts such as, the corresponding oxime derivatives is provided. Methods of making and using the adducts in radio-labelling, molecular imaging applications, and treatment of... Agent:
20130216480 - Amphiphilic polymers and methods of use thereof: The present invention relates to amphiphilic polymers, and micelles and compositions comprising the same, and their use in a variety of biological settings, including imaging, targeting drugs, or a combination thereof for diagnostic and therapeutic purposes.... Agent: Massachusetts Institute Of Technology
20130216481 - Use of utp for the diagnosis of stenoses and other conditions of restricted blood flow: The present invention relates to methods for determining whether blood flow is restricted in a blood vessel of an individual suspected of compromised blood flow in the vessel, the method comprising the steps of delivering UTP, a derivative thereof, or a salt thereof to the vessel, assessing blood flow quantitatively... Agent: P2 Science Aps
20130216482 - Methods and compositions for non-invasive, dynamic imaging of intestinal motility: Described are methods and composition for use in non-invasive imaging of intestinal structure and function. These methods can be used to identify, diagnose, assess, monitor and direct therapies for gastrointestinal diseases and disorders. Embodiments of the methods utilize highly sensitive optical imaging and fluorescent spectroscopy techniques to track or monitor... Agent: The Board Of Regents Of The University Of Texas System
20130216483 - Delivery system for remote treatment of an animal: A method of remotely treating an animal including launching a delivery system at the animal, wherein the delivery system comprises a dosage projectile adapted to deliver a biologically active agent to an animal substantially without piercing the skin of the animal and containing a biologically active agent and a transdermal... Agent: Smartvet Pty Ltd.
20130216484 - Bioenzymatic tablet: It is contemplated that the tablet of the present invention is primarily utilized cleaning of dental instruments. In application a receptacle, such as sonic cleansing machine, is provided with a supply of water. An effervescent tablet containing a bioenzymatic compound is introduced to the water to create a cleaning solution.... Agent:
20130216485 - Dentifrice composition with reduced astringency: A dentifrice composition containing, in combination, an orally acceptable vehicle; a halogenated diphenyl ether; a soluble zinc salt; and a chelating agent to reduce astringency.... Agent: Colgate-palmolive Company
20130216486 - Synthesis of cyclohexane derivatives useful as sensates in consumer products: The present invention provides synthetic routes for preparing various isomers of cyclohexane-based coolants, such as menthyl esters and menthanecarboxamide derivatives, in particular those substituted at the amide nitrogen, for example with an aromatic ring or aryl moiety. Such structures have high cooling potency and long lasting sensory effect, which make... Agent: The Procter & Gamble Company
20130216487 - Teeth-whitening gel: A teeth-whitening gel is provided. The main ingredient of the teeth-whitening gel comprises a polypeptide having halamine (N—X bond, X═Cl, Br or I) groups and a high molecular weight. By the redox properties of halamine group, the gel contacting with the teeth's surface can bleach and whiten the teeth.... Agent: Far Eastern New Century Corporation
20130216488 - Antimicrobial, antibacterial and spore germination inhibiting activity from an avocado extract enriched in bioactive compounds: The present disclosure relates to extracts from Persea sp. (avocado) enriched in bioactive compounds which can be used as antimicrobial, antibacterial or spore germination inhibiting agents, the process for obtaining the extracts, acetogenins and isolated molecules and methods for using the extracts enriched in bioactive compounds for providing antimicrobial, antibacterial... Agent: Instituto Tecnologico Y De Estudios Superiores De Monterrey
20130216489 - Polysaccharide products with improved performance and clarity in phosphate ester surfactant-based aqueous formulations and process for preparation: A personal or household care product includes cationic, nonionic or cationic/nonionic derivatized polysaccharide in combination with a phosphate ester surfactant. The derivatized polysaccharide polymer is formed by reacting the polysaccharide ester surfactant for a sufficient time and at a sufficient temperature in the presence of water, caustic, and at least... Agent: Hercules Incorporated
20130216491 - Composition for cleaning scalp and head hair: This invention provides a cleaning composition comprising a certain amount or more of an acylamino acid type surfactant, and further a non-ionic surfactant and a betaine-type ampholytic surfactant, which has a sufficient viscosity and exerts excellent conditioning effects.... Agent: Otsuka Pharmaceutical Co., Ltd.
20130216490 - Hair treatment agents having low-dose oligopeptides: i
20130216492 - Method for searching for malodor control agent, malodor control agent, and malodor control method: Provided are a method for searching for a malodor inhibitor by using the response of an olfactory receptor as an indicator; a method for inhibiting malodor based on the antagonism of olfactory receptors; and a malodor inhibitor. Disclosed are a method for searching for a malodor inhibitor, the method including:... Agent: Kao Corporation
20130216493 - Peg or peg block copolymers for treating colorectal cancer: The present invention relates to methods for and of treating, ameliorating or preventing colorectal cancer (CRC) in humans using polyethylene glycol (PEG) or a PEG block-copolymer such as Pluronic® F68. Compositions for use in treating, ameliorating and/or preventing CRC comprising PEG are also disclosed. Such compositions may be used in... Agent: Norgine Bv
20130216494 - Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof: One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of... Agent: Syndecrx, Inc.
20130216496 - Methods for treating tweak-related conditions: The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that... Agent: Biogen Idec Ma Inc.
20130216495 - Pharmaceutical composition comprising cd34+ cells: The invention relates to the field of treatment of ischemic conditions and diseases using a cell population comprising CD34+ cells isolated from peripheral blood of a subject. The invention provides a pharmaceutical composition comprising (i) a cell population comprising CD34+ cells, (ii) a plasma protein, and (iii) an isotonic solution... Agent: Baxter International Inc.
20130216497 - Novel tricyclic compounds: e
20130216498 - Imidazopyridine derivatives as jak inhibitors: New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).... Agent:
20130216499 - Compositions of recombinant human endostatin adenovirus injections and methods of production: The invention generally relates to compositions of and methods for production of recombinant adenoviruses that carry therapeutic genes. More particularly, the invention relates to lyophilized recombinant adenoviruses injection and its related production procedures, including production procedures for the recombinant adenovirus vectors (or other viral vectors) that carry the genes of... Agent:
20130216500 - Method of treating or retarding the development of blindness: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the... Agent: University Of Florida Research Foundation, Incorporated
20130216501 - Therapeutic methods based on tyrosine-substituted, capsid-modified raav vectors: Disclosed are tyrosine-modified rAAV vectors, as well as infectious virions, compositions, and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and methods for using the disclosed tyrosine-phosphorylated capsid protein mutant rAAV vectors in a variety of diagnostic and therapeutic applications including in vivo and ex vivo gene... Agent: University Of Florida Research Foundation, Inc.
20130216509 - Chimeric receptors with 4-1bb stimulatory signaling domain: The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate... Agent: St. Jude Children's Research Hospital, Inc.
20130216510 - Probiotic strains for use in improving transepithelial resistance: The invention relates to the use of lactic acid bacteria, for use in improving transepithelial resistance and more particularly in treating and/or preventing constipation and/or irritable bowel disease.... Agent: Compagnie Gervais Danone
20130216511 - Bacillus subtilis isolate from corn: Biologically pure cultures of Bacillus subtilis were isolated from the pericarp of nixtamalized corn. The Bacillus microorganisms were characterized and found to produce novel peptides which have antimicrobial activity. The Bacillus microorganisms are active against Gram-positive bacteria and may be used as an agent to prevent spoilage in foods. The... Agent: Investigacion De Tecnologia Avanzada, S.a. De C.v.
20130216506 - Bioreactor for isolation of rare cells and methods of use: The present invention relates to a bioreactor apparatus, and methods of use, for the isolation of rare blood cells, including hematopoietic stem cells and megakaryocytes. The apparatus includes a soft substrate and an anti-contractility agent, thereby providing a soft microenvironment to cultured cells. The apparatus of the invention is permissive... Agent: The Trustees Of The University Of Pennsylvania
20130216504 - Ccn3 and ccn3 peptides and analogs thereof for therapeutec uses: The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native... Agent: Rosalind Franklin University Of Medicine And Science
20130216508 - Human lung stem cells and uses thereof: Embodiments of the invention relate to human stem cells and their therapeutic use in the treatment and/or prevention of lung diseases. Provided herein are compositions comprising c-kit positive human lung stem cells and methods of preparing and using c-kit positive human lung stem cells for the treatment and/or prevention of... Agent: The Brigham And Women's Hospital, Inc.
20130216505 - Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses: Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an... Agent:
20130216503 - Methods for generating cardiomyocytes: The present disclosure provides method of generating cardiomyocytes from post-natal fibroblasts. The present disclosure further provides cells and compositions for use in generating cardiomyocytes.... Agent: The J. David Gladstone Institutes
20130216507 - Methods for promoting hsc engraftment: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and... Agent: Children's Medical Center Corporation
20130216502 - Methods of treating intestinal injury using heparin binding epidermal growth factor and stem cells: The invention provides for methods of treating, abating and reducing the risk for intestinal injury by administering a combination heparin binding epidermal growth factor (HB-EGF) and stem cells, such as mesenchymal stem cells or intestinal stem cells, in an amount effective to reduce the onset or severity of intestinal injury.... Agent: Nationwide Children's Hospital Inc.
20130216512 - Stable aqueous suspension: An aqueous suspension of a hydrophobic nutrient is disclosed, in particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension.... Agent:
20130216513 - Chimeric clotting factors: Chimeric clotting factors which localize the therapeutic to sites of coagulation (e.g., by being targeted to platelets or being activatable at sites of coagulation), have reduced clearance rates, have improved manufacturability, have reduced thrombogenicity, have enhanced activity, or have more than one of these characteristics are described as are methods... Agent: Biogen Idec Hemophilia Inc.
20130216514 - Compositions comprising glutathione reductase and oxidized glutathione: Compositions comprising Glutathione Reductase (GSSG-r) and Oxidized Glutathione (GSSG) or pharmaceutically acceptable salts thereof for pharmaceutical use as antiviral and antibacterial agents and for the protection against the toxicity of free radicals and in particular radicals produced by the radiolysis of cellular water are provided. Methods of making and using... Agent:
20130216515 - Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes: The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable... Agent: Oxthera Intellectual Property Ab
20130216516 - Method for treating delayed-type hypersensitivity: The invention is directed to treatment of delayed-type hypersensitivity reactions associated with changes of qualitative and/or quantitative composition of blood extracellular DNA and treatment of systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA. The inventive method comprises introducing a DNASE enzyme into... Agent: Cls Therapeutics Limited
20130216517 - Standardized bee venom preparation: Bee venom may be administered in a standardized formulation with or without relatively small amounts of anesthetic. In particular, the results of the combination of venom and anesthetic dramatically decreased pain and discomfort for patients undergoing apitherapy.... Agent:
20130216518 - Composition comprising a combination of at least one proteolytic enzyme and at least one lipolytic enzyme, for use in preventing triglyceride synthesis: The present invention relates to a composition comprising a combination of at least one proteolytic enzyme, such as subtilisin, and at least one lipolytic enzyme, for use in preventing triglyceride synthesis, advantageously by degrading 2-monoacylglycerol in the intestine. The invention also has as an object such a composition for use... Agent: Imarko Research S.a.
20130216519 - Proteases producing an altered immunogenic response and methods of making and using the same: The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention... Agent: Danisco US Inc.
20130216520 - Processing biomass: Biomass (e.g., plant biomass, animal biomass, microbial, and municipal waste biomass) is processed to produce useful products, such as food products and amino acids.... Agent: Xyleco, Inc.
20130216521 - Dietary supplement for enhancing animal health: A dietary supplement system including three general components is provided. The first component is the fatty acid component and this includes sunflower seeds (containing omega 6 fatty acids), flax seed (containing omega 3 fatty acids) and powdered oils (containing omega 3 or omega 6 fatty acids and generally produced from... Agent:
20130216522 - Stabilized human immunoglobulin composition: The invention relates to a liquid pharmaceutical composition comprising human immunoglobulins G (IgGs), comprising at least 200 mM, preferably 250 mM±50 mM, of glycine and between 20 and 100 mg/l of a non-ionic detergent, and having a pH of less than or equal to 4.8.... Agent: Laboratoire Francais Du Fractionnement Et Des Biotechnologies
20130216535 - Antagonist antibodies directed against calcitonin gene-related peptide and methods using same: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.... Agent: Labrys Biologics, Inc.
20130216531 - Anti-cxcr4 as a sensitizer to cancer therapeutics: Inhibition of CXCR4 can inhibit tumor growth and metastasis during certain therapeutic windows. Disclosed are novel methods for treating and preventing cancer in a subject related to administration of CXCR4 inhibitors during a therapeutic window following treatment with another anti-tumor therapy.... Agent:
20130216528 - Anti-gd2 antibodies: In this application are described chimeric, humanized, affinity matured, stability enhanced, and bispecific Anti-GD2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or compositions thereof for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma.... Agent:
20130216533 - Biological markers for identifying patients for treatment with vegf antagonists: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.... Agent: Genentech, Inc.
20130216525 - Concentrated protein formulations and uses thereof: Described are low viscosity, hypotonic formulations containing one or more proteins, e.g., antibodies, at high concentration, uses of the formulations, and articles of manufacture. In particular, the formulations are useful and beneficial for the subcutaneous administration or delivery of a high concentration of a protein drug, such as an antibody,... Agent: Cytodyn, Inc.
20130216529 - Humaneered anti-factor b antibody: This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with reduced immunogenicity. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat (“SCR”) domain and selectively inhibits activation of the alternative... Agent: Alexion Cambridge Corporation
20130216536 - Inhibitors of extracellular hsp90: The present invention describes inhibitors of extracellular Hsp90. The inhibition of extracellular Hsp90 leads to a reduction of the invasiveness of the tumor cells. Furthermore, the invention relates to the use of molecules inhibiting extracellular Hsp90 function for the manufacture of a medicament for the treatment or prevention of invasion... Agent: Trustees Of Tufts College
20130216523 - Methods for facilitating diagnosis, prognosis and treatment of cancer by detecting her1 expression: Methods are provided for facilitating the diagnosis of subjects with HER1-activated cancers. In addition, method of treating subjects with a cancer characterized as having high levels of activated HER1 are provided. Also provided are methods for determining or otherwise assessing the prognosis of an subject with a HER1-activated cancer. The... Agent: Laboratory Corporation Of America Holdings
20130216530 - Methods for optimizing biological response modifier therapy using therapeutic drug monitoring of immunosuppressants: The invention provides methods for treating humans in need of combined immunosuppressant and biological response modifier therapy.... Agent: Exagen Diagnostics, Inc.
20130216526 - Methods for reducing viral load in hiv-1 infected patients: This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load... Agent: Progenics Pharmaceuticals, Inc.
20130216527 - Novel anti-cmet antibody: The present invention relates to a novel divalent antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, preferably both in a ligand-dependent and in a ligand-independent manner as well as the amino acid and nucleic acid sequences... Agent:
20130216524 - Predictors for cancer treatment: The present invention provides methods of predicting a response to a cancer treatment by determining CD68 level or PSMB1 (P11A) polymorphism in a biological sample and the presence or quantity of a second biomarker in the patient. The invention also provides kits and methods for treating cancer.... Agent: Janssen Pharmaceutica Nv
20130216532 - Subcutaneous anti-her2 antibody formulations and uses thereof: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount... Agent: Genentech, Inc.
20130216534 - Use of il-20 antagonists for treating rheumatoid arthritis and osteoporosis: The invention features methods and compositions for preventing or treating rheumatoid arthritis and osteoporosis by administering an antagonist of IL-20. The IL-20 antagonist may be an anti-IL-20 antibody, such as mAB 7E, that is capable of binding human IL-20 and blocking IL-20 interaction with its receptors.... Agent: National Cheng Kung University
20130216538 - Compositions and methods for treating inflammatory disorders: The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders.... Agent: Domantis Limited
20130216539 - Methods of generation and treatment with modified derivatives of hsp 70: The present invention includes methods of generating derivatives of a protein, as well as methods of treating a subject with the derivatized proteins. More particularly, the present invention includes methods of generating derivatives of HSP 70 proteins and methods of treating a subject with the derivatized HSP 70 proteins.... Agent: Als Biopharma, LLC
20130216537 - Methods of treating glucose metabolism disorders and promoting weight loss: Compositions and methods for treating individuals with a glucose metabolism disorder and methods for promoting weight loss in an individual are provided.... Agent: Ngm Biopharmaceuticals, Inc.
20130216540 - Modulation of the innate immune system through the trem-like transcript 2 protein: TREM-like transcript 2 (TLT2), is expressed on neutrophils, macrophages, and B lymphocytes. Expression of TLT2 is up-regulated on neutrophils and macrophages in response to inflammatory stimuli in vivo and synergizes with agonists that bind to G-protein coupled receptors (GPCR) to potentiate the neutrophil antibacterial and chemotactic response. Administration of anti-TLT2... Agent: The Uab Research Foundation
20130216541 - Stable subcutaneous protein formulations and uses thereof: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.... Agent: Bristol-myers Squibb Company
20130216543 - Antibody-based constructs directed against tyrosine kinase receptors: The present invention features antibody-based constructs that include a combination of two or more of a tetrameric antibody, a single chain antibody, a diabody, a triabody, another immunoglobulin-based moiety, as described herein, or biologically active variants thereof.... Agent: Massachusetts Institute Of Technology
20130216542 - Variable region sequences of il-31 monoclonal antibodies and methods of use: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by... Agent: Zymogenetics, Inc.
20130216544 - Anti-la antibodies and their use for immunotargeting: The invention relates to antibodies against the human La protein and to their use in immunotargeting, in particular the immunotargeting of tumour cells. The object of the invention is to provide improved antibodies which bind universal target structures on the surface of tumour cells, and to provide novel anti-La antibodies,... Agent: Technische Universitaet Dresden
20130216547 - Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof: The present invention provides antibodies that bind big-endothelin-1 (“big-ET-1”), and methods of using same. According to certain embodiments of the invention, the antibodies specifically bind human big-ET-1 but do not bind human small-ET-1 (i.e., the active form of endothelin-1 that results from proteolytic cleavage of big-ET-1 by endothelin-converting enzyme-1 [ECE-1]).... Agent: Regeneron Pharmaceuticals, Inc.
20130216545 - Early diagnosis and novel treatment of cancer: The present invention relates to novel therapies for treatment and new biomarkers for earlier detection of pancreatic and other cancers. In particular, the present invention identifies Reg1α and Reg3α, and other members of the Reg protein family, as signaling proteins for a receptor on the surface of human cancer cells,... Agent:
20130216546 - Methods of treating glucose metabolism disorders: Methods of treating individuals with a glucose metabolism disorder, and compositions suitable for use in the methods, are provided.... Agent: Ngm Biopharmaceuticals, Inc.
20130216549 - Anti-ip-10 antibodies and uses thereof: The invention relates to fully human antibodies, and fragments thereof, that bind to interferon-inducible-protein-10 (IP-10, CXCL10), thereby modulating the interaction between IP-10 and its receptor, CXCR3, and/or modulating the biological activities of IP-10. The invention also relates to the use of such anti-IP-10 antibodies in the prevention or treatment of... Agent:
20130216550 - Breast cancer therapeutics: The present invention relates to a method of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of a RANKL inhibitor to said patient.... Agent: Imba-institut Fur Molekulare Biotechnologie Gmbh
20130216548 - Monoclonal antibodies against c-met: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.... Agent: Genmab A/s
20130216552 - Crth2 modulators: Modulators of CRTH2, particularly antagonists of CRTH2, that are useful for treating various disorders, including asthma and respiratory disorders are disclosed herein. The compounds are described by structural Formula I:... Agent: Ironwood Pharmaceuticals, Inc.
20130216551 - Genetic polymorphisms associated with psoriasis, methdos of detection and uses thereof: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a... Agent: Celera Corporation
20130216553 - Compositions and methods for modulation and detection of immune and inflammatory responses: A method for detecting an inflammatory or an autoimmune condition, comprising analyzing bacterial lipids, such as phosphorylated dihydroceramides (PDHC), in a sample; and, comparing results of the analysis of the bacterial lipids in the sample with information on occurrence of the bacterial lipids in a comparable sample, wherein the comparison... Agent: University Of Connecticut
20130216556 - Antibody formulations: Formulations of anti-VLA-1 antibodies are described.... Agent: Santarus, Inc.
20130216557 - Ltbr blockade: methods for optimizing therapeutic responsiveness of patients: The invention provides compositions and methods for predicting therapeutic responsiveness of a subject having an autoimmune disorder to an agent that inhibits signaling via LTβR based on the level of expression of IFN or a marker thereof in the subject. The invention also provides methods of treating selected subjects with... Agent: Biogen Idec Ma Inc.
20130216555 - Method of providing disease-specific binding molecules and targets: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In... Agent: University Of ZÜ Rich
20130216554 - Methods for producing enteroendocrine cells that make and secrete insulin: Methods are described for producing enteroendocrine cells that make and secrete insulin in a mammal by blocking the expression or biological activity of one or more Foxo proteins or biologically active fragments or variants thereof.... Agent:
20130216558 - Compositions and methods for treating haematological proliferative disorders of myeloid origin: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.... Agent: Cellerant Therapeutics, Inc.
20130216559 - Stromal antigen 2 (stag2) compositions and methods: Compositions and methods related to stromal antigen 2 (STAG2) and its role in diverse human cancers, including nucleic acids, polypeptides, vectors, cells and cell lines.... Agent: Georgetown University
20130216560 - Lipidomic biomarkers for identification of high-risk coronary artery disease patients: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific... Agent: Zora Biosciences Oy
20130216561 - Immunoconjugates with an intracellularly-cleavable linkage: The invention relates to therapeutic conjugates with improved ability to target various cancer cells containing a targeting moiety and a therapeutic moiety. The targeting and therapeutic moieties are linked via an acid cleavable linkage that increases therapeutic efficacy of the immunoconjugate.... Agent: Immunomedics, Inc.
20130216562 - Production of closed linear dna using a palindromic sequence: A primer for the amplification of a DNA template comprising a protelomerase target sequence, particularly for production of closed linear DNA, which primer is capable of specifically binding to a palindromic sequence within a protelomerase target sequence and priming amplification in both directions.... Agent:
20130216564 - Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use: Provided herein are compositions and methods for the treatment of cancers. The compositions comprise at least one VEGF peptide mimic, HER-2 epitope, immunogenic VEGF peptides, and HER-2 immunogenic epitopes. The peptides and epitopes may be linear, cyclized, retro-inverso, or a combination of such forms. Also provided herein are antibodies raised... Agent: The Ohio State University Research Foundation
20130216563 - Immunogenic polypeptides encoded by mage minigenes and uses thereof: The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are... Agent:
20130216565 - Vaccines based on peptides of the complement protein c5a: The present invention relates to a vaccine comprising at least one peptide consisting of amino acid sequence LRAN-ISHKDMQLGR (SEQ ID No. 1) or a peptide fragment thereof (SEQ ID No. 2-13) coupled or fused to a carrier protein comprising at least one T cell epitope, wherein said peptide fragment comprises... Agent: Affiris Ag
20130216567 - Avian group d rotavirus: The invention relates to a newly identified avian rotavirus D VP6 nucleotide sequence and uses thereof.... Agent: Novartis Ag
20130216566 - Vectors expressing sars immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using: SARS (severe acute respiratory syndrome virus, a coronavirus) immunogens, antigens, or epitopes, nucleic acid molecules encoding such immunogens, antigens, or epitopes; vectors containing such nucleic acid molecules, e.g., viral vectors such as baculovirus vectors, DNA vectors, such as DNA plasmid vectors, e.g., DNA plasmids that express a nucleic acid molecule... Agent:
20130216568 - Immunogenic proteins and compositions: The invention provides proteins and compositions for the treatment and prevention of Streptococcus agalactiae (Group B streptococcus; GBS).... Agent:
20130216569 - Vaccine: The present invention provides a polypeptide comprising the amino acid sequence as shown as SEQ ID No. 1 or a homologue or fragment thereof, a nucleic acid capable of encoding such a polypeptide and a vaccine comprising such a polypeptide/nucleic acid. The vaccine may be used for the treatment and/or... Agent: The Pirbright Institute
20130216570 - Multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia: Disclosed are immunogenic conjugates which elicit an immune response to Plasmodium proteins. In particular examples, the Plasmodium proteins include sexual stage surface proteins, circumsporozoite protein (CSP), or immunogenic portions of CSP. Also provided herein are immunogenic compositions including one or more of the disclosed immunogenic conjugates and a pharmaceutically acceptable... Agent: Services
20130216571 - Multivalent meningococcal polysaccharide-protein conjugate vaccine: The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and... Agent:
20130216572 - Immediate protection against pathogens via mva: The invention relates to methods and kits comprising poxviruses including, but not limited to modified vaccinia virus Ankara (MVA) and uses thereof to provide immediate protection against pathogens. Poxviruses including, but not limited to MVA can be delivered to a host animal just prior to or after exposure to a... Agent:
20130216573 - Influenza virus reassortment: Methods for producing reassortant viruses are provided wherein the transcription and/or translation of the hemagglutinin and/or neuraminidase genes are suppressed.... Agent: Novartis Ag
20130216574 - Kit providing multiple unmet therapeutic effects: The present invention discloses a unique kit for providing a combinational therapeutic product comprising a medical device and a pharmaceutical composition to treat mammal diseases. The medical device is to meet these unmet needs of cleansing out these harmful substances, such as viruses, multiple drug resistant bacteria, fungi, pollen, dusts,... Agent:
20130216575 - Recombinant subunit dengue virus vaccine: The present invention provides dengue virus vaccines and immunogenic compositions for administration to human subjects. The vaccine compositions of the present invention comprise recombinantly produced monomeric and/or dimeric forms of truncated dengue virus envelope glycoprotein that, when formulated together with an adjuvant and a pharmaceutically acceptable carrier, induce balanced tetravalent... Agent: Merck Sharp & Dohme Corp.
20130216576 - Pneumococcal serotype 6d: Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6D, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit→2) glucose 1 (1→3) glucose 2 (1→3) rhamnose (1→4) ribitol (5→phosphate. This new serotype may be included in... Agent: Uab Research Foundation
20130216577 - Methods and compositions for the dietary management of autoimmune disorders: The present invention describes the use of lactic acid bacteria, particularly lactic acid producing members of the genus Bacillus, in treating digestive-related immune disorders by downregulating of cytokines and by inhibiting pathogenic or deleterious microorganisms in the gastrointestinal tract. Specific formulations of Bacillus coagulans for various immune disorders are elaborated.... Agent:
20130216578 - Recombinant trypanosoma theileri parasite: The present invention relates to the field of the veterinary medicine of bovine animals. In particular the invention relates to a recombinant Trypanosoma theileri parasite, preferably comprising a heterologous nucleic acid sequence that is capable of encoding a protein for instance an antigen, a cytokine, a hormone, an antimicrobial protein,... Agent:
20130216580 - Heterologous prime boost vaccination regimen against malaria: Described are methods for inducing an immune response in a subject against an antigen from a malaria-causing parasite, preferably P. falciparum, the method comprising: (i) administering to a subject a priming composition comprising adjuvanted proteinaceous antigen-comprising circumsporozoite (CS) protein or an immunogenic part thereof from a malaria-causing parasite; (ii) administering... Agent:
20130216579 - Methods and compostitions for gene editing of a pathogen: Disclosed herein are methods and compositions for genome editing of the malarial parasite Plasmodium, and for the use of the edited Plasmodium in the development of vaccines and therapeutics.... Agent: Sangamo Biosciences, Inc.
20130216581 - Carbon nanotube compositions and methods of use thereof: Carbon nanotube (CNT)-based compositions for activating cellular immune responses are provided. The CNTs function as high surface area scaffolds for the attachment of T cell ligands and/or antigens. The CNT compositions function as artificial antigen-presenting cells (aAPCs) or as modular vaccines. The disclosed CNT aAPCs are efficient at activating T... Agent:
20130216582 - Suppression of a type 1 hypersensitivity immune response with an unrelated antigen: The present invention relates to antigens and methods for the suppression of a hypersensitivity immune response via bystander suppression with an antigen unrelated to the allergen triggering a hypersensitivity immune response such as an allergic response in an individual. Treatment regiments covering the administering the unrelated antigen to the oral... Agent: Alk-abello A/s
20130216584 - Compositions and methods for producing dendritic cells: The present invention relates to compositions and methods for producing dendritic cells and particularly to compositions and methods for producing immature dendritic cells that are immunocompetent. We describe a method of producing dendritic cells by cultivation of monocytes, characterised by at least one of: pre-treatment of a tissue culture surface... Agent: Cytovac A/s
20130216586 - Animal feed compositions and methods of using the same: Immune function of an animal can be modulated by administration of a composition that includes beta glucan. The beta glucan can be derived from Euglena, which provides a form of beta glucan that is different from other organisms, where the beta glucan is predominantly unbranched beta-(1,3)-glucan. Beta glucan can also... Agent: Algal Scientific Corporation
20130216585 - Composition and methods for quenching free radicals and modulating inflammation: Compositions and methods useful in quenching free radicals, the compositions including dihydroquercetin, vitamin C and Arabinogalactan, specifically, larch arabinogalactan, effective to enhance the immune modulating properties of Larch Arabinogalactan by quenching the free radicals that initiate a cascade of oxidative stress and inflammation.... Agent: Flavitpure, Inc.
20130216587 - Polarized scorpion venom solution and a method for making polarized scorpion venom solution: The present invention discloses a polarized dilute blue scorpion venom solution and a method for administering dilute scorpion venom solution. The polarized dilute scorpion venom solution provides treatment to various diseases and conditions such as relieving pain, improving immune-system responses, treating cancer, preventing cancer, improving quality of sleep, reducing inflammation,... Agent:
20130216591 - Composition and method for inducing antigen-specific tolerance using iga: The aim of this invention is to induce and maintain tolerance to specific antigens with IgA (Immunoglobulin A). It is theoretically likely that the major role of IgA is to induce and maintain tolerance because: it binds to epitopes(determinants) on the antigens; it does not mount destruction nor elimination of... Agent:
20130216588 - Insulin-gold nanocluster, pharmaceutical composition for reducing blood glucose comprising the same, and method for detecting adipose cells in tissue by using the same: An insulin-gold nanocluster, a pharmaceutical composition for treating diabetes comprising the insulin-gold nanocluster, and a method for detecting adipose cells in a tissue by using the insulin-gold nanocluster are provided. Herein, the insulin-gold nanocluster of the present invention comprises: a gold nanocluster, and insulin connecting to the gold nanocluster, wherein... Agent:
20130216589 - Oral vaccine for aquatic animals: The preset invention relates to an oral vaccine with an enhanced protective efficacy for aquatic animals comprising an antigen, which is expressed in Listonella sp., such as L. anguillarum, as an expression host transformed with an expression vector comprising the nucleic acid encoding the antigen, such as a viral subunit.... Agent: Rich Content Biotech Inc.
20130216592 - Particles consisting of a chitosan polyelectrolyte complex and of an anionic polysaccharide, and having improved stability: The present invention relates to positively charged particles consisting of a chitosan polyelectrolyte complex and of an anionic polymer, characterized in that the chitosan has a degree of acetylation (DA) in the range of 35 to 49% and a mean molar mass by weight (Mw) in the range of 55... Agent: Centre National De La Recherche Scientifique
20130216594 - Preparation of orodispersible films: The invention relates to a process for preparing a composition, more particularly a pharmaceutical composition for oral administration, comprising the steps of forming a suspension of at least one pharmaceutical ingredient and a solvent or solvent mixture, the at least one pharmaceutical ingredient being insoluble or poorly soluble in the... Agent: Hexal Ag
20130216593 - Systems, methods, and devices for plasmid gene transfection using polymer-modified microbubbles: Thiolated polyethylenimine (PEI) polymers can be covalently attached to lipid shell microbubbles. The PEI polymer can be modified with polyethylene glycol (PEG) chains to improve biocompatibility. The covalent attachment of the PEI polymer to the microbubble shell can result from a bond between a free sulfhydryl group (SH) of the... Agent: The Trustees Of Columbia University In The City Of New York
20130216590 - Topical antiviral formulations for prevention of transmission of hsv-2: The present invention relates to formulations of antiviral compounds, in particular [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir, PMPA), suitable for topical application, and to their use in the reduction of or prevention of acquisition and transmission of herpes simplex virus.... Agent:
20130216596 - Nanocapsules containing microemulsions: Delivery system based on polymeric nanocapsules which contain microemulsions, and their use in the preparation of pharmaceutical, cosmetic and/or alimentary compositions.... Agent: Lipotec, S.a.
20130216597 - Pigments: The present invention relates to pigments based on multicoated flake-form substrates which are distinguished by the fact that at least 8 layers [layers (A)-(H)] are on the substrate, where an SiO2 layer (=layer A) is located directly on the surface of the substrate, and to the use thereof, inter alia,... Agent: Merck Patent Gmbh
20130216595 - Soluble tablet, containing abrasive media: In order to obtain steady erosion from soluble tablets and particularly constant dispersion of contained abrasive media, the employment of magnesium oxide and transverse interlaced polyvinylpyrrolidone (PVP) in defined layers and the admixing of randomly scattered silicic acids is suggested.... Agent:
20130216598 - Antimicrobial fibre, fabric and wound dressing containing nano metal and the preparation method thereof: The present invention discloses an antimicrobial fibre, fabric and wound dressing that incorporate nano metal and the preparation method thereof. Nano metal particles are homogenously distributed within the fibre structure or surface, and, the fibre does not contain protective colloid for the prevention of agglomeration of nano metal particles. The... Agent:
20130216599 - Antimicrobial parylene coatings and methods of depositing same: Antimicrobial parylene coatings and methods for their vapor-phase deposition.... Agent: Specialty Coating Systems, Inc.
20130216600 - Antimicrobial nanoparticle conjugates: The present invention provides antimicrobial nanoparticle conjugates and an efficient method of preparing same. In particular, the invention relates to the preparation of antifungal nanoparticle conjugates comprising amphotericin B covalently immobilized to nanoparticles. The conjugates, and suspensions thereof, can be used to form antifungal coatings with particular application to medical... Agent: Matera Lda
20130216601 - Three-dimensional bone implant and method for producing same: A method for ex vivo production of a three-dimensional bone implant adapted for implantation to a patient, implants produced by such a method, and uses of such implants. The method comprises disposing differentiated osteoblasts on a matrix support comprising at least one of collagen, calcium phosphate, calcium sulfate and tricalcium... Agent: Sheltagen Medical Ltd.
20130216602 - Clonidine compounds in a biodegradable polymer: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine in a drug depot at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis,... Agent: Warsaw Orthopedic, Inc.
20130216603 - Pharmaceutical compositions and delivery devices comprising stinging cells or capsules: A pharmaceutical composition is provided. The pharmaceutical composition comprises as an active ingredient a tropane alkaloid drug or a muscarinic receptor antagonist and stinging cells or capsules.... Agent: Nanocyte (israel) Ltd.
20130216608 - Airway administration of angiogenesis inhibitors: The present invention provides methods for the local pulmonary treatment of lung metastases and/or primary lung cancer, such as squamous lung cancer and/or small cell lung cancer, using local deposition of one or more agents capable of inhibiting angiogenesis and/or an agent that acts as an active anti-cancer agent and/or... Agent: Trifoilium Aps
20130216610 - Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery: A biphasic lipid vesicle composition for treating cervical displasia by intravaginal delivery. The composition includes a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and L-methionine, the composition having an interferon alpha-2b specific activity of between about 1-10 MIU (million international units) per gram composition,... Agent: Helix Biopharma Corp.
20130216609 - Controlled release antimicrobial compositions and methods for the treatment of otic disorders: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).... Agent: Otonomy, Inc.
20130216613 - Cytomegalovirus gb antigen: The invention relates to a cytomegalovirus (CMV) gB polypeptide comprising at least a portion of a gB protein extracellular domain comprising a fusion loop 1 (FL1) domain and a fusion loop 2 (FL2) domain, wherein at least one of the FL1 and FL2 domains comprises at least one amino acid... Agent:
20130216614 - Immunogenic compositions and methods for treating nuerologic disorders: The present invention relates to methods and compositions for preventing and reducing amyloid deposition in a subject by administering to the subject a composition containing aTLR4 agonist free of endotoxin, where the composition does not contain beta amyloid.... Agent: Glaxosmithkline Biologicals S.a.
20130216606 - Liposomal formulation for ocular drug delivery: The present invention is directed to a liposomal formulation for ocular drug delivery comprising (i) liposomes comprising at least one lipid bilayer, and (ii) a prostaglandin drug and/or a prostaglandin derivative associated in the liposomes, wherein the liposomes have a mean diameter of less than 2μπι. The present invention is... Agent: Nanyang Technological University
20130216605 - Micro-rnas modulating immunity and inflammation: MicroRNAs are shown to be up- and/or down-regulated in inflammation and immune cells using a mouse model of asthma and regulatory T cells as source of RNA, respectively. Modulating the expression of these microRNAs can be effective in redirecting inflammation and immunity and hence, can be beneficial as biomarkers or... Agent: University Of South Florida
20130216604 - Polypeptide for inhibiting metastasis, uses thereof, and pharmaceutical compositions containing the same: A polypeptide for inhibiting, treating or diagnosing metastasis and an use thereof are disclosed, wherein the polypeptide is a polypeptide, a derivative polypeptide, or a mutated polypeptide of a fibronectin-binding domain of dipeptidyl peptidase IV. In addition, a pharmaceutical composition treating or diagnosing metastasis is also disclosed, which comprises the... Agent: National Cheng Kung University
20130216612 - Targeted intracellular delivery of antiviral agents: The invention relates to methods of targeted drug delivery of antiviral compounds, including, chemical agents (like nucleoside analogs or protease inhibitors) and nucleic acid based drugs (like DNA vaccines, antisense oligonucleotides, ribozymes, catalytic DNA (DNAzymes) or RNA molecules, siRNAs or plasmids encoding thereof). Furthermore, the invention relates to targeted drug... Agent:
20130216611 - Therapeutic agent for fibroid lung: Disclosed are: a substance transfer carrier to an extracellular matrix-producing cell in the lung, which comprises a retinoid; a therapeutic agent for fibroid lung, which utilized the carrier; and a preparation kit of the therapeutic agent.... Agent: Nitto Denko Corporation
20130216607 - Zwitterionic lipids: In various embodiments, the present invention provides zwitterionic lipids, encapsulants incorporating these zwitterionic lipids and such encapsulants encapsulating one or more bioactive agent. An exemplary bioactive agent is a nucleic acid. Also provided are pharmaceutical formulations of the encapsulants and methods of using such formulations to deliver a bioactive agent... Agent: The Regents Of The University Of California
20130216616 - Customized polypills having high drug loads: Patient-specific polypills, or similar drug products with potential to benefit from reduced need for bulking agent and preferably having multiple active ingredients, producible via appropriately adapted “micro-dosing” technologies not requiring fluid-jet or like substrate and solvent dependent approaches, having less need for excipient, particularly filler, so that the products may... Agent: Tailorpill Technologies, LLC
20130216615 - Pharmaceutical compositions containing dimethyl fumarate: Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl... Agent:
20130216617 - Pharmaceutical compositions of (r)-lansoprazole: The present invention relates to stable pharmaceutical compositions of (R)-lansoprazole or pharmaceutically acceptable salts thereof and process of preparing the same. The invention particularly provides pharmaceutical compositions of optically active (R)-isomer of lansoprazole with at least two functional coating layers.... Agent: Cadila Healthcare Limited
20130216618 - Soft capsule based on starch and a method and device for the production thereof: A method for producing starch soft capsules comprises the following steps: preparing a mixture comprising starch, plasticizer and water, wherein more than 50 weight percent of the starch is present in the form of particles of granular starch; shaping the mixture to form a film in a shaping process; solidifying... Agent: Innogel Ag
20130216619 - Pharmaceutical composition of atorvastatin and ezetimibe: The present invention relates to an oral pharmaceutical composition comprising: a) a core comprising atorvastatin or a pharmaceutically acceptable salt thereof and an alkalizing agent; b) an intermediate coating over the core; and c) an outer coating comprising ezetimibe.... Agent: Ranbaxy Laboratories Limited
20130216620 - Extended-release formulation for reducing the frequency of urination and method of use thereof: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount... Agent: Wellesley Pharmaceuticals, LLC
20130216621 - Bifunctional conjugate compositions and associated methods: Bifunctional conjugate compositions are provided comprising a Signal-1 moiety bound to a first polymer carrier, wherein the combined size of the Signal-1 moiety and the first polymer carrier is about 1 nanometer to about 500 nanometers; and a Signal-2 moiety bound to a second polymer carrier, wherein the combined size... Agent:
20130216623 - Apparatus and formulations for suprachoridal drug delivery: Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space... Agent: Iscience Interventional Corporation
20130216622 - Modified beta-lactamases and methods and uses related thereto: u
20130216624 - Sustained-release pellets containing tacrolimus as an active ingredient: The present invention relates to sustained-release pellets containing tacrolimus as an active ingredient. The sustained-release pellets of the present invention have multiple layers of hydroxypropyl methylcellulose, and may control the release of drugs by specific contents of hydroxypropyl methylcellulose and Surelease™, thus rendering the dissolution rate thereof uniform and stable,... Agent:
20130216625 - Treatment of insulin resistance or diseases associated with insulin resistance: The present invention relates to the use of a substance with the core structure of formula (I), or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the manufacture of a composition for the treatment of insulin resistance or diseases associated with insulin resistance, preferably in human subject in a daily... Agent: Stevia Aps
20130216626 - Platelet-rich plasma compositions: The present invention relates to a method of treating functional disability and/or pain associated with joints, tendons or connective tissue diseases, disorders or injuries comprising oral administration of a composition comprising heterologous platelet-rich plasma. The invention also relates to pharmaceutical compositions and nutritional compositions comprising heterologous platelet-rich plasma and uses... Agent: Quimera Ingenieria Biomedica, S.l.
20130216628 - Compositions of hypochlorous acid (hoci) and methods of manufacture thereof: The invention generally relates to compositions of hypochlorous acid (HOCl) and methods of manufacture thereof. In certain aspects, the invention provides air-free compositions of HOCl. In other aspects, the invention provides methods of making HOCl that involve mixing together in water in an air-free environment, a compound that generates a... Agent:
20130216627 - Portable oxygen enrichment device and method of use: Lightweight, small, portable devices and methods are disclosed that provide oxygen-enriched air using an ultra rapid adsorption cycle based on advanced molecular sieve materials.... Agent:
20130216629 - Bio-material composition and method for spinal fusion: The present invention relates to a material and method for providing spinal fusion. One preferred method comprises: accessing the intervertebral space defined between adjacent vertebrae; mixing magnesia, potassium biphosphate, and a calcium phosphate with an aqueous solution forming an activated spinal fusion slurry (ASFS); applying an effective amount of the... Agent:
20130216630 - Biomaterials for use in methods of bone replacement therapy: This invention relates to biomaterials, said biomaterials for use in methods to control and/or induce bone growth. Particularly, the invention relates to macroporous calcium phosphate biomaterials pre-loaded with certain amounts of osteoclastic activity inhibitors for use in methods to control and/or induce bone growth in primates.... Agent: Medical Research Council Of South Africa
20130216631 - Targeted performance of hypohalite compositions thereof: This invention relates to extend the benefits of using hypochlorite compounds such as sodium hypochlorite to clean and disinfect articles while reducing or eliminating the side effects of treating an article with a strong oxidant material. The invention relates to a single step process involving mixing of precursor compositions of... Agent: The Clorox Company
20130216633 - Articles and compositions for enhancing sports scores: Methods and compositions for enhancing the score of an individual in a sport activity are disclosed.... Agent:
20130216632 - Method for controlling hair growth, method for selecting or evaluating hair growth control agent, and hair growth suppression agent: The present invention provides a method for controlling hair growth, a method for selecting or evaluating a hair growth control agent, and a hair growth suppression agent. The present invention provides a method for selecting or evaluating a hair growth control agent, including the steps of administering a test substance... Agent: Kao Corporation
20130216634 - Herbal supplement prepared from pelargonium citronellum: An extraction method for extracts of Pelargonium citronellum with improved methylhexaneamine content is provided. The method involves separating the oil phase from the aqueous phase; concentrating the aqueous phase; purifying the oil phase; and recombining the resulting material. Additionally, extracts of Pelargonium citronellum prepared by the extraction method are provided.... Agent:
20130216635 - Topical skin care formulations comprising plant extracts: Disclosed are compositions and corresponding methods of their use that include an extract from Quassia undulata, Biophytum petersianum, Allophylus africanus, Buchanania reticulata, Melanorrhoea laccifera, Canthium dicoccum, or Aporosa tetrapleura, or any combination thereof, or at least 1, 2, 3, 4, 5, 6, or all 7 of the extracts.... Agent: Mary Kay Inc.
20130216636 - Topical skin care formulations comprising jaboticaba and cashew fruit pulps and extracts thereof: Disclosed are compositions and corresponding methods of their use that include jaboticaba fruit pulp and/or cashew fruit pulp or extracts thereof.... Agent: Mary Kay Inc.
20130216637 - Induction of a physiological dispersion response in bacterial cells in a biofilm: The present invention is directed to a compound which induces a physiological dispersion response in bacterial cells in a biofilm. The present invention is also directed to compositions containing this compound, methods of isolating the compound, and uses thereof.... Agent: Research Foundation Of State University Of New York08/15/2013 > 240 patent applications in 118 patent subcategories. inventions list
20130209355 - Antibodies against human cd38: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.... Agent: Genmab A/s
20130209356 - Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy: Described herein are compositions and methods of use of radionuclide-antibody conjugates (for RAIT) and drug-antibody conjugates (ADC). The combination of RAIT and ADC was more efficacious than either RAIT alone, ADC alone, or the sum of effects of RAIT and ADC. The unexpected synergy resulted in decreased tumor growth rate... Agent: Immunomedics, Inc.
20130209357 - Molecular probes for imaging myelin: A molecular probe for use in the detection of myelin in a subject includes a compound having the general formula selected from the group consisting of: formula (I), and pharmaceutically acceptable salts thereof.... Agent: Case Western Reserve University
20130209358 - Radiotracer compositions: The present invention relates to [18F]-fluciclatide radiopharmaceutical compositions, which are stabilised with a radioprotectant. Also described are methods for the preparation of the radiopharmaceutical compositions, including automated synthesizer methods and cassettes for use in such methods. The invention also includes methods of imaging the mammalian body using the radiopharmaceutical compositions.... Agent: Ge Healthcare Limited
20130209359 - Small peptides specifically bind to colorectal cancers: Cancers are extremely heterogeneous in terms of the frequency and types of mutations present in different malignant tumors. Thus, it is likely that uniform clinical treatment is not optimal for all patients, and that the development of individualized therapeutic regimens may be beneficial. Multiple, unique small peptides bind to cell... Agent: The Johns Hopkins University
20130209360 - Compositions and methods for imaging: The present disclosure provides compositions for in vivo imaging of hydrogen peroxide; and methods for detecting hydrogen peroxide in vivo. The compositions and methods find use in various diagnostic applications, which are also provided.... Agent: The Regents Of The University Of California
20130209361 - Process for producing radiohalogenated bioconjugates and products thereof: The present invention relates to a new synthetic process in which an alkyne and an azide react to form a radioisotopic bioconjugate construct. The reaction is particularly useful for producing compounds for use in imaging and radiotherapy applications. The present invention also provides bioconjugate labels and further relates to the... Agent: Ucl Business PLC
20130209362 - 2-alkoxy-11-hydroxyaporphine derivatives and uses thereof: The invention features 2-alkoxy-11-hydroxyaporphine derivatives that selectively bind D2high receptors. The compounds are useful for imaging D2high receptors and for the treatment of diseases, such as Parkinson's disease, sexual dysfunction, and depressive disorders.... Agent: The Mclean Hospital Corporation
20130209363 - Method for production of f-18 labeled amyloid beta ligands: This invention relates to methods, which provide access to [F-18]fluoropegylated (aryl/heteroaryl vinyl)-phenyl methyl amine derivatives.... Agent: Piramal Imaging Sa
20130209365 - Anti-c-met antibody and methods of use thereof: Antibodies that bind to c-Met are provided herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies and diagnostics. In certain embodiments, antibodies bind mammalian cell surface antigen (e.g., cancer cell surface antigen). The antibodies can also be endocytosed upon binding to cells. Cells... Agent: Academia Sinica
20130209364 - Anti-viral azide containing compounds: Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as... Agent: Life Technologies Corporation
20130209366 - Glutathione-lanthionine compounds and methods related thereto: The present invention concerns glutathione-lanthionine compounds, the process of preparing such compounds, and their use. The invention also concerns methods of using the compounds and derivatives and combinations of these compounds in the treatment and/or prevention diseases, including diseases affecting the central nervous system.... Agent: University Of Toledo
20130209369 - Nanoparticles based on gadoliium coordination polymers as highly sensitive t1 mri contrast agents: An agent for imaging of a biological system or delivering drugs to a biological system including one or more nanoparticles formed of at least one gadolinium coordination polymer.... Agent: Case Western Reserved University
20130209370 - Injectable void filler for soft tissue augmentation: The present invention teaches a micro-porous injectable, soft elastic, fully resorbable fibrin-based composition for use as a soft tissue lumen and void filler. The composition of the present application exhibits physical characteristics, such as mechanical properties, typically seen in elastomers and mechanical stability, which is superior to fibrin alone. A... Agent: Baxter Healthcare S.a.
20130209368 - Near infrared fluorescent particles and uses thereof: The present invention provides particles comprising either a water-soluble polymer or a phospholipid, wherein at least one near infrared (NIR) fluorescent probe and optionally at least one active agent such as a targeting moiety, capable of selectively recognizing a particular cellular marker, are non-covalently bound to the outer surface of... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd
20130209367 - Particle and contrast agent having the particle: There is provided an ICG-loaded polymer nanoparticle that is dynamically stable, prevents the leakage of contained ICG and the resulting discoloration, and has a high molar absorbance coefficient. The particle contains a hydrophilic dye having a sulfonate group and a hydrophobic polymer, and the particle further contains at least one... Agent: Canon Kabushiki Kaisha
20130209371 - Germ solve candle: A candle is provided which includes a unique blend of ingredients that been formulated to reduce a broad spectrum of germs in the area of the candle of the present invention, as well as weakening the spread of infectious contaminates imposed by coughing and sneezing, in the area surrounding the... Agent:
20130209372 - Lyophilized biopesticide effervescent granule and production method thereof: The present invention relates to a granulated lyophilized effervescent biopesticide granule and production method (10) thereof. By means of the inventive method (10), an economical biopesticide with high applicability is obtained, which does not have harmful effect on environment and human health, and is provided in the form of a... Agent: Yeditepe Universitesi
20130209374 - Probiotic composition for oral health: The present invention provides a composition comprising an effective amount of Lactobacillus plantarum CECT 7481 and Lactobacillus brevis CECT 7480. Said strains exhibit various functional properties that make them suitable for their use in the improvement of oral health. Such properties include not only good antagonistic properties against oral pathogens,... Agent:
20130209373 - Tube feed packages and methods for using same: Nutritional compositions that mimic whole foods and methods of using the nutritional compositions are provided. The nutritional compositions may include an increased number and variety of fruits and vegetables, an increased variety of macronutrient sources and an increased amount of other components that are found in whole foods. The nutritional... Agent: Nestec S.a.
20130209375 - Oral care composition comprising dissolved tin and fluoride: An oral care composition comprising a liquid phase containing 30% to 90%, preferably 30% to 80% by weight, based on the liquid phase, of water; dissolved tin; 200 to 2000 ppm fluoride ions, based on the oral composition; and 5 to 60% by weight, based on the oral care composition,... Agent: Gaba International Holding Ag
20130209376 - Oral care compositions: Oral care compositions containing an oral care ingredient and a thickening agent, wherein the thickening agent comprises a strongly swellable, lightly to moderately crosslinked polyvinyl pyrrolidone. The polyvinyl pyrrolidone thickening agent is characterized by an aqueous gel volume of about 15 to 150 ml/g and a Brookfield viscosity of at... Agent: Ips Investments Inc.
20130209377 - Synthesis of amorphous calcium phosphate or poorly crystalline calcium phosphate powders by using ca metal: The present invention relates to the synthesis of bioceramics, in particular, of amorphous or cryptocrystalline calcium phosphates.... Agent:
20130209379 - Lip cosmetic formulations: Cosmetic formulations suitable for application to the lips are described herein. The lip cosmetic formulations can contain at least caffeine, extract of Hoodia gordinii and extract of green tea. The lip cosmetic formulations can also contain a bioavailable chromium source and/or L-carnitine. Optionally, the lip cosmetic formulations can also contain... Agent: Pacific Shore Holdings, Inc
20130209380 - Moisturizing composition with spf 30: Described is a composition for topical application in the form of a moisturizing composition including zinc gluconate and at least one UVA/UVB sunscreen as a moisturizering ingredient, and the use thereof as a cosmetic or a pharmaceutical product. The composition is intended for use in the treatment of acne.... Agent: Galderma S.a.
20130209378 - Skin conditioning and lubricating creme, and method of making and using same: A cosmetic agent that takes the place of powdered talc is described herein. The present cosmetic agent is a skin conditioning and lubricating crème comprising talc; at least one volatile silicone fluid; at least one structuring component; and at least one emollient. The inventive composition provides skin conditioning and lubrication... Agent: The Dial Corporation
20130209381 - Topical application of ivermectin for the treatment of dermatological conditions/afflictions: Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective... Agent: Galderma S.a.
20130209382 - Skin care compositions: Described are skin care compositions comprising an aqueous dispersion comprising a metallocene catalyzed polyolefin, an ethylene acrylic acid copolymer, or a combination thereof.... Agent: Union Carbide Chemicals & Plastics Technology LLC
20130209383 - Series of skin whitening (lightening) compounds: The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the... Agent: Unigen, Inc.
20130209384 - Treatment and composition for achieving skin anti-aging benefits by corneum protease activation: Disclosed is a method of brightening skin or evening out the tone of skin comprising topically applying to skin in need thereof a composition comprising a chemically compatible combination of one or more surfactants and at least one chelating agent, ascorbic acid or a derivative thereof, algae extract, and kelp... Agent: Mary Kay, Inc
20130209385 - Cosmetic composition with watertight fragrance: The present invention refers to a cosmetic composition which, in particular, enables the perfume component resist wash off by water and sweat and to remain fixed on the skin for a long time watertightly. The cosmetic composition comprises fragrance and a fragrance-fixing complex consisting of 0.01-10% by weight of a... Agent: Coty B.v.
20130209386 - New uses: An antibacterial or anti-acne formulation containing (a) tropone or a substituted tropone and (b) a metal or metal salt selected from copper, copper salts, bismuth, bismuth salts, silver, silver salts, and mixtures thereof, for use in the treatment of either acne or body odour. The substituted tropone may be for... Agent: Evocutis PLC
20130209387 - Antiperspirant active compositions and manufacture thereof: An antiperspirant active composition comprising an aluminum salt, the aluminum salt (i) having an aluminum to chloride molar ratio of 0.3:1 to 3:1; and (ii) exhibiting an 27Al NMR spectrum with a species distribution including at least 90% A130 polyhydroxyoxoaluminum cation as the predominant species detectable by 27Al NMR within... Agent: Colgate-palmolive Company
20130209388 - Conditioning composition additive for providing immediate and long lasting benefits to keratin substrates: The presently disclosed and claimed inventive concept(s) relates to a conditioning composition additive for use on keratin substrates in order to provide immediate as well as long lasting benefits to the keratin substrate in conditioning systems, such as leave-on and rinse off conditioners, for hair and skin, or for imparting... Agent:
20130209389 - Loaded gel particles for anti-fouling compositions: The present invention provides polishing control components for anti-fouling paints for vessels which comprise rosin or other water-degradable polymers entrapped in gel particles, such as aerogel or aeromosil particles.... Agent: Fibac Aps
20130209390 - Process for producing drug-block copolymer composite and pharmaceutical preparation containing same: [Solution] Provided is a method for producing a drug-block copolymer composite, the method comprising: mixing a poorly water-soluble drug and a block copolymer including a hydrophilic segment and a hydrophobic segment bonded together, in one or more non-aqueous solvents; optionally heating the mixture as necessary; and spray-drying the resulting mixture... Agent: Nippon Kayaku Kabushiki Kaisha
20130209391 - Functionalized polymer compositions: The invention relates to functionalized polymers including homopolymers and copolymers and their uses in industrial applications and in agricultural applications. In particular, the homopolymers and copolymers may be, for example, used in polymer blends, used as nutritives and in feed compositions, and used in combination with a pharmaceutical or nutritive.... Agent: Novus International Inc.
20130209392 - Heteroatom containing cyclic dimers: The present invention provides cyclic dimers of alpha acids and polymers derived therefrom. Also provided are processes for preparing and methods of using the cyclic dimers and the polymers derived from the cyclic dimers.... Agent: Novus International Inc.
20130209393 - Therapeutic peptide compositions and methods: Therapeutic peptide compositions comprise a therapeutic peptide, such as insulin, together with an alkyl N,N-disubstituted amino acetate, such as dodecyl 2-(N,N-dimethylamino) propionate.... Agent: Nexmed Holdings, Inc.
20130209396 - Chimeric il-1 receptor type i agonists and antagonists: Featured herein are non-naturally occurring cytokine domains that can be used, inter alia, to modulate cellular signalling responsive to interleukin-1 receptor I (IL-1 RI), to treat disorders, and to detect and/or bind to cellular receptors, as well as other agents. Exemplary cytokine domains can contain amino acid residues from at... Agent: Eleven Biotherapeutics, Inc.
20130209398 - Conditioned cell culture medium compositions and methods of use: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned,... Agent: Allergan, Inc.
20130209397 - Heterocyclic antiviral compounds: Compounds having the formula (I) wherein R1, R2, R3 and X are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.... Agent: Roche Palo Alto LLC
20130209394 - Mn/ca ix and egfr pathway inhibition: The invention is based upon the discovery that the EGFR pathway can stimulate a previously unknown tumorigenic function of CA IX, via phosphorylation of the sole tyrosine residue present in CA IX's intracellular domain. EGFR-phosphorylated CA IX then interacts with the p85 subunit of PI3K to activate Akt, which in... Agent:
20130209395 - Nucleic acid molecule encoding hepatitis b virus core protein and surface antigen protein and vaccine comprising the same: Provided herein are nucleic acid sequences encoding hepatitis B virus (HBV) core proteins, surface antigen proteins, fragments and combinations thereof as well as genetic constructs/vectors and vaccines that express said protein sequences. These vaccines are able to induce an immune response peripherally and in the liver by recruiting both cellular... Agent:
20130209399 - Anti-virus therapy for respiratory diseases: The present invention provides the use of IFN-β, an agent that increases the expression of IFN-β, or a polynucleotide which is capable of expressing IFN-β or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive... Agent:
20130209401 - Compositions and methods for inhibiting entry of a hepatic virus: The present invention embraces Niemann-Pick C1-like 1 protein antagonists and agents that inhibit hepatic virus infection for use in the prevention and treatment of a hepatic virus infection.... Agent: The Board Of Trustees Of Th University Of Illinois
20130209400 - Pyrazole derivatives as jak inhibitors: New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).... Agent:
20130209402 - Human papillomavirus e7 antigen compositions and uses thereof: The present invention relates to human papillomavirus E7 antigen compounds and compositions for treating human papillomavirus infection and associated conditions. The invention provides, in part, polypeptide and nucleic acid molecules including sequences substantially identical to the sequences of two or more human papillomavirus (HPV) E7 antigens, where the E7 antigens... Agent: British Columbia Cancer Agency Branch
20130209403 - Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection: The invention relates to Phospholipase A2 (hereinafter also referred to as PLA2) inhibitors for use in the treatment or prevention of flavivirus infection, in particular an infection with a flavivirus of the genus Flavi or the genus Hepaci. The invention also provides a pharmaceutical formulation for use in the treatment... Agent: Twincore Zentrum Fuer Experimentelle And Klinische Infektionsforschung Gmbh
20130209404 - Treatment of ibd and ibs using both probiotic bacteria and fermented cereal as treatment effectors: The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be... Agent: Nordisk Rebalance A/s
20130209408 - Bacteriophage-containing therapeutic agents: The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a... Agent: Biocontrol Limited
20130209409 - Chimeric adenoviruses for use in cancer treatment: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.... Agent:
20130209410 - Expression vector for cholesterol 24 -hydrolase in therapy of huntington's disease: The present invention relates to a vector for use in the treatment of Huntington's disease, which vector comprises a cholesterol 24-hydroxylase encoding nucleic acid.... Agent: UniversitÉ Evry Val D'essonne
20130209407 - Live microbial microbicides: The present invention relates, e.g., to a commensal bacterium which can colonize the genitourinary and/or gastrointestinal mucosa, and which, under suitable conditions, secretes a heterologous antimicrobial polypeptide, wherein the secreted antimicrobial polypeptide is effective to inhibit infectivity by, or a pathogenic activity of, a pathogen. In a most preferred embodiment,... Agent: The Usa, As Represented By The Secretary, Department Of Health And Human Services
20130209405 - Recombinant bacterium to decrease tumor growth: A recombinant bacterium capable of reducing tumor growth is provided, wherein said recombinant bacterium is capable of: a. increased expression of a nucleic acid encoding a chemoreceptor that directs chemotaxis towards tumors, b. accumulation in a quiescent tumor, c. hyper-invasion of a tumor, d. reduced fitness in normal tissue, e.... Agent:
20130209406 - Recombinant rna viruses and uses thereof: Described herein are modified RNA virus gene segments and nucleic acids encoding modified RNA virus gene segments. Also described herein are recombinant RNA viruses comprising modified RNA virus gene segments and the use of such recombinant RNA viruses for the prevention and treatment of disease.... Agent:
20130209427 - Hair follicle neogenesis: This invention provides a skin substitute comprising epithelial cells and modified mesenchymal cells, wherein the modified mesenchymal cells have decreased TSC1/TSC2 function, increased mTORCI function, and/or decreased mTORC2 function compared to wild type mesenchymal cells, and methods for using the same. This invention also provides a method for transplanting cells... Agent:
20130209426 - Method for genome modification: The present disclosure includes methods for manipulation of the genome, to products obtained or obtainable from such methods, and uses of these products.... Agent: Genome Research Limited
20130209428 - Method of inducing differentiation of bone marrow stromal cells to neural precursor cells, neural precursor cells, and uses thereof: There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells in vitro, which... Agent: Sanbio, Inc.
20130209412 - Fermented food and method for producing same: The purpose of the present invention is to provide a technique whereby the flavor of products such as fermented milk that use the Bifidobacterium bacteria can be improved while maintaining the effect of the Rubus suavissimus S. Lee for improving the viability of the Bifidobacterium bacteria. Provided is a fermented... Agent: Kabushiki Kaisha Yakult Honsha
20130209411 - Lactocepins for use in the treatment of ip-10-mediated inflammatory diseases: The invention relates to lactocepins and/or a functionally active fragment thereof for use in the prophylaxis and/or the treatment of a disease and to one or more lactocepin(s) and/or one or more functionally active fragment(s) thereof for use in the prophylaxis and/or treatment of IP-10-mediated inflammatory diseases.... Agent: Technische Universitat Munchen
20130209429 - Modulation of tissue fatty acid composition of a host by human gut bacteria: The current invention provides use of a CLA-producing bacterium for the in vivo conversion in the gut of polyunsaturated fatty acids to CLA. The CLA-producing bacterium is selected from one or more of the group consisting of propionibacteria, lactobacilli, lactococci and streptococci, and bifidobacteria.... Agent: Teagasc - The Agriculture And Food Development Authority
20130209413 - Use of parvovirus for eliminating cancer stem cells (cscs): Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.... Agent: Deutsches Krebsforschungszentrum
20130209422 - \"pharmaceutical composition comprising stem cells treated with nod2 agonist or culture thereof for prevention and treatment of immune disorders and inflammatory diseases\": The present invention relates to a pharmaceutical composition for the prevention or treatment of immune disorders and inflammatory diseases, comprising stem cells that are generated by culturing stem cells expression Nucleotide-binding Oligomerization Domain protein 2 (NOD2) with a NOD2 agonist or a culture thereof. More particularly, the present invention relates... Agent: Kang Stem Holdings Co., Ltd
20130209424 - Compositions for promoting hematopoietic stem cell growth: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and... Agent: Children's Medical Center Corporation
20130209425 - Encapsulation of pancreatic cells derived from human pluripotent stem cells: The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation.... Agent: Viacyte, Inc.
20130209414 - Expansion of stem/progenitor cells by inhibition of enzymatic reactions catalyzed by the sir2 family of enzymes: Provided are ex vivo and in vivo methods of expanding renewable stem cells using agents capable of down-regulating Sir2 protein activity and/or expression, expanded populations of renewable stem cells, and uses thereof.... Agent: Gamida Cell Ltd.
20130209417 - Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase: The present invention relates to the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and/or isolating adult multipotential cells. The present invention also relates to cell populations enriched by methods of the present invention and therapeutic uses of these cells.... Agent: Mesoblast, Inc.
20130209418 - Methods and composition related to brown adipose-like cells: Methods and therapeutics are provided for treating diseases, including metabolic diseases and other weight-related disorders. Generally, methods for making brown adipose-like including culturing a population of artery-derived cells in adipogenic induction medium for a period of time and under conditions sufficient to increase expression of at least one adipocyte marker... Agent: Johnson & Johnson Regenerative Therapeutics, LLC
20130209416 - Methods and compositions for preparing cardiomyocytes from stem cells and uses thereof: The present invention discloses novel compositions and methods for enhancing cardiac differentiation efficiency of stem cells or promoting ventricular and atrial cardiomyocytes formation from stem cells. The present invention also discloses the atrial and ventricular cardiomyocytes formed from the stem cells, and the uses of the cardiomyocytes for repairing cardiac... Agent: Institute Of Biophysics, Chinese Academy Of Scienc
20130209423 - Methods for promoting hematopoietic reconstitution: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and... Agent: Children's Medical Center Corporation
20130209419 - Methods of engraftment: Methods and compositions for improving the engraftment of stem cells are described. The method involves administering an effective amount of hemoglobin. The methods and compositions are useful in stimulating hematopoiesis and may be used to boost human hematopoietic re-engraftment for use in transplant recipients or in patients with bone marrow... Agent: Therapure Biopharma Inc.
20130209420 - Mixed cell populations for tissue repair and separation technique for cell processing: The present invention provides a fluid exchange cell culture technique and tissue repair cells (TRCs) made by these methods, as well as methods using these cells. The method includes a new wash step which increases the tissue repair properties of the TRCs of the invention. This wash step allows for... Agent: Aastrom Biosciences, Inc.
20130209415 - Purified compositions of cardiovascular progenitor cells: Composition and methods are provided for the prospective enrichment of human cardiovascular progenitor cells, which can be differentiated into cardiomyocytes, from in vitro cultures of stem cells. The stem cells are cultured in conditions permissive for differentiation into cardiovascular progenitor cells, and cardiovascular progenitor cells are sorted for expression of... Agent: The Board Of Trustees Of The Leland Stanford Junior University
20130209430 - Methods for regulation of stem cells: Methods are provided for increasing stem cells, hematopoietic progenitor/stem cells, mesenchymal progenitor/stem cells, mesodermal progenitor/stem cells, muscle progenitor/stem cells, or neural progenitor/stem cells in vivo in a mammalian subject. Methods are also provided for treating an immune related disease, a mesenchymal/mesoderm degenerative disease, or a neurodegenerative disease in a mammalian... Agent: University Of Washington
20130209431 - Isolation and culture of erythroid progenitor cells: Disclosed herein are methods of isolating erythroid progenitor cells from a source of human hematopoietic cells and methods of culturing the isolated erythroid progenitor cells in vitro to produce clinically relevant quantities of erythrocytes.... Agent: New York Blood Center, Inc.
20130209433 - Modulation of amino acid metabolism in the hypothalamus: Methods for reducing peripheral blood glucose levels, food intake, glucose production, gluconeogenesis, triglyceride levels, and low density lipoprotein (VLDL) levels in mammals are provided. Also provided are methods of increasing glucose production and food intake in mammals. Further provided are methods of treating a disorder selected from the group consisting... Agent: Albert Einstein College Of Medicine Of Yeshiva University
20130209432 - Product and process for liquefaction of mucus or sputum: Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system.... Agent: National Jewish Health
20130209434 - Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.... Agent: Atyr Pharma, Inc.
20130209435 - Methods for predicting risk of stroke: The invention provides methods of determining risk for stroke in a patient, as well as methods of determining a subject's need for anti-coagulation therapy. In exemplary embodiments, the method comprises measuring a level of derivatives of reactive oxygen metabolites (DROMs) in a biological sample obtained from the subject, wherein an... Agent: The Board Of Trustees Of The University Of Illinois
20130209437 - I-crei homing endonuclease variants having novel cleavage specificity and use thereof: A method for engineering I-CreI homing endonuclease variants able to cleave mutant I-CreI sites having variation in positions ±8 to ±10. A I-CreI homing endonuclease variant obtainable by said method, a vector encoding said variant, a cell, an animal or a plant modified by said vector. Use of said I-CreI... Agent: Cellectis
20130209439 - Inhibitors of pde4 binding to hsp20: The present invention provides methods and materials for use in increasing HSP20 activation in a biological system, for example by increasing phosphorylation of Ser16 of HSP20. In one aspect, the invention provides a method for increasing HSP20 activation in a biological system, comprising contacting the system with an antagonist capable... Agent: The University Court Of The University Of Glasgow
20130209436 - Lysosomal storage disease enzymes: The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of... Agent: Synageva Biopharma Corp.
20130209440 - Methods and compositions for the treatment of insulin-associated medical conditions: A method of increasing insulin content in a pancreatic beta cell is disclosed. The method comprising expressing in the pancreatic beta cell an exogenous polynucleotide encoding at least one microRNA or a precursor thereof, wherein the microRNA is selected from the group consisting of miR-15, miR-16, miR-24, miR-26, miR-27, miR-29,... Agent: Yeda Research And Development Co. Ltd.
20130209438 - Prostatic acid phosphatase for the treatment of pain: Methods and compositions are provided for the treatment of pain and cystic fibrosis. The methods include administering to an animal a composition or a pharmaceutical formulation comprising a therapeutically effective amount of a Prostatic Acid Phosphatase (“PAP”) polypeptide, or an active variant, fragment or derivative thereof, or a therapeutically effective... Agent: The University Of North Carolina At Chapel Hill
20130209442 - Wound cleaning chemical composition and method for manufacturing: A wound cleaning chemical composition that includes an unpurified saline solution in the range of 1.5 to 3 grams per cc, a lactoferrin solution in the range of 0.001% to 1.5% by volume, an ethanol solution in the range of 0.05% to 1.5% by volume, a sodium bicarbonate solution in... Agent:
20130209448 - Carrier nanoparticles and related compositions, methods and systems: Carrier nanoparticles comprising a polymer containing a polyol coupled to a polymer containing a boronic acid, configured to present the polymer containing a boronic acid to an environment external to the nanoparticle and related compositions, methods and systems.... Agent: California Institute Of Technology
20130209446 - Copy number variant-dependent genes as diagnostic tools, predictive biomarkers and therapeutic targets: Provided herein are methods of diagnosing and/or treating malignant or pre-malignant conditions in a subject. Overexpression of copy number variant-dependent genes, e.g., genes encoding a cell surface receptor, resulting from copy number changes compared to control is diagnostic of the condition, such as multiple myeloma or monoclonal gammopathy of undetermined... Agent: Board Of Trustees Of The University Of Arkansas
20130209443 - Method for treating oncological diseases: A method to treat solid tumors and other oncological diseases consists of parenterally injecting an agent which destroy's blood's extracellular DNA into the systemic blood circulation of a cancer patient to slow down malignant. The agent is embodied in the form of a DNAse enzyme and, more particularly, as a... Agent:
20130209447 - Methods and kits for predicting the risk of diabetes associated complications using genetic markers and arrays: A method for diagnosing a genetic predisposition in a subject for diseases, disorders or conditions including a diabetic kidney complication such as kidney disease of type 2 diabetes or type 1 diabetes, end stage renal disease (ESRD) due to type 2 diabetes, ESRD due to hypertension in type 2 diabetes,... Agent: The Chinese University Of Hong Kong
20130209444 - Non-anticoagulant sulfated or sulfonated polysaccharides: The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation,... Agent: Baxter International Inc.
20130209445 - Optimized fc variants: The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.... Agent: Xencor, Inc.
20130209454 - Anti-hiv antibodies having increased potency and breadth: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) antibodies having improved potency and breadth.... Agent: California Institute Of Technology
20130209449 - Anti-psgl-1 antibodies and uses thereof: Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating... Agent: Abgenomics Cooperatief U.a.
20130209450 - Compositions and methods for treating glioblastoma gbm: Methods of treating a malignant glioma in a subject are disclosed. The methods comprise administering to the subject a therapeutically effective amount of a viral vector comprising: (i) a first polynucleotide sequence encoding a Fas-chimera (Fas-c), said first polynucleotide sequence comprising SEQ ID NOs: 2 and 3; and (ii) a... Agent:
20130209458 - Fab-glycosylated antibodies: The present invention pertains to a method for controlling the circulation half-life of antibodies by adjusting the amount of sialic acid in the carbohydrates attached to the Fab part of the antibodies. Furthermore, the present invention provides antibodies having an increased circulation half-life.... Agent: Glycotope Gmbh
20130209452 - Gene defects and mutant alk kinase in human solid tumors: Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have been identified herein in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion... Agent: Cell Signaling Technology, Inc.
20130209455 - Humanized anti-cdcp1 antibodies: The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.... Agent: Roche Glycart Ag
20130209460 - Methods and kits used in identifying glioblastoma: The invention encompasses methods and kits used in the identification of invasive glioblastoma based upon the expression of TROY. The methods and kits also allow prediction of disease outcome as well as therapeutic outcome.... Agent: The Translational Genomics Research Institute
20130209457 - Optimized fc variants: The present invention relates to a variant Fc region comprising an amino acid substitution at position 238 of the Fc region as compared to a human parent Fc region, wherein the variant Fc region comprises a 238D substitution, wherein the variant Fc region binds FcγRIIb with increased binding affinity compared... Agent: Xencor, Inc.
20130209456 - Subtypes of humanized antibody against interleukin-6 receptor: An antibody subtype (1) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which one C-terminal of the heavy chain is Pro-NH2 (447), and an antibody subtype (2) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which... Agent: Chugai Seiyaku Kabushiki Kaisha
20130209459 - Treatment with anti-erbb2 antibodies: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or... Agent: Genentech, Inc.
20130209451 - Treatments for cancer: The present invention provides methods for reducing tumor survival, expansion, and metastasis. In particular, the invention provides methods for reducing pancreatic tumor survival, expansion, and metastasis. The invention also provides agents for use in the methods, particularly agents that reduce the level or activity of connective tissue growth factor (CTGF),... Agent: Fibrogen, Inc.
20130209461 - Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members: alone or in combination with an EGFR modulator, to a warm-blooded animal in need thereof; combinations comprising the compound of formula (I) and an EGFR modulator for the treatment of said diseases; and pharmaceutical preparations for the treatment of said diseases comprising the compound of formula (I), alone or in... Agent: Novartis Ag
20130209453 - Use of tau to monitor immunotherapy: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.... Agent: Janssen Alzheimer Immunotherapy
20130209462 - Cerberus/coco derivatives and uses thereof: The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives.... Agent: Acceleron Pharma, Inc.
20130209466 - Compositions and methods for producing bioactive fusion proteins: Disclosed is a composition of matter involving a recombinant fusion protein comprising a a pharmacologically active protein partner, and a small pharmacologically inactive protein domain partner of human origin, such as but not limited to, a 10th fibronectin III domain, a SH3 domain, a SH2 domain, a CH2 domain of... Agent: Amgen Inc.
20130209463 - Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders: This invention relates to a protein C1ORF32 and its variants and fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development, including but not limited to as immune modulators and for immune therapy, including for autoimmune disorders.... Agent: Compugen Ltd.
20130209464 - Polypeptides having antiviral activity and methods for use thereof: A polypeptide is provided that comprises an actinohivin variant polypeptide having an amino acid sequence selected from SEQ ID NOS: 4-12. The polypeptide can be provided as part of a fusion protein that includes the actinohivin variant polypeptide and either a fragment crystallizable domain of an antibody (Fc), a fragment... Agent: University Of Louisville Research Foundation, Inc
20130209465 - Stabilized aqueous antibody compositions: The present invention provides an aqueous solution comprising an antibody protein at a concentration of at least about 10 mg/m L and a stabilizing amount of polyethyleneimine.... Agent: Arecor Ltd.
20130209467 - Method of treating fibroproliferative disorders: Materials and Methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides,... Agent: Zymogenetics, Inc.
20130209470 - Antibodies that bind both il-17a and il-17f and methods of using the same: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same... Agent: Zymogenetics, Inc.
20130209469 - Antibodies that bind il-4 and/or il-13 and their uses: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma... Agent: Sanofi
20130209468 - Use of mif and mif pathway agonists: The present invention relates to novel methods and compositions for increasing AMPK activity and glucose uptake comprising administering a macrophage migration inhibitory factor (MIF) pathway agonist in a subject in need thereof. The invention also relates to methods for selecting a subject for treatment with an agonist of MIF, identifying... Agent: Yale University
20130209471 - Dc-stamp antibodies: Provided herein are antibodies that specifically bind an epitope of DC-STAMP. Specifically, provided herein are monoclonal antibodies that bind an epitope of DC-STAMP, wherein the epitope comprises the amino acid sequence Glu-Val-His-Leu-Lys-Leu-His-Gly-Glu-Lys-Gln-Gly-Thr-Gln (SEQ ID NO:1). Optionally, the epitope comprises the amino acid sequence His-Gly-Glu-Lys-Gln-Gly-Thr-Gln (SEQ ID NO:2). Optionally, the epitope... Agent: University Of Rochester
20130209475 - Dkk1 antibodies and methods of use: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind DKK1 polypeptides. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases are also disclosed.... Agent:
20130209472 - Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.... Agent: Atyr Pharma, Inc.
20130209473 - R-spondin translocations and methods using the same: Provided are therapies related to the treatment of pathological conditions, such as cancer.... Agent: Genentech, Inc.
20130209474 - Wise/sost nucleic acid sequences and amino acid sequences: The present invention relates to nucleic acid sequences and amino acid sequences which influence bone deposition, the Wnt pathway, ocular development, tooth development, and may bind to LRP. The nucleic acid sequence and polypeptides include Wise and Sost as well as a family of molecules which express a cysteine knot... Agent: Stowers Institute For Medical Research
20130209477 - Agents and method for treating inflammation-related conditions and diseases: Gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. Gene-modified, inflammation-specific macrophages that comprise a 1-alpha-hydroxylase gene. A method for treating one or more than one inflammation-related condition or disease, the method... Agent:
20130209476 - Treatment of inflammatory disorders: A method is provided for treating certain inflammatory disorders by inhibiting cadherin-11 function using a cadherin-11 antagonist.... Agent: The Brigham And Women's Hospital Inc.
20130209479 - Cancer treatment: The present invention relates to methods of treating cancer, such as melanoma, by administering a CTLA4 antagonist to a subject with a serum C-Reactive Protein (CRP) concentration that is less than or equal to some amount. The invention further relates to methods of treating cancer by determining the level of... Agent: Pfizer, Inc.
20130209478 - Formulation comprising an antibody against p-selectin: This invention relates to a pharmaceutical formulation of an antibody against P-Selectin, a process for the preparation of the formulation and uses of the formulation.... Agent: Hoffmann-la Roche Inc.
20130209480 - Methods of treating rheumatoid arthritis using il-17 antagonists: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., rheumatoid arthritis (RA) patients, e.g., high risk RA patients, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule... Agent: Novartis Ag
20130209481 - Anti-tumor antigen antibodies and methods of use: Antibodies that bind to tumor associated antigen CD44 or to tumor associated antigen EphA2, are disclosed herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies, diagnostics, and screening methods.... Agent: The Regents Of The University Of California
20130209482 - Monoclonal antibodies to basic fibroblast growth factor: The present invention is directed toward a neutralizing monoclonal antibody to basic fibroblast growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.... Agent: Galaxy Biotech, LLC
20130209483 - Cannabidinoid derivatives: The disclosure relates to cannabinoid derivative compounds, pharmaceutical compositions made thereof, and methods for treating various diseases and disorders including cancer.... Agent: Sutter West Bay Hospitals
20130209489 - Antibodies that bind myostatin, compositions and methods: There are disclosed selective myostatin antagonists (including antibodies), nucleic acids encoding them, and methods of making and using them. Neutralizing antibodies recognizing the conformational epitope near position 21 to 31 and position 50 to 60.... Agent:
20130209490 - Diagnostic biomarkers for fibrotic disorders: The present invention provides novel methods of inhibiting fibrosis, as well as methods of treating or inhibiting fibrotic disorders, using BMP9 and/or BMP10 antagonists. The present invention also provides methods of assessing whether a subject has or is at risk of developing a fibrotic disorder by detecting levels of BMP9... Agent: Novartis Ag
20130209486 - Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a... Agent: Celera Corporation
20130209488 - Methods and compositions for malic enzyme 2 (me2) as a target for cancer therapy: The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing cancer and other related diseases that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include combination therapy, such as with a combination of two or more ME2 inhibitors or a combination... Agent: Beth Israel Deaconess Medical Center, Inc
20130209491 - Methods of generating antibodies to metalloenzymes: e
20130209484 - Selective ampd2 inhibitors and methods for using the same: The present invention provides compounds and compositions that modulate adenosine monophosphate deaminase (AMPD) and methods for using the same to treat a clinical condition associated with the metabolic syndrome or a disease associated with the metabolic syndrome. In particular, the present invention provides a compound and a composition comprising a... Agent:
20130209485 - Therapeutic agent of non-allergic airway inflammation and/or non-allergic hyperresponsive airway: The invention provides a therapeutic agent for non-allergic airway inflammation and/or non-allergic airway hyperreactivity, containing a substance capable of inhibiting or eliminating the Th17 cell-like function of an IL-17RB positive NKT cells as an active ingredient; a prophylactic or therapeutic method for non-allergic airway inflammation and/or non-allergic airway hyperreactivity, using... Agent: Riken
20130209487 - Treatment of avian species with inhibitors of p110 delta signaling: The invention includes compositions and methods for regulating p110 delta in an avian species. The invention includes inhibiting p110 delta, a component of p110 delta signaling pathway, or any combination thereof in an avian species as an anti-viral therapeutic approach for treating virus infection.... Agent: Philadelphia Health & Education Corporation D/b/a Drexel University College Of Medicine
20130209492 - Anti-tie2 antibodies and uses thereof: The present invention provides antibodies that bind to Tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Tie2 and block the interaction between Tie2 and one or more Tie2 ligands such as angiopoietin 1 (Ang1), angiopoietin... Agent: Regeneron Pharmaceuticals, Inc.
20130209493 - Biomakers for circulating tumor cells: Provided are methods for detecting circulating tumor cells (CTCs) in a subject. The methods may include detecting the expression of at least one epithelial mesenchymal transition (EMT) biomarker. Further provided are kits for detecting CTCs. The kits may include antibodies to at least one EMT biomarker. Further provided are methods... Agent:
20130209494 - Enediyne compounds, conjugates thereof, and uses and methods therefor: Enediyne compounds having a structure according to formula (I), where R0, R2, R3, R4, R5, R6, and R7 are defined herein, can be used in chemotherapeutic drugs, especially in conjugates, for the treatment of diseases such as cancer.... Agent: Bristol-myers Squibb Company
20130209495 - Erbb3 antibodies: Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein;... Agent: Genentech, Inc.
20130209496 - Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.... Agent: Seatle Genetics, Inc.
20130209497 - Whole egg protein peptides, preparation method and use thereof: Provided are whole egg protein peptides and the preparation method thereof, wherein the whole egg protein peptides are obtained by adopting compound proteases composed of pawpaw protease, fig protease and pineapple protease to enzymatically hydrolyze the whole egg protein powder. The whole egg protein peptides can be used for manufacture... Agent: Wuhan Jiushengtang Bioengineering Co., Ltd
20130209498 - Methods to activate or block the hla-e/qa-1 restricted cd8+ t cell regulatory pathway to treat immunological disease: Methods are provided for inhibiting or enhancing down-regulation of an antigen-activated HLA-E+ T cell by an HLA-E-restricted CD8+ T cell comprising contacting the HLA-E+ T cell and CD8+ T cell with an agent which inhibits or enhances, respectively, binding between (i) T cell receptor (TCR) on the surface of the... Agent: The Trustees Of Columbia University In The City Of New York
20130209499 - Vaccines for use in the prophylaxis and treatment of influenza virus disease: Provided herein are polypeptides comprising portions of the influenza virus hemagglutinin, compositions comprising such polypeptides that can be used as immunogens in vaccines and methods of their use to generate an immune response against multiple influenza subtypes in a subject.... Agent: Mount Sinai School Of Medicine
20130209500 - Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.... Agent: Infectious Disease Research Institute
20130209501 - Immunogenic compositions of staphylococcus epidermidis polypeptide antigens: The present invention relates to immunogenic compositions, comprising polypeptides isolated from Staphylococcus epidermidis. The invention also relates to polynucleotides encoding Staphylococcus epidermidis polypeptides and their use in immunogenic compositions. In addition, the invention relates to methods of inducing an immune response in mammals against Staphylococcus epidermidis and Staphylococcus aureus using... Agent: Wyeth LLC
20130209502 - Alumina nanoparticle bioconjugates and methods of stimulating an immune response using said bioconjugates: Disclosed are nanoparticle-autophagosome conjugates capable of stimulating an immune response against a target antigen, wherein the nanoparticle-autophagosome conjugates include autophagosome(s) covalently attached to alumina nanoparticle(s), wherein the autophagosome includes defective ribosomal products (DRiPs) of the target antigen. Also disclosed are immunogenic compositions including these conjugates and/or antigen-presenting cells loaded with... Agent:
20130209503 - Method for stabilization of biological molecules: Thermostable polysaccharide based lyophilized vaccines are disclosed, particularly polysaccharide-protein conjugate vaccines and methods for preparation thereof. In an exemplary embodiment, a stabilized vaccine composition consists essentially of at least one polysaccharide-protein conjugate, at least one amorphous excipient, and a buffer component.... Agent: Serum Institute Of India Ltd.
20130209504 - Cosmetic formulation: Disclosed is a topical skin cleanser comprising Silybum marianum fruit extract, Momordica grosvenorii fruit extract, and a cosmetic vehicle comprising at least 50% by weight of the composition of water and disodium EDTA, glycerin, phenoxyethanol, triethanolamine, 3-Iodo-2-propynyl butyl carbamate, and benzyl alcohol.... Agent: Mary Kay Inc.
20130209505 - Crystalline form of (2s,4r)-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-4-[(1h-[1,2,3]triazole-4-carbonyl)-amino]-pentanoic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester: The invention provides a crystalline form of (2S,4R)-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-4-[(1H-[1,2,3]triazole-4-carbonyl)amino]pentanoic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester or its tautomer. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases.... Agent:
20130209506 - Recombinant virus with diminished latency and methods of using same: The disclosure provides recombinant herpes virus with diminished latency. In embodiments, the recombinant herpes virus comprises a latency gene or transcript linked to an altered or heterologous promoter. The disclosure also provides compositions and methods for inducing immunity in animals using the recombinant herpes viruses.... Agent: The Government Of The United States Of America, As Represented By The Secretary Of The Department Of
20130209507 - Rotavirus subunit vaccines and methods of making and use thereof: The present invention provides Rotavirus antigenic polypeptides or antigens that elicit an immune response in animal or human against rotavirus, compositions comprising said rotavirus polypeptides, methods of vaccination against rotavirus, and kits for use with such methods and compositions. The invention further provide novel expression vectors for producing the vaccine... Agent: Merial Limited
20130209508 - Compositions containing purine and pyrimidine nucleotsides, peptides, and manganese and their uses: The invention provides methods of producing vaccines directed against microorganisms, with the methods comprising culturing, harvesting and/or suspending the microorganism in the presence of a radiation-protective composition and irradiating the bacteria or viruses with a dose of radiation sufficient to render the microorganism replication-deficient and/or non-infective. The radiation-protective compositions used... Agent:
20130209509 - H3 equine influenza a virus: The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.... Agent: Wisconsin Alumni Research Foundation
20130209510 - Methods for preparing squalene: An improved method for preparing squalene from a squalene-containing composition, said method comprising the steps of (a) a purification distillation carried out at a temperature T1; (b) a denaturing distillation carried out at a temperature T2; wherein steps (a) and (b) may be performed in either order; T1 and T2... Agent: Novartis Ag
20130209511 - Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom: The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an OX40L polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the OX40L polypeptide elicit an immune response in animal or human, which is greater than the... Agent: Merial Limited
20130209512 - Universal influenza a vaccines: Universal flu vaccines are disclosed. The vaccines induce broad and sustained protection against a wide range of influenza A viruses, reduce the need for annual vaccination campaigns with vaccines based upon viral strains predicted to be the predominant circulating strains, and ameliorate the threat of future pandemics that can potentially... Agent:
20130209513 - Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions having... Agent:
20130209514 - Aptamer-targeted costimulatory ligand aptamer: Compositions for inducing or enhancing immunogenicity of a tumor comprise bi- and multi-specific aptamers binding to a tumor cell and an immune cell. These compositions have broad applicability in the treatment of many diseases, including cancer.... Agent:
20130209515 - Anti-infective and immunomodulatory compounds: The present invention provides pharmaceutical compositions and methods that include the use of anti-infective compounds that potentiate the host-immune response or limit or prevent the expression or activity of individual virulence factors. In addition, the compositions have immunomodulatory activity, and therefore can be used to prime host defenses to prevent... Agent:
20130209516 - Immunomodulatory compositions: Isolated immunomodulatory (e.g. immunostimulatory) polyhydroxlated pyrrolizidine compounds having the formula (I), wherein R is selected from the group comprising hydrogen, straight or branched, unsubstituted or substituted, saturated or unsaturated acyl, alkyl (e.g. cycloalkyl), alkenyl, alkynyl and aryl groups, or a pharmaceutically acceptable salt or derivative thereof, are useful in therapy... Agent: Summit (wales) Limited
20130209517 - Cancer therapy: The present invention relates to a method of preventing, treating or inhibiting the development of tumors or metastases in a subject and to an immunomodulator for use in such therapy, in combination with a chemotherapeutic agent. An aspect the present invention is a method of preventing, treating, reducing, inhibiting and/or... Agent: Immodulon Therapeutics Limited
20130209523 - Amorphous medicinal fine particles produced by pulsed laser ablation in liquid and the production method thereof: The present disclosure is directed to an in-liquid laser-based method for fabricating a solution of fine particles of amorphous solid medicinal compounds, a solution of fine particles of amorphous medicinal agents made with the method, and fine particles made with the method. By using a target solidified via a phase... Agent:
20130209518 - Combinations and modes of administration of therapeutic agents and combination therapy: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations... Agent:
20130209525 - Controlled release formulations of opioid and nonopioid analgesics: Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective... Agent: Alza Corporation
20130209522 - Drug release from a polymer-controlled local antibiotic delivery system using a degradable bone graft: In some embodiments, the implant is a solid, a paste, or a liquid. In some embodiments, the solid implant is carved or molded for insertion into a site of implantation in a vertebrate host prior to implantation. In some embodiments, the paste implant hardens following implantation. In some embodiments, the... Agent: University Of Utah Research Foundation
20130209526 - Flexible bone composite: The present invention relates in general to implantable flexible bone composites, and method for preparing the same. The flexible bone composite includes at least one polymeric layer and at least one calcium-containing layer. The polymeric layer can be a polymeric layer including a synthetic polymer. The calcium-containing layer can include... Agent: Synthes Usa, LLC
20130209520 - Foams, including microcellular foams, containing colloidal particulates: The present invention generally relates to foams and particles made from such foams, for applications such as drug delivery. The foams or particles may comprise a pharmaceutically acceptable polymeric carrier. In some cases, the foams may include colloidal particulates. A first aspect of the present invention is generally related to... Agent: Basf Se
20130209519 - Formulations of flibanserin: The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin.... Agent: Sprout Pharmaceuticals Inc.
20130209524 - Method of using amnion allograft in heart transplant surgery: Improved methods for heart transplant are described. The methods utilize an allograft comprising a layer of amnion to improve the performance and reduce complications of the heart transplant surgery and the allograft has a pre-made size and shape suitable for the application.... Agent: Afcell Medical
20130209521 - Nanostructured aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them: The present invention is directed to nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Aprepitant according to the invention have an average particle size of less than about 200 nm. The stable nanostructured particles of the invention are presented by increased solubility,... Agent:
20130209527 - Process for the preparation of water-in-oil and oil-in-water nanoemulsions: 2) the dilution of the blend (I) in a dispersing phase consisting of oil or water with the addition of a surface-active agent, selected from non-ionic, anionic, polymeric surface-active agents, the quantity of the dispersing phase and surface--active agent being such as to obtain a nanoemulsion having a HLB different... Agent:
20130209529 - Pva-boronic acid containing copolymer compositions for protein delivery: Provided herein are phenylboronate containing co-polymers (PCC), compositions containing PCC and polyvinyl alcohol (PVA), such compositions further including proteins, methods of making these compositions by water in oil polymerization, and methods of using the protein containing compositions for releasing proteins. Such phenylboronate containing co-polymers are of Formula I: where m,... Agent: Indian Institute Of Technology Kanpur
20130209528 - Use of exosomes to promote or enhance hair growth: We describe the use of an exosome for the preparation of a pharmaceutical composition to promote or enhance would healing or hair growth, or both, in an individual. The exosome may be derived from a stem cell such as a mesenchymal stem cell (MSC).... Agent: Agency For Science, Technology And Research
20130209530 - \"nanoparticles for the encapsulation of compounds, preparation thereof and use of same\": The present invention relates to nanoparticles for encapsulating compounds, the preparation and uses thereof, comprising a casein matrix, a basic amino acid and a metal selected from a divalent metal, a trivalent metal and combinations thereof. Said nanoparticles can encapsulate a water soluble or fat soluble biologically active compound. The... Agent: Universidad De Navarra
20130209531 - Applications of partially and fully sulfated hyaluronan: Described herein is the use of partially and fully sulfated hyaluronan or the pharmaceutically acceptable salt or ester thereof for therapeutic and cosmetic applications as well as the treatment of a number of systemic, dermatological, periodontal, ophthalmic, and urological inflammatory diseases.... Agent: University Of Utah Research Foundation
20130209532 - Polysaccharide gel formulation having increased longevity: Described herein are polysaccharide gel formulations including at least one inhibitor of polysaccharide degradation and methods of making the same. The methods described herein involve the steps of providing at least one polysaccharide and incorporating at least one inhibitor of degradation into the polysaccharide. In some embodiments, the incorporating step... Agent: Allergan, Inc.
20130209533 - Solid powder cosmetic: A foundation and the like which contains latent means for masking skin dullness at the time of application thereof to the skin, the means gradually working a few hours after application, is provided by providing a solid powder cosmetic composition comprising the following ingredients (1) to (3): (1) an interference... Agent: Shiseido Company, Ltd.
20130209534 - Substrate of polymeric material and method of carrying out thereof: A substrate of polymeric material for wound care contains at least one oleous antimicrobial and/or helping tissue regeneration substance that is selected from Hyperforin, Adhyperforin, 1-3 Diapigenin, 11-8 Diapigenin, Rutin, Quercetin, Hypericin, Azadirachtin α-β, Nimbin, Nimbidin, Salanin, Gallic Acid, Gedunin and combinations thereof.... Agent: Moses S.r.l.
20130209535 - Waterborne coating composition containing low molecular weight polytrimethylene ether glycol: The present disclosure is directed to a low VOC (volatile organic content) waterborne coating composition comprising low molecular weight polytrimethylene ether glycol. This disclosure is further directed to an antimicrobial coating layer formed from the coating composition comprising low molecular weight polytrimethylene ether glycol. The coating compositions can be used... Agent: U S CoatingsIPCo LLC
20130209536 - Antimicrobial elastomeric articles: The present invention relates generally to methods of preparing antimicrobial elastomeric articles that include an elastomeric article having an antimicrobial coating provided thereon. The antimicrobial elastomeric articles exhibit enhanced ability to reduce or eliminate microbes that come in contact with the article. Certain aspects of the invention are further directed... Agent: Allegiance Corporation
20130209537 - Controlled-release antibiotic nanoparticles for implants and bone grafts: The present invention relates to the preparation and use of antibiotic-containing nanoparticles for coating an implant including cranial implants and bone graft sites to provide for the extended release of antibiotics to treat infection.... Agent:
20130209538 - Biodegradable ocular implant: The present invention relates to a biodegradable ocular implant for sustained drug delivery, comprising a first layer comprising a first biodegradable polymer, wherein the first layer contains a drug dispersed or dissolved therein. A multi-layered biodegradable ocular implant is also disclosed.... Agent: Nanyang Technological University
20130209539 - Core sheath drug delivery devices: It relates to a device comprising (a) a core comprising polyurethane; (b) a sheath comprising ethylene vinyl acetate copolymer, said sheath substantially or completely surrounding said core; and (c) one or more active pharmaceutical ingredients dissolved or dispersed in said core and/or said sheath; and to a process for its... Agent: Chemo Research, S.l.
20130209540 - Multi-layer nicotine-containing pharmaceutical composition: The invention provides a multi-layered pharmaceutical composition comprising two or more formulations with varying properties. In some embodiments, the pharmaceutical compositions provide combinations of different organoleptic properties within the same product. In certain embodiment, these combinations allow for a modified release profile of active ingredients as the user enjoys the... Agent: Niconovum Usa, Inc.
20130209550 - Anti-viral azide containing compounds: Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as... Agent: Life Technologies Corporation
20130209552 - Aripiprazole compositions and methods for its transdermal delivery: The present invention discloses compositions of liquid and gel formulation containing aripiprazole in the form of a patch for transdermal delivery.... Agent: Transdermal Research Pharm Laboratories, LLC
20130209546 - Combinatorial methods and compositions for treatment of melanoma: The invention relates to combining targeted therapies with selected chemotherapeutics for the treatment of melanoma. The invention provides a method for inducing apoptosis in a melanoma tumor cell by reducing Akt3 activity. A method for inducing apoptosis in a melanoma tumor cell comprising contacting a melanoma tumor cell with an... Agent: The Penn State Research Foundation
20130209543 - Enhanced treatment regimens using mtor inhibitors: The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability.... Agent: Intellikine LLC
20130209541 - Il-13 receptor binding peptides: A targeting peptide that specifically binds to an IL13 receptor (e.g., wherein said targeting peptide is not an IL13 fragment) is described. The targeting peptide is optionally conjugated to at least one effector molecule. In some embodiments, the peptide specifically binds to the IL13Rα2 protein.... Agent:
20130209549 - Materials and methods for treating neurodegenerative diseases: The subject invention concerns materials and methods for treating neurodegenerative diseases and conditions associated with aggregation of the microtubule-associated protein tau. A method of the invention comprises administering an effective amount of a heat shock protein 27 (Hsp27), or a biologically-active fragment or variant thereof, or a polynucleotide encoding the... Agent: University Of South Florida
20130209544 - Microvesicles carrying small interfering rnas, preparation methods and uses thereof: Microvesicles containing interfering RNAs, preparation methods and uses thereof are provided. Pharmaceutical compositions and kits comprising the microvesicles containing interfering RNAs are also provided. Microvesicles containing interfering RNAs, pharmaceutical compositions and kits comprising such microvesicles can be used to study the effects of interfering RNAs on receptor cells. As microvesicles... Agent: Jiangsu Micromedmark Biotech Co., Ltd.
20130209551 - Pentapeptide derivatives for promoting hair growth: The invention relates to substituted pentapeptide compounds of the formula R1-Gly-Pro-Ile-Gly-A1 (I), where A1 is Ser or Thr and R1 denotes —C(═O)—H, —C(═O)—C1-C24 alkyl, —C(═O)—CH2CH(OH)CH2N+(CH3)3 (carnitinoyl), 1,2-Dithiolane-3-pentanoyl (liponoyl), —C(═O)-(CH2)2NHC(═O)CH(OH)C(CH3)2CH2OH (pantothenoyl) or (II) (biotinyl) in free form or in salt form, to the use thereof to produce cosmetic dermatologically active compositions,... Agent:
20130209542 - Pharmaceutical carrier and pharmaceutical composition for inhibiting angiogenesis: A pharmaceutical carrier and a pharmaceutical composition for inhibiting angiogenesis are disclosed. The pharmaceutical carrier of the present invention comprises: a drug carrier; and a polypeptide linked to a surface of the drug carrier, wherein the polypeptide comprises a receptor binding domain of vascular endothelial growth factor.... Agent: National Chiao Tung University
20130209547 - Sustained release formulation of a non-steroidal anti-inflammatory drug: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments... Agent: Pacira Pharmaceuticals Inc.
20130209548 - Sustained release formulation of a non-steroidal anti-inflammatory drug: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments... Agent: Pacira Pharmaceuticals, Inc.
20130209545 - Topical therapeutic formulations: The invention provides topical compositions and methods for using the compositions. The compositions can be used for the treatment of fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations, or fibrosis of muscle tissue. The disorders can be painlessly treated by the topical application of a composition described herein.... Agent: Hybrid Medical, LLC
20130209553 - Extended release pharmaceutical compositions of pramipexole: The present invention discloses an extended release pharmaceutical composition of pramipexole or salts thereof comprising at least 40% w/w of hydrogenated castor oil, and one or more pharmaceutically acceptable excipients.... Agent: Cadila Healthcare Limited
20130209556 - Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form: DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.... Agent: Omthera Pharmaceuticals, Inc.
20130209555 - Formulations and dosage forms of oxidized phospholipids: The current disclosure provides pharmaceutical compositions containing an oxidized phospholipid, such as 1-hexadecyl-2-(4′-carboxybutyl)-glycero-3-phosphocholine (VB-201) and a thermosoftening carrier, e.g., a poloxamer. The pharmaceutical compositions may further comprise an anti-adherent agent, such as talc and/or a thixotropic agent. The current disclosure further provides processes for preparing the pharmaceutical compositions. The disclosure... Agent: Vascular Biogenics Ltd.
20130209554 - Novel gelatin capsule compositions and methods of making: A gelatin capsule composition that includes one or more first distinct regions comprising a gelatin and one or more second distinct regions comprising a water-insoluble rapid-release agent is provided.... Agent: Gelita
20130209557 - Tamper resistant dosage form comprising inorganic salt: The invention relates to a pharmaceutical dosage form exhibiting a breaking strength of at least 500 N, said dosage form containing a pharmacologically active ingredient (A); an inorganic salt (B); and a polyalkylene oxide (C) having a weight average molecular weight of at least 200,000 g/mol, wherein the content of... Agent: Grunenthal Gmbh
20130209559 - Method for treating intestinal diseases presenting at least one inflammatory component: The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (IBD) or diverticular disease using budesonide MMX compositions.... Agent: Cosmo Technologies Limited
20130209558 - Oral dosage forms of bendamustine and therapeutic use thereof: In the present invention there is provided a pharmaceutical composition for oral administration which comprises bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient and which shows a dissolution of the bendamustine of at least 60% in 20 minutes, 70%... Agent: Astellas Deutschland Gmbh
20130209560 - Abuse-resistant formulations: This disclosure relates to a sustained-release oral dosage form suitable for twice-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydrocodone. The dosage form can have a release profile such that 6 hours following administration, less than about 80 percent of the hydrocodone is released. In... Agent: Cima Labs Inc.
20130209561 - Abuse-resistant opioid dosage form: We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.... Agent: Endo Pharmaceuticals Inc.
20130209562 - Methods and devices for providing prolonged drug therapy: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose... Agent: Alza Corporation
20130209563 - Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin: A combination immediate/delayed release delivery system for compounds which have short half-life's, such as the antidiabetic remogliflozin etabonate, is provided which provides a dosage form that has two distinct phases of release, a formulation that promotes immediate release of the compound upon ingestion and another formulation which delays the release... Agent: Bhv Pharma, Inc.
20130209564 - Polysaccharide particle vaccines: Particle compositions are prepared for use as polysaccharide particle vaccines.... Agent:
20130209565 - Posology and administration of glucocorticoid based compositions: The present invention relates to an improved method of administration of glucocorticoid based compositions in glucocorticoid replacement therapies enabling an objectively based regimen for administration enabling correct individual dosing of glucocorticoids resulting in an optimised individual replacement therapy and thus an improved long-term outcome for patients with temporary or chronic... Agent: Duocort Pharma Ab
20130209566 - Nanoparticle composition and methods to make and use the same: The present invention provides a novel nanoparticle drug delivery system generated from poly(ortho ester) polymers with sustained drug release capability and can be functionalized to allow for systemic delivery to various organ systems throughout the body. One important aspect of this invention is that the nanoparticle drug delivery system generated... Agent:
20130209567 - Modified release dosage forms of skeletal muscle relaxants: A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population... Agent: Aptalis Pharamtech, Inc.
20130209568 - Biodegradable phase separated segmented multi block co-polymers and release of biologically active polypeptides: The invention is directed to biodegradable, thermoplastic, phase separated segmented multi-block copolymers. The copolymers of the present invention find use in various biomedical applications as well as in pharmaceutical applications. Provided is a composition for the controlled release of at least one biologically active polypeptide to a host, comprising the... Agent: Innocore Technologies B.v.
20130209569 - Novel formulation of diclofenac: The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way... Agent: Iceutica, Inc.
20130209570 - Drug delivery systems and use thereof: The invention provides a microsphere formulation for the sustained delivery of an aptamer, for example, an anti-Vascular Endothelial Growth Factor aptamer, to a preselected locus in a mammal, such as the eye. In addition, the invention provides methods for making such formulations, and methods of using such formulations to deliver... Agent: Massachusetts Eye And Ear Infirmary
20130209571 - Bioengineered human corneal stromal tissue: Provided herein is a method of making an aligned ECM scaffold useful in refractive correction of the eye and repair of the cornea. Methods of use of the scaffold as well as a scaffold construct are provided.... Agent: University Of Pittsburgh- Of The Commonwealth System Of Higher Education
20130209572 - Xenograft soft tissue implants and methods of making: The present application is directed to the field of implants comprising soft tissue for use in implantation in humans. The soft tissue implants of the present application are preferably obtained from xenograft sources. The present application provides a chemical process that sterilizes, removes antigens from and/or strengthens xenograft implants. The... Agent: Tutogen Medical Gmbh
20130209573 - Efficient, catalytic and scalable method to produce chlorine dioxide: Methods, kits, cartridges and compounds related to generating chlorine dioxide by exposing ClO2− to at least one of a manganese porphyrin catalyst or a manganese porphyrazine catalyst are described.... Agent: The Trustees Of Princeton University
20130209575 - Multi-part kit system for the preparation of a disinfectant: A multi-part kit system comprising (i) a solid part A which comprises 10 to 80 wt. % of peroxy compound selected from the group consisting of KHSO5, K2S2O8, Na2S2O8, magnesium monoperoxyphthalate hexahydrate, sodium percarbonate and sodium perborate, 0.1 to 10 wt. % of LiCl, NaCl and/or KCl and 1 to... Agent: E I Du Pont De Nemours And Company
20130209574 - Oxygen treatment of water and pulp from paper or cardboard production: Methods for treating water and pulp used in a paper or cardboard manufacturing process. Oxygen and nutrients are added to the water or pulp to increase the activity of aerobic bacteria resulting in a reduction of organic substances such as fatty acids. Alternatively oxygen alone is added to the water... Agent:
20130209576 - Water purification compositions and applications for same: Disclosed herein are compositions and corresponding methods for treating contaminated water and/or contaminable surfaces in order to kill, or otherwise reduce to non-harmful levels the survival of, biological contaminants resident therein and thereon, respectively.... Agent: Safewaterdrops
20130209577 - Buffered upper gi absorption promoter: The present invention relates to compositions of an active pharmaceutical compound or nutritional ingredient with one or more buffering agents between a pH of 1.0 and 6.0, preferably 2.0 and 4.0. The buffering agents are constituted to maintain or reduce the pH of the duodenal fluid in the proximal, mid... Agent: Albion International, Inc.
20130209578 - Combinatory cancer treatment: The present invention relates to a pharmaceutical composition for treating a neoplasm, a preneoplasm, a proliferative disorder and/or a precancerous lesion, the use of such compositions for the treatment of the listed conditions, and methods of treating the listed conditions. The composition of the present invention comprises an inhibitor of... Agent: Universite De Montreal
20130209579 - Therapeutic combination for the treatment of cancer: This invention relates to therapeutic combinations comprising a platinum-based anti-neoplastic agent, such as cisplatin, and an extract from a species of the genus Nerium, such as Nerium oleander, as well as methods of using such combinations to treat subjects, including humans, suffering from certain cancers, such as prostate cancer, melanoma,... Agent: Nerium Biotechnology, Inc.
20130209580 - Method for treating alzheimer's disease: A method of treating Alzheimer's Disease of users comprising daily use of a lotion, the components of which are disclosed, a daily supplementation with powdered whey protein and Vitamin D, and a mild exercise component.... Agent:
20130209582 - Hydrogen iodide-containing health food and hydrogen iodide-containing drug, and method for producing same: To propose a health food or a drug, which comprises an iodine compound as a substitute for organic iodine and can exert a similar effect as organic iodine. To propose a method for producing a liquid to be used as a starting material for the aforesaid health food or drug.... Agent:
20130209581 - Iodinated activated charcoal for treating symptoms of depression: The present invention relates to the use of iodinated activated charcoal, optionally in combination with a bromide salt, in treatment of one or more symptom(s) caused by depression, wherein said symptom(s) is/are selected from the group consisting depressive mood, emotional fatigue, mental fatigue which can be chronic, burnout, withdrawal from... Agent: Pharmalundensis Ab
20130209583 - Methods and compositions suitable for promoting healthy skin: The invention provides methods, compositions, and dietary formulations useful for preventing or treating dermatitis, promoting healthy skin, and retarding skin aging. The methods comprise administering to an animal a therapeutically effective amount of a combination of at least two of one or more antioxidants; one or more anti-glycation agents; one... Agent: Nestec S.a.
20130209584 - Pharmaceutical formulations of nitrite and uses thereof: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion... Agent: Theravasc Inc.
20130209586 - Prevention and treatment of cardiac arrhythmias: Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of... Agent: Amylin Pharmaceuticals, LLC
20130209585 - Topical nmda antagonist formulations for the treatment of peripheral neuropathy: The presenting invention is directed to methods and compositions for the topical or transdermal treatment of neuropathy. More particularly, transdermal or topical compositions including a combination of ingredients that provide a surprising degree of effective relief from the symptoms of peripheral neuropathy and methods for administering the compositions to treat... Agent:
20130209588 - Agave syrup extract having anticancer activity: The present invention comprises an agave extract stored for at least eight weeks, having phytochemicals preferably selected from the group comprising flavonoids, polycosanols and sapogenins, that inhibit cancer cell growth over cells of breast and lymphoma and which provides the agave extract with antioxidant and chemopreventive properties.... Agent: Instituto Technologico Y De Estudios Superiores De Monterrey
20130209587 - Methods for administering tube feed formulations: Nutritional compositions that mimic whole foods and methods of using the nutritional compositions are provided. The nutritional compositions may include an increased number and variety of fruits and vegetables, an increased variety of macronutrient sources and an increased amount of other components that are found in whole foods. Methods of... Agent: Nestec S.a.
20130209589 - Insect repelling methods and compositions: Compositions and methods for repelling biting midges, sand flies, and mosquitoes comprising applying to human skin compositions comprising neem oil, coconut oil, jojoba oil, and monoi oil. This composition is non toxic to mammals, marine vertebrates or invertebrates and other forms of aquatic life.... Agent:
20130209590 - Use of a chinese medicine composition in preparing medicaments for treating secondary prevention of myocardial infarction: The present invention relates to a use of Chinese medicine composition in preparation of medicine for secondary prevention of myocardial infarction. Said Chinese medicine composition is prepared from a formula comprising the crude drugs by the following weight percentages: Radix Astragali 22.2%˜66.8%, Radix Salviae Miltiorrhizae 11.6%˜33.4%, Radix Notoginseng 2.5%˜13.5%, and... Agent: Tasly Pharmaceutical Group Co., Ltd.
20130209591 - Composition and method for minimizing bulling behavior of cattle: A method and composition for treating feedlot cattle in order to mask odor or pheromones given by cattle that trigger other cattle to mount them in a behavior pattern known as Buller Steer Syndrome, or to at least provide a scent which neutralizes that behavior.... Agent:
20130209592 - Plant extract based compositions and methods for treating chronic wounds: A therapeutic healing compound is provided. The therapeutic healing compound includes a sugarcane plant extract and a gelling agent that includes at least one of xanthan gum and hydroxyethyl cellulose. The compound may also include collagen. The therapeutic healing compound may be used for treating wounds, burns and cosmetic enhancement,... Agent:
20130209593 - Pharmaceutical composition for treating drug addiction: The present invention relates to a pharmaceutical composition for treating drug addiction comprising herb Gelsemium elegans Benth. and the flower of herb Datura metel L., and optionally any pharmaceutically acceptable excipient, wherein the weight/weight ratio of the raw material of Gelsemium elegans Benth. to the raw material of the flower... Agent: Yunnan Mingjinghengli Pharmaceutical Co., Ltd.
20130209594 - Optimized extraction process for obtaining labisia pumila extract: The present invention relates to a process for obtaining a Labisia pumila water extract comprising the steps of: obtaining an extract from dried Labisia pumila plant material using water extraction, filtering the extract to obtain filtrate and Labisia pumila plant material residue, re-extracting the Labisia pumila residue using water extraction,... Agent: Pharmaniaga Bhd08/08/2013 > 201 patent applications in 98 patent subcategories. inventions list
20130202525 - Multifunctional nanoplatforms for fluorescence imaging and photodynamic therapy developed by post-loading photosensitizer and fluorophore to polyacrylamide nanoparticles: A composition comprising PAA nanoparticles containing a post loaded tetrapyrollic photosensitizer and a postloaded imaging agent and methods for making and using same.... Agent: The Research Foundation Of State University Of New York
20130202526 - Paa nanoparticles for pet imaging and pdt treatment: PAA nanoparticles containing at least one tetrapyrrolic photosensitizer and at least one PET imaging agent.... Agent: The Research Foundation Of State University Of New York
20130202528 - Differential gene expression in physiological and pathological angiogenesis: Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4... Agent: The Government Of The United States Of America As Represented By The Secretary Of The Department Of
20130202527 - Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies for the treatment of cancer (e.g., renal and ovarian cancer). In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences... Agent: Celldex Therapeutics, Inc.
20130202529 - Benztropine compounds and uses thereof: in which Ar is a C6-C20 monocyclic aryl group or a C10-C20 bicyclic aryl group or a heteroaryl, heterocyclic, or arylheterocyclic group having 2 to 12 carbon atoms and one or more heteroatoms selected from the group consisting of N, O, S, P, and any combination thereof; m=1 to 5;... Agent: The United States Of America, As Represented By The Secretary, Department Of Health And Human
20130202530 - Novel radiotracer: Novel radiotracer(s) for Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) imaging of disease states related to altered choline metabolism (e.g., tumor imaging of prostate, breast, brain, esophageal, ovarian, endometrial, lung and prostate cancer—primary tumor, nodal disease or metastases). The present invention also describes intermediate(s), pre-cursor(s), pharmaceutical... Agent: Ge Healthcare Limited
20130202531 - Indicators for detecting the presence of metabolic byproducts from microorganisms: Polymeric indicator films and pH indicating wraps are provided for visually monitoring, detecting, and/or determining the presence of metabolic byproducts from harmful or potentially harmful microorganisms. Also provided are methods of use and preparation of the polymeric indicator films.... Agent:
20130202532 - Multiple input biologic classifier circuits for cells: Provided herein are high-input detector modules and multi-input biological classifier circuits and systems that integrate sophisticated sensing, information processing, and actuation in living cells and permit new directions in basic biology, biotechnology and medicine. The multi-input biological classifier circuits described herein comprise synthetic, scaleable transcriptional/post-transcriptional regulatory circuits that are designed... Agent: President And Fellows Of Harvard College
20130202533 - Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination: This invention is based, at least in part, on the discovery that Shn2 and Shn3 play an important role in skeletal remodeling and skeletal patterning. Accordingly, the present invention provides methods for identifying medulators of Shn2 activity and methods for modulating bone formation and mineralization and Shn2-associated disorders using agents... Agent: President And Fellows Of Harvard College
20130202534 - Pathological animal model simultaneously developing testicular pain or discomfort behaviors and urinary frequency: A pathologic animal model characterized in that a pain or discomfort behavior and urinary frequency are induced by administering a stimulative substance into the testes of a small-sized mammal, and a screening method for a therapeutic agent for pelvic pain syndrome, particularly non-bacterial chronic prostatitis, which comprises administering a test... Agent: Astellas Pharma Inc.
20130202538 - Molecular switch: Photosensitive molecular switch, having a chelate ligand, a metal ion bonded coordinatively to the chelate ligand, the metal ion being selected from the group of metal ions consisting of Mn2+, Mn3+, Fe2+, Fe3+, Co2+ and Ni2+, a photochromic system which is bonded covalently to the chelate ligand and can be... Agent: Christan-albrechts-universitat Zu Kiel
20130202535 - X-ray visible medical device and preparation method thereof: The present invention relates to an X-ray visible medical device comprising a medical device and a layer bound onto the medical device, wherein the layer is composed of an X-ray contrast material or a composite of the X-ray contrast material and a biocompatible polymer. Also disclosed is a method for... Agent: Snu R&db Foundation
20130202537 - Compositions for labeling nerves and methods of use: The present invention provides methods for guiding preservation of neurons or nerves during surgery by administering a fluorescently-labeled peptide that associates with (e.g., specifically binds to) the neurons or nerves. The invention further provides targeting molecules of fluorescently-labeled peptides or aptamers that associate with (e.g., specifically bind to) neurons or... Agent: Avelas Biosciences, Inc.
20130202536 - Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency: The invention relates to novel luminescent compositions of matter containing a fluorophore, synthetic methods for making the compositions, macromolecular conjugates of the compositions, and the use of the compositions in various methods of detection. The invention also provides kits containing the compositions and their conjugates for use in the methods... Agent: University Of Medicine And Dentistry Of New Jersey
20130202539 - Oral care compositions: The invention provides an oral care composition obtainable by: (i) preparing an oil-in-water emulsion by dispersing an oil phase into an aqueous continuous phase, the aqueous continuous phase comprising an oil-in-water emulsifier which is selected from one or more hydrophobins, so that emulsified particles of oil phase are formed which... Agent:
20130202541 - Composition containing extract of venus flytrap for cosmetic treatment: The present invention relates to an extract of Dionaea muscipula and a composition comprising such an extract for cosmetic treatment of the skin and skin appendages such as sebaceous glands, hair and nails especially skin changes due to accelerated or chronological aging e.g. wrinkles loss of firmness and elasticity, and... Agent: Quantum Pharmaceuticals Ltd.
20130202540 - Method for repair of acute and chronic injury, such as burned and photodamaged skin: A chemical compound and a method for its use as a topical medication that can reverse the effects of sun-damage, reverse the signs of aging, demonstrate anti-scarring properties and allow for the treatment of acne while still permitting the patient the ability to simultaneously expose the affected area to the... Agent:
20130202542 - Use of silane and siloxane bis(biphenyl) triazine derivatives as uv absorbers: Disclosed is the use of silane and siloxane bis(biphenyl)triazine derivatives of formula (1), wherein n is a number from 1 to 4; if n=1, X is *-L-Sil; or a radical of formula (11′), L is a linker selected from a radical of formula (2); R1, R2, R3 independently from each... Agent: Basf Se
20130202543 - Use of polyols for enhancing the cooling effect of a cooling substance and cooling mixtures having an enhanced cooling effect: The invention relates to a use of one, two, three or more certain polyols for enhancing the cooling effect of a cooling substance. It further relates to a cooling mixture comprising a cooling effect enhancing polyol and a cooling substance consisting of one or more physiologically cooling compounds and optionally... Agent: Symrise Ag
20130202545 - Stablised polyphenol derivatives, process for their manufacture, and uses thereof: The present invention relates to derivatized polyphenols, wherein all of the reactive phenolic hydroxyl functional groups are completely esterified or etherified, as demonstrated by the absence of free hydroxyl groups in an infrared absorption spectrum of the derivatized product. Due to their increased stability, the derivatized polyphenols can be used... Agent: Berkem S.a.
20130202546 - Cosmetic compositions having persistent tightening effects: Cosmetic compositions are provided, which are capable of having a tightening and/or curling effect on a human integument when applied thereto. Cosmetic compositions according to the invention typically include a cosmetically acceptable vehicle and a pH-dependent film-forming polymer of either a poly(methacrylic acid-co-methyl methacrylate) or a poly(methacrylic acid-co-ethyl acrylate). The... Agent: Avon Products, Inc.
20130202544 - Thickened compositons of high ph: Provided herein are thickened compositions produced upon assembling a first sub-formulation having a hydroxide, and at least one second sub -formulation having an alkaline material, wherein at least one sub-formulation is thickened by lightly-to moderately-crosslinked PVP. Unlike other compositions not having the lightly-to moderately-crosslinked PVP, those described herein maintain or... Agent: Isp Investments Inc.
20130202547 - Ophthalmic compositions containing diglycine: Ophthalmic composition that includes 0.05% w/v to 2% w/v diglycine or a salt thereof; 0.01 ppm to 3 ppm poly(hexamethylene biguanide); 1 ppm to 10 ppm α-[4-tris(2-hydroxyethyl)ammonium chloride-2-butenyl]poly[1-dimethylammonium chloride-2-butenyl]-ω-tris(2-hydroxyethyl)ammonium chloride; and 0.1% w/v to 2% w/v of one or more boron buffering compounds.... Agent:
20130202548 - Immunomodulatory protein constructs with a helical polymeric backbone: The present invention relates to protein constructs that comprise one or more peptides, proteins, factors, compounds or other components as further described herein that are linked to and/or are linked to each other via a helical polymeric backbone. The constructs of the invention are suitable for administration to a human... Agent: Stichting Katholieke Universiteit Of Nijmegen
20130202549 - Use of dpas and co-polymers for hyperlipidemia and atherosclerosis along with reducing feeding rate and adipose tissue weight of obesity animal: The disubstituted piperazine analogs (DPAs) derivative compound and DPAs amine complex compound disclosed in the present aspects have characterized by presented pharmaceutics having functions to improve lipolysis, such as inhibiting obesity hyperlipidemia, and atherosclerosis.... Agent:
20130202550 - Non-anticoagulant sulfated or sulfonated synthetic polymers: The present invention provides pharmaceutical formulations including a non-anticoagulant, non-saccharide polymer that with at least one sulfate or sulfonate moiety. The pharmaceutical formulations of the invention are of use to improve blood clotting in a subject. Also provided are useful analytical methods utilizing these polymers to query the dynamics of... Agent: Baxter International Inc.
20130202551 - Ionic compound, composition, cured material, hydrogel and ophthalmic lens: In formula (1), P represents a polymerizable functional group. Q+ represents a cationic group: Z represents an n-valent siloxanyl group in which the total atomic weight of a group of constituent atoms is no less than 70 and no greater than 1,000; Xm− represents an m-valent anion; and n is... Agent:
20130202552 - Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins: The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. Said oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a... Agent: Apotech Research And Development Limited
20130202554 - Compositions and methods that enhance an immune response: Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen. In... Agent: Chrontech Pharma Ab
20130202553 - Mobilization of hematopoietic stem cells: Methods, processes, uses, and pharmaceutical compositions are provided herein for mobilizing hematopoietic progenitor cells and/or cancer stem cells from bone marrow into peripheral blood, comprising the administration of an effective amount of an inhibitor of GTPases, such as a Cdc-42 specific inhibitor alone or in combination with one or more... Agent: Children's Hospital Medical Center
20130202555 - Treatment of multiple sclerosis with masitinib: The present invention relates to a tyrosine kinase inhibitor or a mast cell inhibitor, and in particular masitinib or a pharmaceutically acceptable salt thereof, for the treatment of human multiple sclerosis.... Agent: Ab Science
20130202556 - Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent: Methods of treating a hepatitis C virus (HCV) related disease, such as HCV infections in subjects non-responsive to anti-HCV therapy, are described herein, comprising administering to the subject a therapeutically effective amount of hydroxychloroquine. An antiviral agent may be co-administered with the hydroxychloroquine. Methods utilizing synergistic combinations of hydroxychloroquine and... Agent: Panmed Ltd.
20130202557 - Oral delivery of nucleic acid-based gene interfering agents by salmonella: The present invention provides vectors, including a novel attenuated strain of Salmonella, for efficient gene transfer into an animal, e.g. a mammalian host.... Agent: The Regents Of The University Of California
20130202560 - Pharmaceutical composition for cancer prevention and treatment containing the c12orf59 gene or protein as an active ingredient: As explained hereinbefore, the C12orf59 gene of the present invention suppresses cancer cell invasion and inhibits cancer cell survivability, and the over-expression of C12orf59 protein or a fragment thereof inhibits cancer cell invasion, so that C12orf59 gene or a fragment thereof not only can be effectively used for the pharmaceutical... Agent: Korea Research Institute Of Bioscience And Biotechnology
20130202558 - Recombinant replication competent oncolytic viruses and methods of use thereof for the treatment of cancer: Improved NCD variants exhibiting enhanced bioavailability and stability for the treatment of cancer are provided.... Agent:
20130202559 - Use of microvesicles in the treatment of medical conditions: This invention relates generally to populations of microvesicles containing or otherwise associated with viral particles, methods of producing these purified populations, and methods of using these purified populations in a variety of diagnostic, therapeutic and/or prophylactic indications.... Agent: The General Hospital Corporation D/b/a Massachusetts General Hospital
20130202569 - Transgenic ungulates expressing ctla4-ig and uses thereof: The present invention provides ungulates, including pigs, expressing CTLA4-Ig, as well as tissue, organs, cells and cell lines derived from such animals. Such animals, tissues, organs and cells can be used in research and medical therapy, including xenotransplanation. In addition, methods are provided to prepare organs, tissues and cells expressing... Agent:
20130202562 - Liquid microorganism consortia formulation: The present invention is directed to compositions and methods using microorganisms to benefit an environment or recipient subject. The present invention relates to the use of microorganism based compositions and methods to enhance the health of recipient subjects, improve soil conditions, and accelerate biodegradation. The present invention also relates to... Agent:
20130202561 - Method of treating drains using fungus cultures: A method of treating drain systems containing organic matter and providing a biopesticide for killing insects is provided. The method comprises introducing into a drain system a bacterial culture, such as Bacillus sp or Pseudomonas sp, which metabolizes the organic matter, and a biocidal amount of an entomopathogenic fungal culture,... Agent: Osprey Biotechinc Inc.
20130202570 - Treatment of neurocutaneous syndrome, including compositions, methods and uses thereof: A treatment protocol for use in the treatment of neurocutaneous syndrome is described and comprises at least one xanthone component, which may comprise at least one mangosteen component, and at least one detoxification component. Additional embodiments comprise at least one herbal component, at least one vitamin component, or a combination... Agent:
20130202571 - Use of probiotic bacteria to prevent and treat listerial infections: This invention relates to LAP-expressing probiotic bacteria and methods of use thereof to prevent and treat a pathogenic bacterial infection.... Agent: Purdue Research Foundation
20130202568 - Ameliorating nervous systems disorders: The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition.... Agent: The Regents Of The University Of California
20130202563 - Decellularized adipose cell growth scaffold: Provided herein are methods of making a cell growth scaffold from adipose tissue, cell growth scaffolds having low lipid content and methods of using the cell growth scaffold.... Agent: University Of Pittsburgh Of The Commonwealth System Of Higher Education
20130202565 - Method for inducing differentiation of adult stem cells and nerve cells using electromagnetic field: The present invention relates to a method for differentiation of mesenchymal stem cells or dental pulp stem cells. More specifically, the invention relates to a method for differentiating stem cells to neural cells by applying mesenchymal stem cells or dental pulp stem cells with a low-frequency electromagnetic field. The differentiation... Agent: Dongguk University Industry-academic Cooperation Foundation
20130202566 - Method for inducing differentiation of mesenchymal stem cells to nerve cells using sound waves: The present invention relates to a method for differentiation of mesenchymal stem cells. More specifically, the invention relates to a method for differentiating mesenchymal stem cells to neural cells by treating the mesenchymal stem cells with low-frequency sound waves. The differentiation method of the present invention can induce differentiation even... Agent: Dongguk University Industry-academic Cooperation Foundation
20130202564 - Systems and methods of cell activated, controlled release delivery of growth factors for tissue repair and regeneration: This invention provides a composition for controlled-release of polypeptide growth factors useful in tissue repair or engineering. The composition include a polypeptide growth factor covalently cross-linked to a biocompatible substrate by a transgultaminase. The cross-linking tethers the growth factor to a substrate so that it will not diffuse away from... Agent: University Of Southern California
20130202567 - Tissue culture media containing trimethylamine n-oxide: The present disclosure provides cell culture medium comprising trimethylamine N-oxide (TMAO). Progenitor cells cultured with such medium can form connective tissue with enhanced mechanical properties. Also provided are methods of forming connective tissue and methods of treatment for connective tissue defects.... Agent: The Trustees Of Columbia University In The City Of New York
20130202572 - Caffeine-free dietary supplements for increasing energy and methods of administering the same: Disclosed herein are caffeine-free dietary supplements for increasing energy in a subject and methods of administering the same. The method comprises administering to a subject a caffeine-free dietary supplement comprising omega-3 fatty acids, resveratrol, beta-alanine, gamma aminobutyric acid, and valerian root extract product, in amounts such that the supplement is... Agent: Reliv International, Inc.
20130202581 - Enzyme compositions and use thereof for wound healing: Compositions and methods of using the compositions for wound healing are provided. The compositions include one or more digestive enzymes, for example, one or more protease, lipases, and amylases. The compositions can be formulated as topical pharmaceutical compositions and can be used for faster healing through stimulation of epidermal cells... Agent: Curelon LLC
20130202573 - Thioacetate compounds, compositions and methods of use: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.... Agent: Ardea Biosciences, Inc.
20130202576 - Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.... Agent: Atyr Pharma, Inc.
20130202575 - Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.... Agent: Atyr Pharma, Inc.
20130202574 - Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl-trna synthetases: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.... Agent: Atyr Pharma, Inc.
20130202578 - Compositions and methods for selectively producing sirna: The disclosure provided herein provides compositions and methods for producing siRNA. Also disclosed are compositions and methods for modulating the production of siRNA. Also disclosed herein are compositions and methods of treating a disease in a subject comprising administering a Dicer enzyme comprising a helicase domain or a mutated Dicer... Agent:
20130202577 - Diagnostic and prognostic assay for breast cancer: The invention relates to the finding that T cell protein tyrosine phosphatase (TCPTP) has a tumour suppressor function. In one particular application, the invention provides a method of diagnosis and/or prognosis of cancer in a subject involving the assessment, in a suitable body sample, of any lack or reduction of... Agent: Monash University
20130202580 - Use of 2,5-dihydroxybenzene derivatives for treating actinic keratosis: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, actinic keratosis.... Agent: Amderma Pharmaceuticals, LLC
20130202579 - Use of choline-phosphate cytidylyltransferase-alpha (cct-alpha) as a biomarker for cancer prognosis: It has previously been demonstrated that positive 8F1 immunohistochemistry is an indicator of a poor cancer prognosis and poor response to chemotherapy. The 8F1 antibody was generated by immunization against ERCC1, a DNA repair protein, but recognizes a second, previously unidentified protein in cells and tissues. Disclosed herein is the... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education
20130202582 - Agent delivery system capable of selectively releasing an agent: The present invention provides a composition for selectively delivering an active agent to a portion of an organism. The composition comprises first and second polymer portions, having first and second functional groups attached as a side-chain thereto, respectively. The first and second functional groups form cross-links between the first and... Agent: Lucent Technologies Inc.
20130202583 - Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof: Methods and diagnostic agents for identification of subjects for cancer treatment with an anti-hyaluronan agent, such as a hyaluronan-degrading enzyme, are provided. Diagnostic agents for the detection and quantification of hyaluronan in a biological sample and monitoring cancer treatment with an anti-hyaluronan agent, for example a hyaluronan-degrading enzyme, are provided.... Agent:
20130202585 - Stabilising formulation for immunoglobulin g compositions in liquid form and in lyophilised form: This invention is related to a stabilising formulation for immunoglobulins G compositions comprising a sugar alcohol, glycine and a non-ionic detergent, which is suitable for the stabilisation of immunoglobulins G compositions in liquid form and in lyophilised form. The invention also relates to an immunoglobulins G composition in liquid form... Agent: Laboratoire Francais Du Fractionnement Et Des Biotechnologies
20130202584 - Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8: The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.... Agent: Idera Pharmaceuticals, Inc.
20130202591 - Antibodies directed against il-17: The disclosure relates to an isolated IL-17-binding agent which comprises an immunoglobulin heavy chain polypeptide comprising SEQ ID NO: 1 and optionally an immunoglobulin light chain polypeptide comprising SEQ ID NO: 23, except that one or more specific of residues of SEQ ID NO: 1 and SEQ ID NO: 23... Agent: Anaptysbio, Inc.
20130202588 - Antitumor t cell response enhancer: An objective of the present invention is to provide novel therapeutic agents for cancer, which have an excellent antitumor effect in cancer patients by enhancing their immune function. The present inventors discovered that the administration of at IL-6 inhibitor and/or gemcitabine or a salt thereof to tumor-bearing organisms yields an... Agent: Chugai Seiyaku Kabushiki Kaisha
20130202589 - Diagnosis and treatment of autoantibody-mediated heart disease: Provided herein are, inter alia, methods of diagnosing and treating autoimmune cardiomyopathy in subjects, based upon the detection of IgG4 antibodies to cardiac autoantigens.... Agent:
20130202587 - Identification of genetic variants: The present disclosure provides a method for identifying whether a subject is more or less likely to be responsive to VEGF-based therapy, comprising screening a nucleic acid sample obtained from the subject to provide output information which identifies the presence or absence of an allelic variant, wherein the presence or... Agent: Randox Laboratories Ltd.
20130202590 - Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine: Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine.... Agent: Celgene Corporation
20130202586 - Stem cell therapy using inhibitors of lysophosphatidic acid: Methods are provided for stem cell therapy using inhibitors of lysophosphatidic acid (LPA). Inhibition of LPA may be direct or indirect; particularly preferred direct inhibitors of LPA are antibodies to LPA, including humanized monoclonal antibodies to LPA. Such inhibitors are used in combination with stem cells for the treatment of... Agent:
20130202598 - Activatable toxin complexes comprising a cleavable inhibitory peptide: The present invention relates to activatable toxin complexes which include a cleavable inhibitory peptide. More specifically, the complexes comprise a cell targeting domain, a toxin catalytic domain, a specific protease cleavage site and an inhibitory peptide domain. The inhibitory peptide prevents the catalytic domain from exerting toxic effects until its... Agent: Ramot At Tel-aviv University Ltd.
20130202594 - Alk1 antagonists and their uses in treating renal cell carcinoma: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit tumor growth of renal cell carcinoma (RCC) in vivo. In additional aspects the disclosure relates to the insight... Agent:
20130202597 - Anti-serum albumin binding variants: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.... Agent: Glaxosmithkline Intellectual Property Development Limited
20130202601 - Assays, methods and kits for predicting renal disease and personalized treatment strategies: Assays, methods and kits for predicting a subject's (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such... Agent:
20130202592 - Composition for the anti-cancer metastasis containing dlk1-fc fusion protein as an effective ingredient: A recombinant expression vector, comprising extracellular soluble domain genes of DLK1 and IgG antibody Fc domain genes, is constructed, and DLK1-Fc fusion protein is expressed and purified at 293E cell. The invention confirmed the efficacy as a drug for inhibiting cancer metastasis by confirming markedly reduced migration of cancer cells... Agent: Korea Research Institute Of Bioscience And Biotechnology
20130202595 - Factor ix polypeptides and methods of use thereof: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.... Agent: Biogen Idec Hemophilia Inc.
20130202593 - Intracellular immunity: A compound which may comprise a ligand which binds, directly or indirectly, specifically to an antigen of a pathogen, provided that said ligand is not the PRYSPRY domain of TRIM21; and a RING domain and/or an inducer of TRIM21 expression.... Agent: Medical Research Council
20130202599 - Novel immunoglobulins insertions, deletions, and substitutions: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more FcγRs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.... Agent: Xencor, Inc.
20130202600 - Polypeptides and methods for modulating d1-d2 dopamine receptor interaction and function: The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor... Agent: Centre For Addiction And Mental Health
20130202596 - Processable single chain molecules and polypeptides made using same: The present invention features inter alia nucleic acid molecules which encode polypeptides comprising a single chain Fc region and the polypeptides they encode. The Fc moieties of these constructs are linked by a cleavable scFc linker which is adjacent to at least one enzymatic cleavage site, e.g., an intracellular processing... Agent: Biogen Idec Hemophilia Inc.
20130202602 - Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies: The present disclosure relates to anti-CD200 antibodies (e.g., variant anti-CD200 antibodies having decreased or no effector function) and to biomarkers for use in a variety of diagnostic and therapeutic methods, e.g., determining whether a human has been administered one or more of the antibodies at a dose sufficient to induce... Agent: Alexion Pharmaceuticals ,inc.
20130202603 - Bispecific single chain fv antibody molecules and methods of use thereof: Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.... Agent: The Regents Of The University Of California
20130202605 - Protein sustained-release injectable formulation: The present invention provides sustained-release pharmaceutical formulations for administering proteins to the eye. In particular, the invention provides formulations comprising single chain antibodies and hydrophobic polyester hexylsubstituted poly(lactic acid) (hexPLA). The invention further provides processes for the production of sustained-release pharmaceutical formulations and medical uses thereof.... Agent: Esbatech - A Novartis Company LLC
20130202606 - Identification and engineering of antibodies with variant fc regions and methods of using same: The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to... Agent: Macrogenics, Inc.
20130202607 - Anti-system asc amino acid transporter 2 (asct2) antibody: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes... Agent: Kyowa Hakko Kirin Co., Ltd
20130202609 - Gas57 mutant antigens and gas57 antibodies: The invention provides mutants of GAS57 (Spy0416) which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against S. pyogenes. The invention also provides antibodies which specifically bind to GAS57 and which inhibit its ability to cleave IL-8 and similar substrates. The... Agent:
20130202610 - Methods of treating psoriasis using il-17 antagonists: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.... Agent: Novartis Ag
20130202608 - Monoclonal antibody specific to major neutralizing epitope of influenza h5 hemagglutinin: The present invention relates to the murine monoclonal antibody 4C2 or to chimeric or humanized monoclonal antibodies specific to a major neutralizing epitope of influenza H5 hemagglutinin and active fragments thereof. The present invention also relates to methods and compositions for the prophylaxis and treatment of H5N1 influenza using such... Agent: Temasek Life Sciences Laboratory Limited
20130202611 - Use of inhibitors of bruton's tyrosine kinase (btk): Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more... Agent: Pharmacyclics, Inc.
20130202615 - Anti-vegf antibodies and uses thereof: Provided are monoclonal antibodies and antigen binding fragments thereof that specifically bind vascular endothelial growth factor (VEGF). The anti-VEGF monoclonal antibodies block VEGF binding to its receptors (e.g., VEGFR1 and/or VEGFR2) and prevent phosphorylation of VEGFR2 by VEGF. Also provided are methods of using the monoclonal anti-VEGF antibodies for treatment... Agent: Vaccinex, Inc.
20130202614 - Autotaxin pathway modulation and uses thereof: Disclosed are methods for preventing, treating, or reducing symptoms of a disorder involving the autotaxin (ATX) pathway. In one embodiment, the method features administering to a mammal a sufficient amount of an autotaxin (ATX) or lysophosphatidic acid (LPA) signaling inhibitor, to prevent, treat or reduce symptoms of an inflammatory disorder,... Agent: B.s.r.c. "alexander Fleming"
20130202616 - Compositions and methods for immunization against bacteria expressing a carbapenemase: The present invention provides vaccine and pharmaceutical compositions for treating or preventing bacterial inventions. The vaccine compositions of the invention include a carbapenemase such as a serine carbapenemase, a metallo-β-lactamase or an immunogenic fragment thereof. The pharmaceutical compositions include an anti-carbapenemase antibody or fragment thereof. Also provided are methods for... Agent: Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center
20130202612 - Compositions and methods for treating bone conditions: A method of treating a degenerative bone condition of a subject includes administering to hematopoietic progenitor cells or osteoclast progenitor cells of the subject at least one agent that substantially reduces the interaction of at least one of C3a or C5a with the C3a receptor (C3aR) and/or C5a receptor (C5aR),... Agent: Case Western Reserve University
20130202613 - Pharmacological vitreolysis: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to,... Agent: Thrombogenics Nv
20130202617 - Hemorrhagic feline calicivirus, calicivirus and method for preventing calicivirus infection or disease: The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus or in addition to other... Agent: Boehringer Ingelheim Vetmedica, Inc.
20130202618 - Antibodies for the treatment of clostridium difficile-associated infection and disease: Provided herein are reagents, compositions, and therapies with which to treat Clostridium difficile infection and related disease conditions and pathologies, such as Clostridium difficile-associated diarrhea, resulting from infection by Clostridium difficile bacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen-binding fragments thereof that bind specifically to... Agent: Progenics Pharmaceuticals, Inc.
20130202621 - Antibodies directed to alpha v beta 6 and uses thereof: Targeted binding agents, such antibodies directed to the antigen αVβ6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen αVβ6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy... Agent: Medimmune Limited
20130202620 - High concentration antibody formulations: Discloses herein are high concentration antibody formulations comprising an anti-sclerostin immunoglobulin and an acetate salt and/or an acetate buffer and methods of use.... Agent: Amgen Inc.
20130202622 - Method for the treatment of obesity: The present invention relates to therapeutic compositions for treating or preventing obesity and obesity-related disorders in a subject using immunotherapy to target and eliminate adipocytes.... Agent: Fred Hutchinson Cancer Research Center
20130202619 - Methods and materials for reducing liver fibrosis: This document relates to methods and materials for treating diseases or disorders that are caused by or associated with lumican deposition (e.g., liver fibrosis). For example, methods and materials for reducing liver fibrosis by reducing lumican expression or activity within a mammal (e.g., a human) are provided.... Agent: Mayo Foundation For Medical Education And Research
20130202624 - Human b1 cells and uses thereof: The present invention is directed to isolated populations of human natural immunoglobulin-producing B1 lymphocytes, wherein the B1 lymphocytes display surface biomarkers CD20, CD43 and CD27 and are either CD11b+ or GD11b−. The present invention is also directed to a method of isolating human natural immunoglobulin-producing B1 lymphocytes from a blood... Agent:
20130202623 - Pd-1 modulation and uses thereof for modulating hiv replication: Methods, uses, compositions and kits for modulating HIV replication based on PD-1 modulation are disclosed. Methods, uses, compositions and kits useful for the elimination of latent HIV reservoirs based on PD-1 inhibition are also disclosed. Methods and kits useful for identifying agents useful for modulating HIV replication are also disclosed.... Agent:
20130202625 - Use of human erythrocytes for prevention and treatment of cancer dissemination and growth: The technology relates in part to methods of preventing and treating diseases and conditions associated with cancer, including methods, compositions, and kits used for preventing and treating cancer dissemination and growth.... Agent: The Regents Of The University Of Californa
20130202626 - Method for purifying active polypeptides or immunoconjugates: The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography.... Agent: Medimmune, LLC
20130202631 - Composition for preventing or treating liver diseases, containing plant stem cell lines derived from the cambium of panax ginseng including mountain ginseng or ginseng as active ingredient: The present invention relates to a composition for preventing or treating liver diseases, which contains, as an active ingredient, any one or more of a homogeneous cell line derived from the cambium of Panax ginseng, including wild ginseng or ginseng, a lysate thereof, an extract thereof and a culture medium... Agent: Unhwa Corporation
20130202630 - Compositions and methods for enhancing immune responses to vaccines: The disclosure provides adjuvants, immunogenic compositions, and methods useful for vaccination and immune response. In particular, the disclosure provides a class of adjuvants comprising cationic lipid:co-lipid mixtures and methods for delivering formulated compositions.... Agent: Vical Incorporated
20130202628 - Production and therapeutic uses of th1-like regulatory t cells: A unique CD4+CD25+ regulatory T cell population develops from naive CD4+CD25− T cells during a TH1 polarized immune response (called TH1-TR cells). These TH1-TR cells can be generated by contacting naïve T cells with mature CD8α+ dendritic cells (DCs) that have been exposed to a TH1 polarizing adjuvant and, in... Agent: The Board Of Trustees Of The Leland Stanford Junior University
20130202627 - Use of flagellins from the genus marinobacter as vaccination adjuvants: Use of flagellins from the genus Marinobacter as vaccine adjuvants. This invention is based on the use of two recombinant flagellins, F and FR, from the species Marinobacter algicola (DG893T strain), as vaccine adjuvants capable of developing a specific immune response, against peptides or proteins fused to said flagellins, or... Agent: Instituto Nacional De InvestigaciÓ N Y TecnologÍ A Agraria Y Alimentaria (inia)
20130202629 - Uses of phospholipid conjugates of synthetic tlr7 agonists: The invention provides uses for phospholipid conjugates of TLR agonists, for instance in vaccines, and to prevent, inhibit or treat a variety of disorders including inflammation, cancer and pathogen, e.g., microbe, infection.... Agent: The Regents Of The University Of California
20130202633 - Determination of immunogenic peptides in lysosomal enzymes and induction of oral tolerance: Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to... Agent: Saint Louis University, A Non-profit Organization
20130202632 - Minimal motifs of linear b-cell epitopes in l1 protein from human papillomavirus type 58 and their applications: Minimal Motifs of linear B-cell epitopes in L1 structure protein from human papillomavirus type 58 (HPV 58) and their applications are disclosed. Eighteen linear epitope motifs and their extended 8-mer peptides in the L1 protein from HPV 58 are described, which can be used as antigens separately or in combination... Agent: Hengsun Pharmaceutical Technology Co. Ltd.
20130202634 - Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof: Dengue virus (DV) peptides, including T cell epitopes, structural and non-structural (NS) polypeptide sequences, subsequences and modifications thereof, nucleotide sequences encoding such peptides, and compositions including such peptides and encoding nucleotide sequences, and cells expressing such peptides, are provided. Such DV peptides, nucleotide sequences and compositions, can be used to... Agent: La Jolla Institute For Allergy And Immunology
20130202636 - Compositions and methods for topical application and transdermal delivery of botulinum toxins: A composition for topical application of a botulinum toxin (including botulinum toxin derivatives) comprises a botulinum toxin and a carrier comprising a polymeric backbone comprising a long-chain polypeptide or nonpeptidyl polymer having attached positively charged branching or “efficiency” groups. The invention also relates to methods for reducing muscle paralysis and... Agent: Revance Therapeutics, Inc.
20130202635 - Peptide vaccines against group a streptococci: This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can... Agent: The United States Of America, As Represented By The Secretary, Department Of Health And Human
20130202637 - Dietary supplements including ellagitannins and ellagic acid: A dietary supplement containing a source of ellagic acid, such as black raspberry seed powder, is combined with one or more of blue green algae, brown seaweed, phycocyanin and phenylathylemine. Additions of one or more vitamins and/or one or more minerals further improves the health enhancing benefits of the dietary... Agent:
20130202638 - Vaccine against beta-herpesvirus infection and use thereof: The present invention is related to a beta-herpesvirus, wherein the beta-herpesvirus is spread-deficient.... Agent:
20130202640 - Compositions and methods for vaccinating against hsv-2: This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful... Agent: The University Of Washingtion
20130202639 - Synthetic herpes simplex viruses for treatment of cancers: New recombinant oncolytic viral vectors have been constructed based on a known herpes simplex virus-1 with a single 34.5 gene and a synctial mutation (called OncSyn (OS) virus), which was designed to be more immunogenic than the parental OS virus largely due to deletion of the viral gene viral host... Agent:
20130202641 - Immunology treatment for biofilms: The invention provides a composition for use in raising an immune response to P. gingivalis in a subject, the composition comprising an amount effective to raise an immune response of at least one polypeptide having an amino acid sequence substantially identical to at least 50 amino acids, or an antigenic... Agent: Oral Health Australia Pty Ltd
20130202642 - Immunogenic compositions against tuberculosis: Methods of preparing mutants of Mycobacterium tuberculosis with one or more disrupted genes are presented, where the disrupted genes include ctpV, rv0990c, rv0971c, and/or rv0348. Compositions containing mutants with attenuated virulence and pathogenesis, which are capable of stimulation of an immune response against tuberculosis, are described. Compositions and methods relating... Agent:
20130202643 - Avirulent salmonella gallinarum variants and pharmaceutical composition using the same: The present invention relates to avirulent Salmonella Gallinarum variants by inactivating virulence gene clusters of Salmonella Gallinarum (SG), a main pathogen of avian salmonellosis, and various uses thereof notably in the production of Salmonella-specific lytic bacteriophages, pharmaceutical compositions and feed additives.... Agent: Cj Cheiljedang Corporation
20130202645 - Composition for treating lung cancer, particularly of non-small lung cancers (nsclc): The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use... Agent: Curevac Gmbh
20130202644 - Methods of treating cancer: The present invention relates to compositions and methods for treating an animal with a tumor or other metabolic disorder. In particular, the presently disclosed subject matter relates to methods of electroporating exosomes shed by tumors and by other metabolic disorders into immune cells such as dendritic cells and T cells.... Agent:
20130202649 - Activation of innate immunity for nuclear reprogramming of somatic cells: The nuclear reprogramming of somatic cells with non-integrating factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of toll-like receptors, e.g. TLR3. Somatic cells with activated innate immune responses can be reprogrammed to induced pluripotent... Agent: The Board Of Trustees Of The Leland Stanford Junior University
20130202647 - Chloroplast expression of membrane proteins: Disclosed herein are chloroplast transformation vectors constructed to enable expression and hyperaccumulation of membrane proteins in chloroplasts. Another embodiment relates to plants transformed with such vectors. Another embodiment relates to seeds and other plant tissues transformed with such vectors. Another embodiment relates to a method of increasing expression of membrane... Agent: University Of Central Florida Research Foundation, Inc.
20130202651 - Composite vaccine adjuvant: The invention provides a composite vaccine adjuvant, which is comprised of sodium ferulate and zinc hydroxide in a mass ratio of 10:1˜50:1. When the composite vaccine adjuvant and vaccine used in combination, the humoral immunity response is enhanced effectively, the enhanced effects is similar with aluminum adjuvant, superior to single... Agent: Institute Of Medical Biology, Chinese Academy Of Medical Sciences And Peking Union Medical College
20130202646 - Compositions and methods for modulating autophagy: In alternative embodiments, the invention provides cell-permeable recombinant or synthetic proteins to modulate autophagy, including a Tat-Atg5K130R (inhibitor of autophagy) and a Tat-Beclin 1 (stimulant or activator of autophagy), and nucleic acids expressing them and methods for making and using them, e.g., to treat conditions and disorders responsive to autophagy... Agent: San Diego State University (sdsu) Foundation
20130202648 - Immunoregulator compounds: The invention relates to sphingosine derivative compounds, like D-erythro-sphingosine 1-phosphate (S1 P), to be used as immunomodulators in a microbicidal treatment of infections derived from bacteria and specifically Mycobacterium tuberculosis. Such compounds are characterised in that they stimulate macrophagic Phospholipase D (PLD) (FIG. 1). The invention further relates to pharmaceutical... Agent: Universita Degli Studi Di Roma "tor Vergata"
20130202652 - Methods and compositions for delivery of active agents: A targeting lipid can have the formula (I) in which T4 is a targeting moiety. The targeting moiety can be chosen to favor the lipid being localized with a desired organ, tissue, cell, cell type or subtype, or organelle. The targeting moiety can include, for example, transferrin, anisamide, an RGD... Agent: Alnylam Pharmaceuticals, Inc.
20130202650 - Topical composition comprising a combination of at least two penetration enhancing agents: The present invention relates to a composition for improved transdermal drug delivery comprising a drug, a combination of at least two penetration enhancing agents, wherein at least on the of the penetration enhancing agents is selected from the group consisting of esters of saturated or unsaturated fatty acids and lower... Agent: Moberg Derma Ab
20130202658 - Compositions comprising buprenorphine: This disclosure relates to a buprenorphine sustained release delivery system for treatment of conditions ameliorated by buprenorphine compounds. The sustained release delivery system includes a flowable composition containing a suspension of buprenorphine, a metabolite, or a prodrug thereof.... Agent: Rb Pharmaceuticals Limited
20130202657 - Foams or particles for applications such as drug delivery: The present invention generally relates to foams and, in particular, to foams for applications such as drug delivery, and particles that are made from such foams. One aspect relates to foams or particles containing pharmaceutically active agents. The foam may comprise a pharmaceutically acceptable polymeric carrier. In some cases, the... Agent: President And Fellows Of Harvard College
20130202661 - Formulations of viloxazine: Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.... Agent: Supernus Pharmaceuticals, Inc.
20130202660 - Functional nanostructured chitosan coatings for medical instruments and devices: Disclosed herein is an approach for coating a biocompatible material, in particular chitosan, onto a surface in need thereof. This approach results in a coating that is highly uniform, even on irregular surfaces, and enables ready adjustment of the morphology of the coated material. A convenient means to add a... Agent: Nano And Advanced Materials Institute Limited
20130202664 - Medical adsorbent and method for producing same: A medical adsorbent for oral administration that has low dosage and excellent adsorptive capacity and selective adsorption for toxins to be removed, and is also economical and environmentally friendly. The medical adsorbent comprises granular activated carbon that is activated carbon obtained by carbonization and activation of refined cellulose or regenerated... Agent:
20130202659 - Polymer-agent conjugates, particles, compositions, and related methods of use: Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making... Agent: Cerulean Pharma Inc.
20130202663 - Remedy: It is intended to provide a remedy for diseases caused by macrophages with dysfunction or mediated by macrophages. Namely, a remedy which activates the phagocytic capacity of macrophages and thus is efficiently incorporated into the macrophages due to the vigorous phagocytosis. As a result, the macrophages with dysfunction are normalized,... Agent:
20130202656 - Systems and kits for the fabrication of tissue patches: Tissue patches and associated systems and methods are described. Certain embodiments are related to inventive systems and methods in which tissue patches can be made quickly and robustly without the use of complicated fabrication or sterilization equipment.... Agent: Dynasil Biomedical Corporation
20130202654 - Topical foam composition: A topical foam pharmaceutical composition for rectal administration comprising rifaximin in the form of nanosized particles is described. Also described is a method of making the composition and the use of the composition to as a medicament.... Agent: Cipla Limited
20130202655 - Vaccines, methods of administering vaccines, methods and products for treating and/or delaying onset of dysplastic lesions, and wafers for oral administration: Methods and products for treating and/or delaying onset of dysplastic lesions, and wafers for oral administration employ dry powder compositions including myo-inositol. Methods for administering a vaccine for a virus or bacteria to an individual comprising administering a first portion of the vaccine to the individual via one route and... Agent: Aktiv-dry LLC
20130202666 - Hair treatment composition: An aerated composition comprising, surfactant aggregates, perfume and a hydrophobin.... Agent:
20130202667 - Hydrogel particle coated with lipid and method for manufacturing same: The present invention relates to hydrogel particles coated with lipid, which are made from dispersing hydrogel particles in an organic solvent in which lipids are dissolved, and to a method for manufacturing same. Unlike the existing method for manufacturing hydrogel core vesicles, the present invention can effectively manufacture same by... Agent: Amorepacific Corporation
20130202665 - Oily solid cosmetic: An oily solid cosmetic is capable of effectively diminishing morphological problems, such as vertical wrinkles, in particular on the lip, over a long period of time. The present invention provides an oily solid cosmetic which contains: (A) a plate-like composite powder presenting interference colors, (B) a spherical composite powder wherein... Agent:
20130202669 - Albumin fibers and fabrics and methods of generating and using same: Provided are method of generating a fiber from a globular protein such as albumin. Also provided are albumin fibers and fabrics and methods of using same for bonding a damaged tissue or for ex vivo or in vivo formation of a tissue.... Agent: Technion Research & Development Foundation Limited
20130202668 - Personal towelette with cooling composition for relief of heat symptoms: A cooling composition impregnated on a personal towelette which provides a cooling sensation to the body when wiped across the skin. The application of the towelette containing the cooling composition reduces the symptoms of heat due to hot flashes due to menopause, physical exertion, or high temperatures. The composition provides... Agent:
20130202670 - Bioactive antibacterial bone graft materials containing silver: The present invention generally relates to silver-containing bioactive antibacterial materials and composites that enhance bone growth while preventing surgical site infection. The present invention also relates to bioactive antibacterial materials and composites that include a bimodal bioactive glass particle size distribution. The bioactive antibacterial composite finds utility in a variety... Agent: Orthovita, Inc.
20130202672 - Fiber-assembled tissue constructs: The present invention relates to a fiber-assembled tissue construct comprising at least one sinusoid unit, the unit comprising at least two polymeric fibers arranged in a sinusoid structure and fused together, each of said fibers comprising a porous matrix supporting biological components encapsulated in the fiber, wherein the biological components... Agent: Singapore Agency For Science, Technology And Research Act
20130202673 - Heterogeneous implantable devices for drug delivery: The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance... Agent: Titan Pharmaceuticals, Inc.
20130202676 - Cross-linked dehydrated placental tissue grafts and methods for making and using the same: Described herein are tissue grafts produced by contacting dehydrated placental tissue grafts with a cross-linking agent. The tissue grafts described herein provide barrier and prevent the migration of a bioactive agent from the wound. Thus, the tissue grafts enhance wound healing while preventing the undesirable migration of a bioactive agent... Agent: Mimedx Group, Inc.
20130202677 - Patch: Provided is a patch that ensures high storage stability of donepezil or a salt thereof and allows stable transdermal administration of the donepezil or salt thereof in an amount that provides a pharmaceutical effect. The patch includes a substrate 1 and an adhesive layer 2 stacked on and integrated with... Agent: Sekisui Medical Co. Ltd
20130202675 - Systems and methods for the fabrication of tissue patches: Tissue patches and associated systems and methods are described. Certain embodiments are related to inventive systems and methods in which tissue patches can be made quickly and robustly without the use of complicated fabrication or sterilization equipment.... Agent: Dynasil Biomedical Corporation
20130202674 - Tissue patch: Tissue patches and associated systems and methods are described. Certain embodiments are related to inventive systems and methods in which tissue patches can be made quickly and robustly without the use of complicated fabrication or sterilization equipment.... Agent: Dynasil Biomedical Corporation
20130202687 - Lipid vectors delivering gene silencers: Lipid vector delivering gene silencers which vector carries on its external surface at least one recognizing molecule directed against a cellular target molecule. The recognizing molecule is directed against GD2 disialoganglioside epitope, a tumor-associated membrane antigen expressed abundantly by neuroectodermal tumor cells, and which lipid vector contains as therapeutic agent... Agent: Istituto Giannina Gaslini
20130202681 - Liposomally encapsulated reduced glutathione for management of cancer and disruption of cancer energy cycles: A method of treatment of cancer with a formulation of liposomally encapsulated glutathione, that is preferably used orally, increases the level of glutathione in tissues in order to prevent and reverse the metabolic changes in cells that results in the formation of the metabolic “fuel supply” that supports cancer cells,... Agent:
20130202686 - Liposome composition and process for production thereof: A liposome composition into which a drug can be introduced in a high encapsulation amount, which has sustained release properties to such an extent that an effective concentration can be maintained at a clinically satisfactory level, and which is suitable for subcutaneous administration or the like. The liposome composition includes:... Agent: Terumo Kabushiki Kaisha
20130202684 - Pegylated liposomes for delivery of immunogen encoding rna: Nucleic acid immunisation is achieved by delivering RNA encapsulated within a PEGylated liposome. The RNA encodes an immunogen of interest. The PEG has an average molecular mass of between 1 kDa and 3 kDa. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i)... Agent: Lichtstrasse
20130202680 - Prevention and treatment of alzheimer's disease by amyloid beta peptide and sphin-gosine-1-phosphate: The invention provides compositions and methods for treatment of Alzheimer's disease. Such methods entail administering agents that induce a beneficial immune and therapeutic response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In certain preferred embodiments of such... Agent: Euroespes BiotecnologÍ A, S.l
20130202678 - Puf-a and related compounds for treatment of retinopathies and sight-threatening ophthalmologic disorders: Methods and compositions for treating retinal diseases comprising therapeutic amounts of a compound selected from a normal Puf-A gene product, an active polypeptide fragment thereof, an analog thereof or a peptidomimetic thereof. Vectors, including AAV vectors comprising the therapeutic compound are provided. Puf-A compositions suitable for subretinal, intravitreal, topical, subconjunctival,... Agent: Academia Sinica
20130202682 - Synthetic matrix vesicles for biomimetic mineralization: Compositions of synthetic matrix vesicles with mineralization relevant ions which direct mineralization of a biomimetic mineral phase and methods for use thereof are provided.... Agent: The Trustees Of Columbia University In The City Of New York
20130202679 - Targeted particles comprising landscape phage fusion proteins and heterologous nucleic acid: Disclosed are targeted particles comprising or consisting of a plurality of landscape phage fusion proteins complexed with heterologous nucleic acid, the landscape phage fusion proteins displaying a heterologous peptide and the targeted particle binding specifically to a target site. The particles may be utilized in methods for modulating expression of... Agent: Auburn University
20130202683 - Topical formulations having enhanced bioavailability: The present disclosure provides compositions suitable for delivering lipophilic bioactive agents. The compositions may be utilized to treat numerous diseases and conditions that would benefit from the application of a lipophilic bioactive agent.... Agent: Berg Pharma LLC
20130202685 - Use of a histamine h4 antagonist for the treatment of post-operative adhesions: The present invention includes methods for the inhibition of post-operative adhesion formation between tissue surfaces in a body cavity having been subjected to a surgical procedure, which methods involve administering a histamine H4 receptor antagonist, systemically, directly to tissue surfaces in the body cavity, or both, and to delivery vehicles... Agent: Janssen Pharmaceutica Nv
20130202688 - Delayed release oral disintegrating pharmaceutical compositions of lansoprazole: The present invention relates to delayed release oral disintegrating pharmaceutical compositions of lansoprazole or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of such compositions.... Agent:
20130202689 - Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications: A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.... Agent: Neptune Technologies & Bioressources, Inc.
20130202690 - Encapsulated picoplatin: The invention provides an encapsulated unit dosage form for picoplatin that is adapted for oral administration of the picoplatin containing a substantially dry powder with about 20 to 55 wt % picoplatin in the physical form of a picoplatin particulate wherein an average picoplatin particle diameter is less than about... Agent: Poniard Pharmaceuticals, Inc.
20130202691 - Modified starch derivative-based matrix for colon targeting: e
20130202693 - Oral dosage forms of bendamustine: In the present invention there is provided an oral pharmaceutical composition, comprising bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient, which is a pharmaceutically acceptable non-ionic hydrophilic surfactant.... Agent: Astellas Deutschland Gmbh
20130202692 - Organic compounds: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D2 receptor signaling systems.... Agent:
20130202694 - Agent for use in the case of fructose intolerance: There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of... Agent:
20130202695 - Agent for use in the case of fructose intolerance: There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of... Agent:
20130202696 - Agent for use in the case of fructose intolerance: There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of... Agent:
20130202697 - Chimeric surface active proteins: The present invention relates to a nucleic acid molecule encoding a chimeric protein having the biochemical activity of a surface active protein, wherein said chimeric protein comprises: (a) an N-terminal portion of a first surface active protein, wherein the N-terminal portion is devoid of between 0 and 10 of the... Agent: B.r.a.i.n. Biotechnology Research And Information Network Ag
20130202698 - L-ornidazole formulations and their applications in treatment of parasitic infections: This invention relates to new methods of treating parasitic infections, such as trichomonas vaginalis infection and cecum amoeba infection, using L-enantiomer enriched ornidazole, in particular enantiomerically pure L-ornidazole, which provides benefits such as higher efficacy and lower toxicity to central nervous system over the existing racemic Ornidazole drug. New methods... Agent: Nanjing Sanhome Pharmaceutical Co., Ltd.
20130202699 - Phosphate binder formulation for simple dosing: The invention relates to a pharmaceutical composition in the form of pourable granules or a chewable tablet containing at least one phosphate binding substance and at least one effervescent agent. The composition may be taken orally without adding water.... Agent: Fresenius Medical Care Deutschland Gmbh
20130202700 - Rapidly disintegrating coated tablets: Coated dosage forms comprising a tablet core, preferably in compressed form, that has a coating over its exterior surface and one or more patterns debossed in the tablet surface are disclosed. Methods for manufacturing such dosage forms are also disclosed.... Agent: Mcneil-ppc, Inc.
20130202701 - (1r,4r)-6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro-[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for treating fibromyalgia and chronic fatigue syndrome: The invention relates to a pharmaceutical dosage form comprising (1r,4r)-6′-Fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4′,9′-dihydro-3′H-spiro-[cyclohexane-1,1′-pyrano[3,4,b]-indol]-4-amine or a physiologically acceptable salt thereof, for use in the treatment of fibromyalgia or chronic fatigue syndrome.... Agent: Gruenenthal Gmbh
20130202702 - Oral formulations: A solid pharmaceutical composition containing AP23573 suitable for oral administration is disclosed.... Agent: Ariad Pharmaceuticals, Inc.
20130202703 - Method for producing gardenia blue pigment: Provided is a method for producing a gardenia blue pigment resistant to discoloration which may occur in colored sugar-coated food or pharmaceutical products. The method for producing such a gardenia blue pigment comprises performing membrane separation using a membrane (for example, an ultrafiltration membrane) with a molecular weight cut-off of... Agent:
20130202704 - Use of mexiprostil in the treatment of inflammatory bowel disease and/or of irritable bowel syndrome: The invention relates to the use of mexiprostil in the treatment and/or prevention of inflammatory bowel disease and of irritable bowel syndrome, to the combinations of mexiprostil with other drugs, and also to a novel method for the synthesis of mexiprostil.... Agent: Cosmo Technologies Ltd.
20130202705 - Alcohol-resistant formulations: This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing a high water-soluble, high dose drug. The dosage form has alcohol resistance and may also have crush resistance.... Agent: Cima Labs Inc.
20130202707 - Controlled delivery of tlr agonists in structural polymeric devices: The present invention comprises compositions, methods, and devices for creating an stimulating an antigen-specific dendritic cell immune response. Devices and methods provide prophylactic and therapeutic immunity to subjects against cancer and infectious agents.... Agent: President And Fellows Of Harvard College
20130202706 - Nanostructured atorvastatin, its pharmaceutically acceptable salts and compositions of them, process for the preparation thereof and pharmaceutical compositions containing them: The present invention is directed to nanostructured Atorvastatin, its pharmaceutically acceptable salts and compositions of them, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Atorvastain, its pharmaceutically acceptable salts and compositions of them according to the invention have an average particle size of less than... Agent: Druggability TechnologiesIPHoldco (jersey) Ltd.
20130202709 - Methods of treatment of pancreatic cancer: The present invention provides methods and compositions for treating pancreatic cancer in an individual who has been previously treated for pancreatic cancer (e.g., gemcitabine-based therapy) by administering a composition comprising nanoparticles that comprise a taxane and an albumin. The invention also provides combination therapy methods of treating pancreatic cancer (for... Agent:
20130202708 - Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof: The present invention is related to a viral particle released after infection of mammalian cells by human cytomegalovirus (HCMV), wherein a) the particle is surrounded by a lipid membrane in which viral glycoproteins are embedded, b) the particle contains neither viral DNA nor capsids; and c) the particle contains a... Agent: Valzine Projekt Management Gmbh
20130202710 - Pharmaceutical composition for the prolonged release of trimetazidine: Composition for the prolonged release of trimetazidine wherein the inner phase comprises trimetazidine and the outer layer comprises a retardant and an anti-agglomerant.... Agent: Les Laboratoires Servier
20130202711 - Substance-encapsulating vesicle and process for producing the same: Provided is a method for easily and efficiently producing encapsulated substance vesicles wherein a substance is encapsulated in the cavity of vesicles obtained by polymer self-assembly. Empty vesicles that have membranes comprising a first polymer that is a block copolymer with uncharged hydrophilic segments and a first kind of charged... Agent: Japan Science And Technology Agency
20130202712 - Compositions and methods for treating or preventing immuno-inflammatory disease: The present invention relates to compositions and methods for the treatment of immuno-inflammatory conditions comprising the administration of a polyphenolic phytoalexin compartmentalized in a biocompatible and/or biodegradable polymeric carrier, and to the use of biocompatible and/or biodegradable polymeric carriers comprising resveratrol and block copolymers and these compositions with an additional... Agent: Vindico Nanobio Technology, Inc.
20130202714 - Mite composition, method for rearing a phytoseiid predatory mite species, and use of the composition for controlling crop pests: The present invention relates to a mite composition, the rearing thereof and to the use of the composition for controlling crop pests. The invention provides a mite composition comprising: a rearing population of a phytoseiid predatory mite species, a population of at least one species from the order Astigmata, and... Agent: AgrobÍ O S.l.
20130202715 - Aluminosilicate glass for touch screen: An aluminosilicate glass for touch screens is provided. The glass includes, calculated based on weight percentage: SiO2, 55 to 65%; Na2O, 12 to 17%; Al2O3, 15 to 20%; K2O, 2 to 6%; MgO, 3.9 to 10%; ZrO2, 0 to 5%; ZnO, 0 to 4%; CaO, 0 to 4%; Na2O+K2O+MgO+ZnO+CaO, 15... Agent: Schott Ag
20130202717 - Materials and methods for diagnosing and predicting the course of prostate cancer: Expression of Forkhead-box protein A1 (FOXA1), a transcription factor important for the normal development of the prostate gland is thought to be controlled by steroid hormones and GATA-3. Expression of FOXA1, GATA-3 and androgen receptor (AR) was retrospectively analyzed by immunohistochemistry (IHC) in a series of 80 primary tumors and... Agent: Indiana University Research And Technology Corporation
20130202718 - Monitoring immunoglobulin heavy chain evolution in b-cell acute lymphoblastic leukemia: The invention is directed to methods of monitoring B-cell lymphoid proliferative disorders, such as B-cell acute lymphoblastic leukemias, by measuring the presence, absence and/or levels of correlating, or index, clonotypes and related clonotypes that have evolved therefrom, for example, as part of the disease condition. In one aspect, such methods... Agent: Sequenta, Inc.
20130202716 - Treatment of cancer using hypoxia activated prodrugs: Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anti-cancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated... Agent:
20130202719 - Stabilized chlorite solutions in combination with fluropyrimidines for cancer: Pharmaceutical compositions for treating neoplastic disorders and uses thereof are provided. Said pharmaceutical compositions comprise stabilized chlorite solutions (e.g. WFIO) and a fluoropyrimidine, 5-FU, or a 5-FU prodrug (e.g. capecitabine, doxifluridine, UFT, S-1, or BOF-A2). The use of the above stabilized chlorite solution in combination with a fluoropyrimidine dramatically improves... Agent: Nuvo Research Ag
20130202720 - Methods of treating hepatitis: The present invention relates to a method of treating hepatitis in a patient, which includes administering a pharmaceutical composition that includes carbon monoxide to the patient.... Agent: Beth Israel Deaconess Medical Center, Inc.
20130202721 - Sensors for detecting substances in bodily fluids: A system is disclosed that extracts bodily fluid to a reaction chamber for monitoring a substance or property of the patient fluid. In one embodiment, a pump is used to advance the sample of bodily fluid through a filter to produce a filtrate. Another pump advances filtrate into the reaction... Agent:
20130202722 - Treatment of neurocutaneous syndrome, including compositions, methods and uses thereof: A treatment protocol for use in the treatment of neurocutaneous syndrome is described and comprises at least one xanthone component, which may comprise at least one mangosteen component, and at least one detoxification component. Additional embodiments comprise at least one herbal component, at least one vitamin component, or a combination... Agent:
20130202723 - Method of producing a chinese herbal composition for treating terminal cancer patients with constipation: Constipation is a common and serious problem for terminal cancer patients, often resulting in deterioration of the overall condition of the patients and causing great anxiety in their family members. Terminal cancer patients, according to the principle of palliative care and the symptoms of pain, are usually given morphine-like analgesics... Agent:
20130202724 - Soybean extracts for the treatment of hepatic disorders: The invention provides methods and uses of different soybean extracts, for example, enzymatic, hexane, ethanol or aqueous soybean extracts and combinations thereof for the treatment of hepatic disorders, drug induced hepatic injury, the Metabolic Syndrome or an immune-related disorder in a subject in need thereof. The invention further provides pharmaceutical... Agent: Hadasit Medical Research Services And Development Ltd.
20130202725 - Method of preparing a muscadine pomace extract: Muscadine grape extracts are disclosed that have antioxidant properties. The extracts are a mixture of extracts from bronze and purple muscadine grapes that unexpectedly increase the solubility of ellagic acid in the mixture. Solvent extracts are obtained in some examples by water extracting the pomaces of the grapes from which... Agent: Shaklee Corporation08/01/2013 > 263 patent applications in 118 patent subcategories. inventions list
20130195752 - Functionalized nanoparticles and methods of use thereof: Certain embodiments of the present invention provide functionalized nanoparticles and methods of use thereof. Certain embodiments provide nanoparticles functionalized with streptokinase. Certain embodiments of the present invention provide methods for treating a pathological fibrin associated disorder (e.g., cancer) in an animal.... Agent: Regents Of The University Of Minnesota
20130195754 - Il-l binding proteins: Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.... Agent: Abbvie Inc.
20130195751 - Self-assembed conjugate and use thereof: Provided are a self-assembled conjugate of a host molecule containing compound and a guest molecule containing compound, a delivery composition of a bioactive material comprising the self-assembled conjugate and a bioactive material to be delivered, and a composition for tissue engineering containing the self-assembled conjugate and a cell.... Agent: Postech Academy-industry Foundation
20130195753 - Temporary embolization using inverse thermosensitive polymers: One aspect of the present invention relates to methods of embolizing a vascular site in a mammal comprising introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, which composition may be injected through a small catheter,... Agent: Genzyme Corporation
20130195755 - Micellular combination comprising a nanoparticle and a plurality of surfmer ligands: The field of the present invention relates to the stabilisation of nanoparticles in aqueous dispersion and, in particular, the stabilisation of nanoparticles by encapsulating the nanoparticles in a micellular combination. The field of the present invention further relates to a micellular combination of nanoparticles and a method of manufacture of... Agent: Centrum Fur Angewandte Nanotechnologie (can) Gmbh
20130195756 - 99mtc imaging agents and methods of use: wherein R1 and R2 are independently an alkyl or cycloalkyl; R3 is and alkyl; X is CO or SO2; Y is (CH2)n, C6H4, (OCH2CH2)n(NHCH2CH2)n and (OCH2CH2CH2)n, or a combination thereof; Z is linker group capable of conjugating to a vector; and n is an integer between 0 and 10. Also... Agent: General Electric Company
20130195757 - Sparc binding aptamers and uses thereof: The invention relates to nucleic acid aptamers having the ability to bind human SPARC protein (osteonectin) with specificity. The invention also relates to compositions including such aptamers, as well as methods of identifying such aptamers. The invention further relates to methods for using such aptamers in treating and diagnosing proliferative... Agent: Abraxis Bioscience, LLC
20130195758 - Paa nanoplatforms containing fluorophores and targeted moieties covalently linked and photosensitizer post-loaded: A PAA nanoparticle containing a covalently linked fluorescent dye and a post-loaded tetrapyrrolic photosensitizer.... Agent: The Research Foundation Of State University Of New York
20130195760 - Chlorotoxin variants, conjugates, and methods for their use: Chlorotoxin variants, chlorotoxin variant conjugates, compositions that include the chlorotoxin variants or conjugates, and methods for using the chlorotoxin variants, conjugates, and compositions.... Agent: Fred Hutchinson Cancer Research Center
20130195761 - Compositions comprising anti-cap37 antibodies and methods of production and use thereof: Compositions comprising antibodies raised against CAP37 and isoforms thereof, along with antigen binding fragments thereof, are disclosed. These compositions have many uses, such as in detection of CAP37 and as an early detection marker for various disease conditions. In addition, the compositions may be used therapeutically to inhibit, mitigate, or... Agent: The Board Of Regents Of The University Of Oklahoma
20130195759 - Nanostructures suitable for sequestering cholesterol and other molecules: Articles, compositions, kits, and methods relating to nanostructures, including those that can sequester molecules such as cholesterol, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanoparticle core may be surrounded by a shell including a material, such as a lipid bilayer, that... Agent: Northwestern University
20130195762 - Fat cells and methods of using thereof: Beige cells that contain a reporter gene are disclosed herein. Such cells can be used to identify therapeutic agents for treatment of obesity and its associated disorders, such as diabetes.... Agent: Ember Therapeutics, Inc.
20130195763 - Methods and compositions for improving sleep and memory: A method for determining whether a substance can increase the expression level of a fatty acid binding protein (FABP) in an animal. The method includes using a cell that includes an expression construct that comprises a FABP promoter operably linked to a polynucleotide sequence encoding a reporter molecule, wherein the... Agent:
20130195766 - Ultrafine nanoparticles comprising a functionalized polyorganosiloxane matrix and including metal complexes; method for obtaining same and uses thereof in medical imaging and/or therapy: m
20130195767 - Magnetic nanoparticles: A magnetic nanoparticle includes a magnetic core and a superparamagnetic outer shell, in which the outer shell enhances magnetic properties of the nanoparticle. The enhanced magnetic properties of the magnetic nanoparticle allow for highly sensitive detection as well as diminished non-specific aggregation of nanoparticles.... Agent:
20130195768 - Cest systems exhibiting a concentration independent responsiveness: The present invention relates to the use of non-equivalent mobile protons belonging to NMR distinguishable steroisomers of a CEST agent in a ratiometric based CEST imaging procedure and to Lanthanide (III) complex compounds displaying at least two NMR-distinguishable steroisomers in solution useful as concentration independent CEST responsive agents.... Agent: Bracco Imaging S.p.a.
20130195765 - Method for treating and diagnosing cancer by using cell-derived microvesicles: Disclosed is a method for the treatment and/or diagnosis of cancer, using bacterial cell-derived microvesicles, which is highly effective in cancer therapy with a significant reduction in side effects. Also, a method is provided for delivering of a drug therapeutic or diagnostic for a disease, using bacterial cell-derived microvesicles loaded... Agent: Postech Academy-industry Foundation
20130195764 - Nanoparticle targeting to ischemia for imaging and therapy: The invention provides compositions and methods that provide a solution to the difficulties in diagnosing ischemia, e.g., identifying specific affected anatomical areas, and treating ischemic tissue so as to minimize damage and promote healing of damaged tissue in a subject such as a human or other animal.... Agent: President And Fellows Of Harvard College
20130195769 - Oleaginous pharmaceutical and cosmetic foam: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein... Agent: Foamix Ltd.
20130195770 - Composition and method for reducing atherosclerotic lesions: The present invention relates to a method for reducing cholesterol absorption and the occurrence of atherosclerotic lesions in an animal comprising administering to the animal a composition comprising an effective amount of at least one cholesterol ester.... Agent: Dupont Nutrition Bioscience Aps
20130195772 - Color change of chalcone-containing oral care formulations: Oral care compositions and methods are described in which the composition includes a chalcone color change component, which may be phenyl-3-methoxy-4-hydroxystyryl ketone. The color change component is induced to change colors by addition of saliva and/or by a change in pH of the composition. The composition and methods provide benefits... Agent: Colgate-palmolive Company
20130195773 - Compositions: Compositions, comprising menthofuran and selected menthol compounds which feature improved flavour and odour properties, are provided and, in addition, the production of compositions, specifically, of emulsions with an improved storage stability.... Agent: Symrise Ag
20130195771 - Gantrez hydrogel with dry tack: A Gantrez hydrogel comprising sodium, calcium, zinc, strontium, and ferric cations, and a polyvinylpyrrolidone based tack agent is disclosed. A method for preparation of the Gantrez hydrogel is also disclosed.... Agent:
20130195774 - Processes of making oral compositions containing gel networks: The present invention is directed towards a process for making oral compositions comprising gel networks. The gel networks are formed from a fatty amphiphile dispersion and swelling surfactant. The fatty amphiphile dispersion comprises one or more fatty amphiphiles, one or more dispersing surfactants, and one or more solvents. A gel... Agent: The Procter & Gamble Company
20130195776 - Cosmetic composition based on ellagic acid or a derivative thereof and a bacterial extract: The invention relates to a cosmetic composition comprising, in a cosmetically acceptable medium: (i) from 0.01% to 10% by weight, relative to the total weight of the composition, of one or more compounds chosen from ellagic acid, ethers thereof and ellagic acid salts or ethers thereof, in a content ranging... Agent: L'oreal S.a.
20130195777 - Hair treatment composition containing gambogic acid, ester or amide: The present invention relates to a cosmetic composition comprising compounds or salts of formula (I) or formula (II), wherein R1 and R2 are both independently hydrogen (H), or a saturated, straight or branched C1-C8 alkyl group. More particularly, the present invention also relates to the use of said cosmetic composition... Agent: DsmIPAssts B.v.
20130195775 - Ionic/ionogenic comb copolymer compositions and personal care products containing the same: in which Y is a moiety forming part of a copolymer backbone, Z is a moiety that exhibits association with other Z moieties or with other moieties within the ultimate formulation in which the copolymer will be employed, and b is a bond or moiety that links the Z moiety... Agent: Air Products And Chemicals, Inc.
20130195780 - Skin care products contianing anatabine or derivative thereof: A skin care product includes a compound of Formula I, IA, or IB (e.g., anatabine), or a salt thereof, and a suitable cosmetic or pharmaceutical vehicle. In some aspects, the skin care product is a paste, cream, lotion, gel, moisturizer, cleanser, or sunscreen. In some embodiments, the skin care product... Agent: Rock Creek Pharmaceuticals, Inc.
20130195779 - Substantive sunscreen formulation: Disclosed is a substantive emulsion and methods for its use comprising 40 to 45% by weight of water, 25 to 30% by weight of a combination of octocrylene, avobenzone, octisalate, homosalate, and oxybenzone, and 3 to 5% by weight of a combination of VP eicosene copolymer, acrylates/C12-22 alkyl methacrylate copolymer,... Agent: Mary Kay Inc.
20130195781 - Modified variant bowman birk protease inhibitors: The present invention relates to modified variant Bowman Birk Protease Inhibitor proteins (BBPIs) that comprise peptides that bind target proteins, and that are further modified to have greater protease inhibitory activity and/or be produced at greater yields than the unmodified BBPIs. The invention encompasses polynucleotide constructs and expression vectors containing... Agent: Danisco US Inc.
20130195783 - Methods for smoothing wrinkles and skin texture imperfections: A skin smoothing composition that has from about 0.5 to about 4% sodium silicate as measured by silica content (SiO2) and from about 0.1% to about 4.0% of a polyvalent silicate. The composition is provided in a carrier, for example, from about 10 to 98% water, and can be in... Agent: The Procter & Gamble Company
20130195784 - Water dispersible solid dispersion of pigment: A solid dispersion of pigment for an aqueous composition includes a pigment and an ethoxylated alcohol. The solid dispersion of pigment is adapted for being directly incorporated into the aqueous composition with reduced shear for coloration. A method of preparing a solid dispersion of pigment for an aqueous composition with... Agent: Sun Chemical Corporation
20130195785 - Antiperspirant emulsion compositions and processes for making antiperspirant emulsion compositions: Processes for making an antiperspirant emulsion composition and antiperspirant emulsion compositions are provided herein. In an embodiment, a process for making an antiperspirant emulsion composition includes combining water and an antiperspirant active component to form a water phase. A hydrophobic carrier and a structurant are combined to form an oil... Agent: The Dial Corporation
20130195786 - Shampoo containing a gel network: A shampoo composition comprising: i) a cleaning phase comprising a cleansing anionic surfactant which is a salt and comprises an alkyl group with from 8 to 14 carbons; ii) an aqueous conditioning gel network having no overall charge or is anionic, the gel network comprising: (a) fatty material; (b) a... Agent:
20130195787 - Substituted cellulose acetates and uses thereof: The present invention relates to substituted cellulose acetates and methods of use thereof. One embodiment of the present invention provides a drilling fluid having a base fluid and a viscosifier having a substituted cellulose acetate having a polar substituent that comprises an oxygen atom covalently bonded to a nonmetal selected... Agent: Celanese Acetate LLC
20130195788 - Hair fixatives: Described are hair fixative compositions comprising an aqueous dispersion comprising an ethylene acrylic acid co-polymer, and optionally a metallocene catalyzed polyolefin.... Agent: Union Carbide Chemicals & Plastics Technology LLC
20130195789 - Low swell, long-lived hydrogel sealant: A low swell, long-lived hydrogel sealant formed by reacting a highly oxidized polysaccharide containing aldehyde groups with a multi-arm amine is described. The hydrogel sealant may be particularly suitable for applications requiring low swell and slow degradation, for example, ophthalmic applications such as sealing wounds resulting from trauma such as... Agent: Actamax Surgical Materials LLC
20130195790 - Spinosyn antifouling compositions, methods of use thereof and articles protected from attachment of biofouling organisms: Disclosed herein are antifouling compositions including at least one spinosyn active material. These compositions provide protection to surfaces coated or impregnated therewith from attachment of various biofouling organisms. Compositions include, for example, paint, varnish, and sealant formulations.... Agent: Entarco Sa
20130195791 - Conjugates comprising an n-oxime bond and associated methods: s
20130195792 - Method of treating inflammation: The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.... Agent: Cytosorbents Corporation
20130195793 - Radiation-curable antimicrobial coatings: The present invention relates to radiation-curable antimicrobial coatings, to a process for preparation thereof, and to the use thereof.... Agent:
20130195794 - Cancer vaccine: The disclosure relates to a vaccine including at least one adjuvant useful in the prevention and treatment of blood cancers, for example lymphoma, leukaemia or myeloma.... Agent: Adjuvantix Limited
20130195795 - Compositions and methods of treating inflammatory and autoimmune diseases: Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.... Agent: Amgen Inc.
20130195797 - High potency formulations of vx-950: High potency pharmaceutical compositions comprising VX-950, sodium lauryl sulfate and a polymer selected from the group consisting of hypromellose acetate succinate-M, hypromellose acetate succinate-L and hypromellose acetate succinate-H.... Agent: Vertex Pharmaceuticals Incorporated
20130195796 - Inhibitors and methods of inhibiting bacterial and viral pathogens: Compounds, pharmaceutical compositions and methods for treating viral and bacterial infections, by administering certain thiourea compounds, specifically acylthiourea, carboximidoylthiourea and S-alkyl isothiourea derivatives and analogs, in therapeutically effective amounts are disclosed.... Agent: Siga Technologies Inc.
20130195798 - Combination therapy for treatment of viral infections: One can treat a viral infection by first administering at least one first antiviral compound for a first time period and then, after the end of the first time period, concurrently or subsequently administering the at least one first antiviral compound and at least one second antiviral compound for a... Agent: United Therapeutics Corporation
20130195799 - Synergistic biomolecule-polymer conjugates: The synergistic biomolecule-polymer conjugates are the long-acting, in vivo controlled continuous-release and hybrid synergy systems of biomolecules that provide increased biological activities and enhanced pharmacological properties for achieving greater therapeutic efficacies.... Agent: Peg Biosciences, Inc.
20130195802 - Cellular constituents from bacteroides, compositions thereof, and therapeutic methods employing bacteroides or cellular constituents thereof: A cellular constituent is lysed from, produced by and/or isolated from one or more bacteria from the genus Bacteroides, and the cellular constituent, a derivative thereof, and/or one or more bacteria from the genus Bacteroides, or a modified form thereof, is employed in compositions and methods for modulating an inflammatory... Agent: Moore Research Enterprises LLC
20130195801 - Cns targeting aav vectors and methods of use thereof: The invention in some aspects relates to recombinant adeno-associated viruses useful for targeting transgenes to CNS tissue, and compositions comprising the same, and methods of use thereof. In some aspects, the invention provides methods and compositions for treating CNS-related disorders.... Agent: University Of Massachusetts
20130195800 - Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof: This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be... Agent: Intrexon Corporation
20130195816 - Compositions to effect neuronal growth: Compositions containing neurogenic agents for inhibition of neuron death and inducing proliferation of neural cells are disclosed.... Agent: Neuralstem, Inc.
20130195815 - Method for labeling insulin-secreting pancreatic beta cells and obtaining purified insulin-secreting pancreatic b-cells and an insulin reported: A method for labeling insulin-secreting pancreatic β-cells in human islets by using a genetically-encoded preproinsulin fluorescent protein reporter which targets an insulin fusion protein to correct insulin vesicles. The reporter system comprising an insulin and fluorescent protein construct provides real time tracking of secretory granules in live cells and allows... Agent: North Carolina Central University
20130195818 - Method of producing myeloid blood cells: An object of the present invention is to provide a method of producing a myeloid blood cell possessing a proliferative capability. According to the present invention, provided is a method of producing a myeloid blood cell possessing a proliferative capability, including forcedly expressing (A) a cMYC gene, and (B) at... Agent: National University Corporation Kumamoto University
20130195817 - Methods and compositions for modulating angiogenesis and vasculogenesis: Disclosed herein are methods and compositions for stimulating angiogenesis, using cells descended from marrow adherent stromal cells that have been transfected with sequences encoding a Notch intracellular domain. Applications of these methods and compositions include treatment of ischemic disorders such as stroke.... Agent: Sanbio, Inc.
20130195819 - T cell receptors and related materials and methods of use: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated... Agent: The U.s.a , As Represented By The Secretary, Department Of Health And Human Services
20130195803 - Bovine milk oligosaccharides: Oligosaccharides from bovine milk, whey and dairy products, and methods of producing bovine milk oligosaccharides are provided.... Agent: The Regents Of The University Of California
20130195804 - Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of... Agent:
20130195820 - Use of blood group status iii: The present invention relates to a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. The present invention further relates to a method of tailoring a microbial composition based on the spectrum... Agent: Suomen Punainen Risti Veripalvelu
20130195821 - Treatment of ibd and ibs using both probiotic bacteria and fermented cereal as treatment effectors: The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be... Agent: Nordisk Rebalance A/s
20130195822 - Probiotic strains for use in improving the enteric nervous system: The invention relates to the use of lactic acid bacteria, for use in modifying the enteric nervous system and more particularly in treating and/or preventing intestinal disorders such as constipation and/or irritable bowel disease.... Agent: Compagnie Gervais Danone
20130195823 - Use of lactobscilli inhibiting gas products coliform bacteria isolated from infants affected by colic: The present invention relates to a composition comprising two probiotic strains of bacteria capable of performing an antioxidant and/or antibacterial and competitive action against species of coliform bacteria that produce gas by fermentation of sugar, in particular lactose, isolated from infants affected by colic.... Agent: Probiotical S.p.a.
20130195824 - Methods for reducing cholesteron using bacillus coagulans spores, systems and compositions: The invention describes therapeutic compositions including a lactic acid-producing bacteria, such as isolated Bacillus coagulans, in combination with a cholesterol-reducing agent for use in reducing LDL cholesterol and serum triglycerides. Also described are therapeutic methods using the compositions and systems containing the therapeutic compositions.... Agent: Ganeden Biotech, Inc.
20130195826 - Composition comprising bacillus: The present invention refers to a composition comprising Bacillus subtilis (DSM 17231) and Bacillus licheniformis (DSM 17236) with nematicidal effect against phytonematodes on plants and/or its habitat, to its use and process for its preparation, use of Bacillus subtilis (DSM 17231) and Bacillus licheniformis (DSM 17236), processes for controlling, combating... Agent: Chr. Hansen A/s
20130195807 - Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets: Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists.... Agent:
20130195811 - Biomatrix scaffolds: The present invention provides biomatrix scaffolds, a tissue extract enriched for extracellular matrix components and bound growth factors, cytokines and hormones, and methods of making and using same.... Agent: The University Of North Carolina At Chapel Hill
20130195812 - Induced pluripotent stem cells: Described herein is a major breakthrough in nuclear reprogramming and induced pluripotent stem cell (iPSC) technology. Fusion of the powerful transcription activation domain (TAD) of MyoD to the Oct4 protein makes iPSCs generation faster, more efficient, purer, safer and feeder-free. Also, disclosed herein is the first report of the use... Agent: Regents Of The University Of Minnesota
20130195808 - Mesenchymal stem cell and a method of use thereof: Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.... Agent: Aska Pharmaceutical Co., Ltd.
20130195813 - Method for producing cells having characteristics of hepatocytes: The present invention relates to a method of producing cells having at least one characteristic of human hepatocytes as well as to cells produced by said method and uses of these cells.... Agent:
20130195805 - Modification of reactivity of bone constructs: A method of enhancing the binding of growth factors and cell cultures to a demineralized allograft bone material which includes applying ex vivo an effective quantity of an ionic force change agent to at least a portion of the surface of a demineralized allograft bone material to produce a binding-sensitized... Agent: Warsaw Orthopedic, Inc.
20130195809 - Multipotent stem cells and uses thereof: The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which... Agent: The Brigham And Women's Hospital, Inc.
20130195810 - Multipotent stem cells and uses thereof: The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which... Agent: The Brigham And Women's Hospital, Inc.
20130195806 - Pharmaceutical preparations of human rpe cells and uses thereof: This disclosure provides the first description of hESC-derived cells transplanted into human patients. Results are reported for one patient with each of Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (AMD). Controlled hESC differentiation resulted in near-100% pure RPE populations. Immediately after surgery, hyperpigmentation was visible at the transplant... Agent: Advanced Cell Technology, Inc.
20130195814 - Tissue-specific differentiation matrices and uses thereof: In some aspects, this invention provides a method of making a bone marrow-derived tissue-specific stem cell proliferation, expansion, isolation and rejuvenation extracellular matrix. In other aspects, this invention provides a method of making a tissue-specific fibroblast-derived stem cell differentiation extracellular matrix. Also provided are methods of using such a cell-derived... Agent: The Board Of Regents Of The University Of Texas System
20130195825 - Cells expressing th1 characteristics and cytolytic properties: A novel cell type has been generated that has both Th1 characteristics and cytolytic activity. These Th1/killer cells are CD4+ cells purified from peripheral blood and manipulated to have Th1 characteristics such as production of IFN-gamma combined with cytolytic activity similar to cytotoxic T-cells (CTL). The CTL activity is targeted... Agent:
20130195827 - Nutrigenomic methods to overcome carbohydrate bingeing and overeating: This invention concerns Reward Deficiency Syndrome (RDS) and obesity, and the role of catecholaminergic pathways in aberrant substance-seeking behavior, in particular cravings for carbohydrates. Also described are new nutrigenomic formulas having unique combinations of ingredients having a generalized anti-craving effect are, which can inhibit carbohydrate bingeing, inducing significant healthy fat... Agent:
20130195828 - Pharmaceutical compositions and methods for digesting atherosclerotic plaques: Disclosed are pharmaceutical compositions and methods for digesting atherosclerotic plaques in a patient in need thereof. The compositions include and the methods utilize a mixture of collagenases for digesting plaques and optionally may include or utilize additional agents such as cyclodextrins, chelating agents, and tissue plasminogen activator.... Agent: Northwestern University
20130195833 - Methods and compositions for the treatment of symptoms of prion diseases: A therapeutic composition for the treatment of the symptoms of prion diseases and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies.... Agent: Curemark LLC
20130195829 - Themostable phytase variants: The present invention relates to a method for producing phytase variants which has at least 74% identity to a phytase derived from Citrobacter braakii and comprises at least two additional disulfide bonds as compared to this phytase. These phytase variants have modified, preferably improved, properties, such as thermostability, temperature profile,... Agent: Novozymes A/s
20130195830 - Perorally applicable preparation containing histaminase of vegetable origin, resistant to pepsin and trypsin and a process for producing it: The subject of the invention is a perorally applicable preparation of vegetable origin, resistant to pepsin and trypsin, based on histaminase, optionally for the use as an agent for improving digestion, reducing appetite or reducing body weight. The preparation of the invention is a pressed juice—which is optionally in lyophilized... Agent: Debreceni Egyetem
20130195831 - Silk-based drug delivery system: The present invention provides for novel sustained release silk-based delivery systems. The invention further provides methods for producing such formulations. In general, a silk fibroin solution is combined with a therapeutic agent to form a silk fibroin article. The article is then treated in such a way as to alter... Agent: Trustees Of Tufts College
20130195832 - Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.... Agent: A Tyr Pharma, Inc.
20130195835 - Glycosylation of molecules: Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders.... Agent: Vib Vzw
20130195836 - Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof: Described herein are isolated nucleic acid molecules comprising nucleotide sequence encoding mannose receptor, C type 1 (MRC1) wherein the 5′ region of the nucleotide sequence encoding MRC1 is codon optimized; cells comprising such nucleic acid molecules; and methods of detecting antibody production, e.g., neutralizing antibody production, in a subject being... Agent: Shire Human Genetic Therapies, Inc.
20130195834 - Treatment of glycogen storage disease type ii: Methods of treating glycogen storage disease type II, by administering acid α-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II.... Agent: Duke University
20130195837 - Methods for the prevention or treatment of vessel occlusion injury: This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof, wherein the peptide is D-Arg-2 6-Dmt-Lys-Phe-NH2 (SS-31).... Agent: Stealth Peptides International, Inc.
20130195838 - Methods of treating cancer using growth factor retargeted endopeptidases: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.... Agent: Allergan, Inc.
20130195839 - Polymer-based compositions and conjugates of antimicrobial agents: Provided herein are water-soluble polymer conjugates and polymer-based compositions of antimicrobial agents. Also provided are methods for synthesizing and administering such conjugates and compositions.... Agent: Naktar Therapeutics
20130195841 - Biofilm resistant materials: This invention provides a biofilm resistant material comprising an active agent, which active agent consists essentially of an insoluble copper oxide at a concentration of between 3 and 10% w/w of said biofilm resistant material and uses thereof.... Agent: Cupron Scientific Ltd.
20130195843 - Biomarkers for non-hodgkin lymphomas and uses thereof: The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods for classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising... Agent: British Columbia Cancer Agency Branch
20130195842 - Methods for treating disorders of amino acid metabolism: The invention is directed to methods for treating disorders of amino acid metabolism, in particular, phenylketonuria (PKU). Such methods utilize novel compositions including Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) alone or in combination with other agents or treatment modalities.... Agent: Stemnion, Inc.
20130195840 - Therapeutics and processes for treatment of immune disorders: Processes of diagnosing or treating an autoimmune abnormality are provided whereby the presence of IgA anti-neutrophil cytoplasmic antibodies (ANCA) in a subject are detected correlating with both presence and severity of disease such as Wegener's granulomatosis (WG). The FCAR genotype predicts whether IgA ANCA will be stimulatory or inhibitory of... Agent:
20130195845 - Anti-erbb2 antibodies: Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described.... Agent:
20130195844 - Antibodies against human il17 and uses thereof: An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between CH1 and CH2 and/or in the second inter-domain... Agent: Roche Palo Alto LLC.
20130195851 - Articles of manufacture and methods for co-administration of antibodies: The present invention relates to articles of manufacture and methods for co-administration of antibodies and/or antibody-like molecules, and further concerns methods for intravenous administration of more than one antibody and/or antibody-like molecule to a subject in need from a stable mixture contained in the same article of manufacture, such as... Agent: Genentech, Inc.
20130195857 - Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer: The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from pancreatic cancer, in particular metastatic pancreatic cancer by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more... Agent: Hoffmann-la Roche Inc.
20130195850 - Cd3 immunotherapeutics and uses thereof: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell... Agent: Emergent Product Development Seattle, LLC
20130195846 - Combination therapy with type i and type ii anti-cd20 antibodies: The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type I anti-CD20 antibody and a... Agent: Roche Glycart
20130195848 - Imidazopyrazines: The present invention relates to imidazopyrazine compounds of general Formula (I): in which X, R1, R2, R3a, R3b, R4a, R4b, R4C, and R4D are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use... Agent: Bayer Intellectual Property Gmbh
20130195856 - Methods of altering bone growth by administration of sost or wise antagonist or agonist: The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may... Agent: Ossifi Inc.
20130195855 - Methods of antagonizing signal transduction in dorsal root ganglion cells: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.... Agent: Zymogenetics, Inc.
20130195853 - Modulators of candida hyphal morphogenesis and uses thereof: The invention relates to modulation of fungal morphology between yeast-to-hyphal growth transition by controlling muramyl-L-alanine concentration and uses thereof.... Agent: Agency For Science, Technology And Research
20130195854 - Predictive biomarker for cancer treatment with adcc-enhanced antibodies: The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an ADCC-enhanced antibody.... Agent: Roche Glycart Ag
20130195849 - Stable heterodimeric antibody design with mutations in the fc domain: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc... Agent: Zymeworks Inc.
20130195858 - Treatment of b-cell lymphoma with microrna: The invention relates to microRNA-34a and related microRNAs for use in the treatment of B-cell lymphoma. Likewise it relates to microRNA-34a for use in the preparation of a medicament for the treatment of B-cell lymphoma, and for a method of treatment of B-cell lymphoma comprising administering microRNA-34a. These claims are... Agent: University Of Zurich
20130195847 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.
20130195852 - Use of inhibitors of bruton's tyrosine kinase (btk): Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more... Agent: Pharmacyclics, Inc.
20130195862 - Activin-actriia antagonists for inhibiting germ cell maturation: In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.... Agent: Acceleron Pharma, Inc.
20130195860 - Antibody targeting through a modular recognition domain: The present invention provides antibodies containing one or more modular recognition domains (MRDs) for targeting the antibodies to specific sites. The use of the antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also provided... Agent:
20130195859 - Compositions and methods for modulating cardiac conditions: Embodiments herein report methods and compositions for treating cardiac conditions. In certain embodiments, compositions and methods relate to reducing, inhibiting or treating a subject having or suspected of undergoing cardiac remodeling after a cardiac event. Other embodiments herein relate to compounds including naturally occurring and synthetic compositions of alpha-1 antitrypsin... Agent: Virginia Commonwealth University
20130195864 - Fgfr-fc fusion protein and use thereof: The present invention belongs to the field of biotechnology and relates to the treatment of diseases, especially the treatment of FGF overexpression-related diseases. Particularly, the present invention relates to FGFR-Fc fusion proteins and the use thereof in the treatment of angiogenesis regulation-related diseases. More particularly, the present invention relates to... Agent: Yantai Rc Biotechnologies
20130195865 - Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis: The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule.... Agent: Bristol-myers Squibb Company
20130195863 - Methods and pharmaceutical compositions for the treatment of bone density related diseases: The invention relates to methods and pharmaceutical compositions for the treatment of bone density related diseases. More particularly, the present invention relates to a ROBO1 modulator for use in a method for the treatment of a bone mineral density related disease in a subject. In a particular embodiment the ROBO1... Agent:
20130195861 - Serum amyloid p-antibody fusion proteins: Functionalized pentraxin-2 (PTX-2) protomers and functionalized PTX-2 pentamers, methods for preparing functionalized PTX-2 protomers and functionalized PTX-2 pentamers, pharmaceutical compositions including functionalized PTX-2 pentamers, and methods for using the same are described herein.... Agent: Promedior, Inc.
20130195869 - Anti-human ccr7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier: An object of the present invention is to provide a novel anti-human CCR7 antibody useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having... Agent: Sekisui Chemical Co., Ltd.
20130195866 - Methods to inhibit neurodegeneration: Disclosed herein are methods, and compositions for inhibiting neurodegeneration, e.g., in neuronal cells. The methods and compositions the invention can be used to treat a neurodegenerative disorder, e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, and frontotemproal dementia. In some embodiments, the methods and compositions can be used to inhibit neurodegeneration,... Agent:
20130195867 - Rna-coded antibody: The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, auto-immune diseases, virus diseases and monogenetic diseases, e.g.... Agent: Curevac Gmbh
20130195868 - Treating surface of the eye disorders: Disclosed herein are methods for administering an IL-1 or IL-17 antagonist for treating ocular surface disorders, e.g., a dry eye disorder. The antagonists can be administered topically using an opthalmic composition.... Agent: Eleven Biotherapeutics, Inc.
20130195872 - Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof: This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.... Agent: Novimmune S.a.
20130195871 - Dual variable domain immunoglobulins and uses thereof: Engineered multivalent and multispecific binding proteins that bind two different (e.g., nonoverlapping) epitopes of the same receptor or two different receptors expressed on the same cell are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.... Agent: Abbvie Inc.
20130195870 - Erbb3 mutations in cancer: The present invention concerns somatic ErbB3 mutations in cancer including methods of identifying, diagnosing, and prognosing ErbB3 cancers, as well as methods of treating cancer, including certain subpopulations of patients.... Agent: Genentech, Inc.
20130195873 - Carbohydrate hapten-based anti-cancer vaccines and antibody drugs: Immunogenic compositions that contain haptens consisting of carbohydrate moieties are useful to induce an immune response to provide antibodies to epitopes contained in CA215 and also to elicit an immune response to cancers expressing these epitopes.... Agent: Vancouver Biotech Ltd.
20130195874 - Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition: According to the present invention it has been found that the administration of an anti-ADM antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold may reduce considerably the risk of mortality in a patient having a severe chronical or acute disease. In a preferred embodiment of the present... Agent: Adrenomed Ag
20130195878 - Anti-asic1 antibodies and uses thereof: The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. The antibodies of the invention are useful for the treatment of pain,... Agent: Regeneron Pharmaceuticals, Inc.
20130195876 - Human streptococcus pneumoniae antibodies and uses therefor: The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of Streptococcus pneumoniae infections. In particular, these antibodies may kill Streptococcus pneumoniae or limit the replication of Streptococcus pneumoniae. Also disclosed are improved methods for producing such monoclonal antibodies.... Agent: Oklahoma Medical Research Foundation
20130195877 - Treatment of cachexia by targeting interleukin-1 beta: Administration of a mAb that specifically binds IL-1β is used for treating cachexia in human subjects.... Agent: Xbiotech, Inc.
20130195880 - Identification of polymorphisms and their use as markers for disease susceptibility, diagnosis and treatment optimization: Provided are methods and kits to determine whether a subject is predisposed to developing a disease or condition associated with structural polymorphisms in genes CNTNAP2 and CNTNAP4, along with the methods to optimize treatment with various pharmaceutical preparations which modulate ion channels, neurite outgrowth, and myelination signaling.... Agent:
20130195885 - Compositions with hematopoietic and immune activity: The present invention provides methods of using Bv8 and EG-VEGF polypeptides and nucleic acids to promote hematopoiesis. Also provided herein are methods of screening for modulators of Bv8 and EG-VEGF activity. Furthermore, methods of treatment using Bv8 and EG-VEGF polypeptides or Bv8 and EG-VEGF antagonists are provided.... Agent: Genentech, Inc.
20130195882 - Mcpip protection against osteoclast production: Disclosed herein are methods of treating a patient at risk of developing an inflammatory joint disease. In exemplary embodiments, the method involves inhibiting MCPIP levels in a patient in need, wherein said patient in need is exhibiting pre-arthritic or pre-osteoporotic symptoms.... Agent:
20130195886 - Methods for fructanase and fructokinase inhibition: Provided are methods and compositions method for inhibiting fructokinase activity within the gastrointestinal tract cell of a subject. The compositions and methods treat or prevent conditions associated with increased permeability and oxidative stress in the gastrointestinal tract of a subject.... Agent: The Regents Of The University Of Colorado, A Body Corporate
20130195891 - Micro-rna family that modulates fibrosis and uses thereof: The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice... Agent: The Board Of Regents, The University Of Texas System
20130195884 - Novel modulators of trail signalling: The present invention relates to an agent for use as a modulator of apoptosis-factor-associated cell death, apoptosis, cell survival, migration and/or proliferation, a method of diagnosing or monitoring apoptosis-factor-associated conditions or disorders as well as a method of identifying a modulator of apoptosis-factor-associated cell death, apoptosis, cell survival, migration and/or... Agent: Deutsches Krebsforschungszentrum
20130195887 - Pharmacological vitreolysis: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to,... Agent: Thrombogenics Nv
20130195881 - Potent, stable and non-immunosuppressive anti-cd4 antibodies: Novel antibodies and their fragments are disclosed that specifically bind to CD4. Anti-CD4 antibodies are disclosed having amino acid substitutions in the hinge region that prevent intrachain disulfide bond formation resulting in antibody molecules with surprisingly improved bivalent stability. Increased stability facilitates manufacturing and provides increased in vivo stability. Antibodies... Agent:
20130195889 - Trabeculectomy outcome: The current invention relates to the improvement of trabeculectomy surgery. The improvement more specifically resides in an extended lifetime of the sclera-corneal drainage channel created by trabeculectomy surgery. The improvement is obtained by post-surgical administration of an anti-PlGF antibody or fragment thereof.... Agent: Thrombogenics Nv
20130195890 - Treatment of ms with goat serum: A serum composition from a goat immunised with HIV contains anti-HLA antibody and is suited for palliative improvement of the condition of an animal.... Agent: Aimsco Limited
20130195888 - Ultrafiltration and diafiltration formulation methods for protein processing: Disclosed herein are methods of purifying proteins using ultrafiltration and diafiltration processes.... Agent: Abbvie
20130195883 - Use of vap-1 inhibitors for treating fibrotic conditions: The present invention relates to inhibitors of VAP-1 and their use as medicaments in treating fibrotic conditions. Furthermore, the present invention relates to a method of diagnosing a fibrotic condition on the basis of elevated level of soluble VAP-1 or SSAO activity in a bodily fluid, and to a kit... Agent: Biotie Therapies Corp.
20130195892 - Bvdv vaccine: The present invention relates to BVD virus and to its uses, to vaccines and combination vaccines comprising such a virus, their use as a medicament, their use in the treatment of Bovine Viral Diarrhoea and to methods for the preparation of such vaccines.... Agent:
20130195893 - Use of a pneumococcal p4 peptide for enhancing opsonophagocytosis in response to a pathogen: Methods for enhancing opsonophagocytosis of a pathogen of interest are disclosed. The disclosed methods include administering to a subject an isolated P4 peptide, which includes the amino acid sequence set forth as SEQ ID NO: 1 and optionally an isolated opsonic antibody or a fragment thereof that specifically binds to... Agent: The Government Of The United States Of America As Represented By The Secretary Of The Department Of
20130195894 - Detection and treatment of autoimmune disorders: Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) as well as clinical assays for detection of autoimmune disease activity in patients utilizing a PD1 ligand.... Agent: Children's Hospital And Regional Medical Center
20130195895 - Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function: The invention relates to methods of modulating immune responses in a subject such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not... Agent: The Brigham And Women's Hospital, Inc.
20130195896 - Compositions and methods for the treatment of a neoplasia: The invention provides methods for the treatments of neoplasia featuring agents that interfere with the expression or activity of a TNFa receptor.... Agent: Steward Research And Specialty Projects Corporation
20130195897 - Removal of serine proteases by treatment with finely divided silicon dioxide: The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized... Agent: Baxter International Inc.
20130195900 - Identification of t cell target antigens: The present invention relates to a method of identifying a target antigen of T cells comprising (a) contacting (aa) cells expressing (i) a functional T cell receptor complex comprising predefined matching T cell receptor α and β chains; and (ii) a read-out system for T cell activation; with (ab) antigen-presenting... Agent: Ludwig-maximilians-universitat Munchen
20130195898 - Microemulsions with adsorbed macromolecules and microparticles: Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the... Agent: Novartis Vaccines And Diagnostics, Inc.
20130195899 - Therapeutic immune modulation by stem cell secreted exosomes: Disclosed are methods, compositions of matter, and protocols useful for the induction of a therapeutic immune modulatory response through administration of exosomes derived from a stem cell source. In one embodiment, said stem cell source is endometrial regenerative cells. Specifically, in one embodiment stem cell derived exosomes are used as... Agent: Medistem, Inc.
20130195903 - Compositions for use in the treatment of chronic obstructive pulmonary diseases and asthma: The present invention provides compounds and methods for treating or preventing pulmonary diseases include COPD and asthma. In particular, the present invention provides for compounds comprising type V collagen, or tolerizing fragments thereof, for the treatment of COPD and asthma.... Agent: Indiana University Research & Technology Corporation
20130195902 - Recombinant allergen: Dander from the domestic cat (Felis domesticus) is one of the most common causes of IgE mediated allergy. The present invention relates to a recombinant folded Fel d 1 with molecular and biological properties similar to the natural counterpart and specifically a synthetic gene coding for a direct fusion of... Agent: Alk-abello A/s
20130195901 - Ssx-2 peptide analogs: Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which... Agent: Mannkind Corporation
20130195905 - Composition for preventing or treating cervical cancer having human papillomavirus plasmodium and immunity enhancer: A composition for preventing or treating cervical cancer comprising a human papillomavirus plasmodium and an immunity enhancer is provided. A fusion protein including a fusion polypeptide recombined to transform a 3D structure of E6 and E7, which are antigens against types 16 and 18 human papillomavirus (HPV), a signal peptide... Agent: Genexine Co., Ltd.
20130195906 - H3 equine influenza a virus: The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.... Agent: Wisconsin Alumni Research Foundation
20130195904 - Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications: We identified regions of the HIV-1 proteome with high conservation, and low variant incidence. Such highly conserved sequences have direct relevance to the development of new-generation vaccines and diagnostic applications. The immune relevance of these sequences was assessed by their correlation to previously reported human T-cell epitopes and to recently... Agent: The Johns Hopkins University
20130195907 - Omv vaccines: The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The... Agent: Norvartis Ag
20130195909 - Composite antigenic sequences and vaccines: The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition, the invention relates... Agent: Longhorn Vaccines And Diagnostics. LLC
20130195908 - Molecular complex for targeting antigens towards cells comprising antigens and uses thereof for vaccination: The invention relates to a molecular complex for targeting the antigen towards cells comprising antigens, including at least one antigen associated with at least two ligands of surface molecules of cells comprising antigens, said complex including at least one first ligand of a sulphated sugar of the glycosaminoglycan family and... Agent:
20130195910 - Vaccine delivery method: The present invention includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also include are methods of inducing an immune response... Agent: University Of Georgia Research Foundation, Inc.
20130195911 - Compositions and methods for treating skin: A skin treatment composition comprising a combination of at least one extract from the Hippophae genus and at least one extract from the Pleurotus genus and a method for treating sensitive skin for improvement comprising administering a topical composition comprising at least one extract from the Hippophae genus and at... Agent:
20130195912 - Poxvirus expression system: There is provided a method for inserting a nucleic acid sequence that encodes a foreign peptide into a poxvirus genome, said method comprising: identifying in the poxvirus genome a poxvirus open reading frame wherein said open reading frame is characterised by an initial ATG start codon and wherein expression of... Agent: Isis Inovation Limited
20130195913 - Live attenuated parvovirus: The invention relates to live attenuated parvoviruses, their uses, vaccines comprising such live attenuated parvoviruses, as well as methods for their production.... Agent:
20130195914 - Expression of positive sense single stranded rna virus and uses thereof: The invention relates to the fields of viruses, vaccines and compounds and methods for expression. In particular, the invention includes methods and agents capable of producing quantities of a vaccine to a positive sense single stranded RNA (“(+)sense RNA”)virus.... Agent: Viracine Therapeutics Corporation
20130195917 - Immunoadjuvant: The invention thus relates to a method for boosting the efficiency of a vaccine by co-administering a probiotic bacterium such as L. casei 431 or BB-12 with an influenza vaccine. The invention further relates to a composition for use in such a treatment.... Agent:
20130195915 - Influenza c virus and vaccine: A novel influenza C virus with only low homology to any influenza C virus previously characterized. Challenge studies show that the virus can infect pigs and be transmitted between pigs. Additionally, influenza C is commonly thought of as a human pathogen and serological studies have been performed, looking at the... Agent: Newport Laboratories
20130195916 - System and method for identifying complex patterns of amino acids: A method and system are disclosed for identifying and/or locating complex patterns in an amino acid sequence stored in a computer file or database. According to an aspect of the present invention, techniques are provided to facilitate queries of protein databases. For protein descriptions received in response to the queries,... Agent:
20130195918 - Equine herpesvirus 1 vaccine and vector and uses thereof: We have constructed a mutant EHV-1 that is lacking the entire 12.7 kbp IR segment of the viral genome and found the mutant EHV-1 to be replication competent, to have the ability to replicate in mammalian cell types (including human cells), and to exhibit reduced virulence in the mouse model... Agent:
20130195919 - Induced dendritic cell compositions and uses thereof: The invention provides, for example, compositions comprising induced tolerogenic dendritic cells which are capable of suppressing an antigen specific T cell-mediated immune response, and to methods of making and using the same. The invention also provides compositions comprising induced immunogenic dendritic cells and methods of making and using them.... Agent: President And Fellows Of Harvard College
20130195920 - Biodegradable lipids for the delivery of active agents: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also... Agent: Alnylam Pharmaceuticals, Inc.
20130195935 - Abuse-proofed dosage form: A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from... Agent: Grunenthal Gmbh
20130195929 - Active ingredient delivery system with an amorphous metal salt as carrier: An active ingredient delivery system and a method of making or using the same, wherein the delivery system includes an active ingredient and a carrier component of an amorphous metal salt, with the active ingredient at least partly fixed to and partly encapsulated by the carrier component. The active ingredient... Agent: Firmenich Sa
20130195925 - Anti aging application and method for treating aging: There is a topical anti-aging composition which is configured to interfere with the production of tyrosinase, as well as melanin by reacting with melanocytes as well as reacting with, or acting on keratinocytes. The anti-aging composition comprises an emulsion comprising a plurality of active ingredients comprising a plurality of pigmentation... Agent: Vaskin, LLC
20130195931 - Antimicrobial composite: An antimicrobial composite which comprises a first, liquid-permeable layer which is substantially completely bonded to a second liquid-absorbing layer. The first layer comprises a coating of at least one antimicrobial metal as such on the side which is bonded to the second layer. Substantially no antimicrobial metal in elemental form... Agent:
20130195932 - Archaeal polar lipid aggregates for administration to animals: The invention provides non-replicating compositions, and methods for the delivery of these compositions containing pharmaceuticals, biologically relevant molecules, and/or antigens to the host, by administration via a mucosal route such as the intranasal. This invention provides non-replicating vaccine compositions and methods for the delivery of antigens in these vaccine compositions... Agent: National Research Council Of Canada
20130195927 - Cerium oxide nanoparticles and associated methods for promoting wound healing: Novel compositions and methods for the treatment and promotion of wound healing are disclosed herein. There is included a method for treating a wound including administering to a subject in need thereof a wound composition comprising an effective amount of ceria nanoparticles.... Agent: University Of Central Florida Research Foundation Inc.
20130195928 - Continuous matrix with osteoconductive particles dispersed therein, method of forming thereof, and method of regenerating bone therewith: The present disclosure provides compositions useful in regeneration of connective tissue, particularly bone. The compositions comprise a continuous matrix formed of a polypeptide crosslinked with a second polymer and further comprise particles of a porous, osteoconductive material dispersed in the continuous matrix. The composition can be provided in a dehydrated... Agent: Pioneer Surgical Technology
20130195930 - Inulin and inulin acetate formulations: The disclosure provides compositions that include microparticles or nanoparticles of beta inulin or inulin acetate and an active agent, where the active agent is contained within individual microparticles or nanoparticles. The active agent can be, for example, a vaccinating antigen, an antigenic peptide sequence, or an immunoglobulin. The compositions can... Agent: South Dakota Sate University
20130195938 - Method of modifying dissolution rate of particles by addition of hydrophobic nanoparticles: Method of modifying dissolution rate of a plurality of particles in an aqueous-based solvent by adding hydrophobic surface modified nanoparticles to the plurality of particles, and exposing the plurality of particles to the aqueous-based solvent.... Agent: 3m Innovative Properties Company
20130195940 - Method to inhibit recruitment of monocytes and macrophages by an icam-3 inhibitor: The present disclosure relates generally to methods and materials for modulating the recruitment of macrophages or monocytes to sites at which they may contribute to disease initiation or progression. Embodiments of the disclosure comprise providing a modulator of the activity of ICAM-3 or proximal to the site.... Agent: Aston University
20130195939 - Methods and compositions for oral administration of exenatide: This invention provides compositions comprising a byetta, fish oil, and a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral or rectal administration of a byetta.... Agent: Oramed Ltd.
20130195922 - Methods and compositions for treating proliferative diseases: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations... Agent: Abraxis Bioscience, LLC
20130195934 - Methods and devices for providing prolonged drug therapy: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose... Agent: Alza Corporation
20130195921 - Methods for regulating gelation of hydrogel solutions and uses thereof: The present invention provides a method for preparing chitosan and xylan composite thereto-gelling solutions to allow regulating the conditions in which the chitosan and xylan solution will gel. The present invention also provides methods for using chitosan/xylan solutions as compositions and for using chitosan/xylan solutions in vitro and in vivo.... Agent: University Of Virginia Patent Foundation
20130195923 - Microemulsions with adsorbed macromolecules and microparticles: Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the... Agent: Novartis Vaccines And Diagnostics, Inc.
20130195926 - Modulation of nitric oxide signaling to normalize tumor vasculature: The instant invention provides methods for treating a solid tumor in a subject comprising modulating nitric oxide production in the tumor to normalize tumor vasculature and administering an anti-tumor therapy to the subject. The invention further provides methods of treating a solid tumor in a subject comprising selectively increasing cyclic... Agent: The General Hospital Corporation
20130195936 - Ophthalmic oil-in-water emulsions containing prostaglandins: The present invention refers to an oil-in-water emulsion for ophthalmic application comprising at least one prostaglandin as active agent and a surfactant component comprising a combination of at least two non-ionic surfactants. The emulsion is suitable for medical applications, particularly for the treatment of glaucoma, and has an increased chemical... Agent: Azad Pharma Ag
20130195933 - Pharmaceutical composition and use: An injectable, flowable composition, kits that include the same, and methods of medical treatment of a mammal (e.g., human) that include the administration of the same are provided.... Agent: Spinethera
20130195937 - Use of carbon nanotubes for preventing or treating brain disease: A method for preventing or treating a brain nervous disease includes administering to a subject in need thereof a therapeutically effective amount of a carbon nanotube, wherein the nervous disease is a brain disease or a traumatic central nervous system injury. The composition of the present invention enables patients to... Agent: Brainguard Co., Ltd.
20130195924 - Water-soluble pharmaceutical composition comprising at least one therapeutically active substance having hydrophobic properties and at least one compound selected from among sialoglycosphingolipids, glycosphingolipids or a mixture of sialoglycosphingolipi: This invention discloses water soluble pharmaceutical compositions including at least one therapeutically active substance and at least one compound selected from the sialoglycosphingolipids, the glycosphingolipids or a mixture of sialoglicosphingolipids and glycosphingolipids, in which at least one of the therapeutically active substances is a drug with hydrophobic characteristics. In particular,... Agent:
20130195942 - Abrasive system for oral care compositions: Oral compositions comprising a first and a second abrasive are provided. The first abrasive preferably has an Einlehner hardness of greater than about 5 mg loss per 100,000 revolutions, and the second abrasive preferably has an Einlehner hardness of less than about 5 mg loss per 100,000 revolutions. A ratio... Agent: Colgate-palmolive Company
20130195943 - Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists: The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition... Agent: Allergan, Inc.
20130195944 - Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists: The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition... Agent: Allergan, Inc.
20130195941 - Pullulan-containing powder, method for producing the same and use thereof: The present invention aims to provide a particulate composition containing pullulan, which can be produced without employing any complicated purification step such as solvent precipitation and, when formed into a film, exhibits a higher rupture strength compared to conventional ones; a process for producing the same; and uses thereof. The... Agent: Hayashibara Co., Ltd.
20130195945 - Compositions and methods for bed bug control using entomopathogenic fungi: Barrier treatment compositions using conidia of entomopathogenic fungi and methods for applying and using the same for bed bug population control and prevention are disclosed. The compositions and methods of the invention provide residual biopesticides control for bed bug populations using barrier treatment compositions transferring conidia of entomopathogenic fungi to... Agent: The Penn State Research Foundation
20130195947 - Biocide powder formulation: A storage stable, free flowing powder concentrate for use in the manufacture of a biocide formulation comprises a t biocide containing an iodopropynyl group and an inert filler, wherein the wt % ratio of biocide: inert filler is from about 1:1 to about 1:100 and the wt % of biocide... Agent:
20130195946 - Insecticidal hydrogel feeding spheres: Unique spherically shaped insecticidal hydrogel feeding spheres are described comprising insecticide active, food source, optional adjuvant, water, and super-absorbent polymer. The large discrete spheres with diameters of about 2 mm to about 6 mm are made possible by the use of coarse dry granulated polyacrylamide/acrylates copolymer having particle size of... Agent:
20130195948 - Composition: i
20130195949 - Antimicrobial layer for chromatographic containers: A chromatographic container (1) incorporating an antimicrobial layer (5) or an antimicrobial device (10) with such a layer (15) for use with a standard chromatographic container (11), which layer (5, 15) inhibits, in use, microbial growth. The antimicrobial layer (5, 15) can be on an internal surface of the container... Agent: Waters Technologies Corporation
20130195950 - Heterogeneous implantable devices for drug delivery: The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance... Agent: Titan Pharmaceuticals, Inc.
20130195951 - Heterogeneous implantable devices for drug delivery: The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance... Agent: Titan Pharmaceuticals, Inc.
20130195952 - Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules: A drug delivery system is disclosed. The drug delivery system includes a recognitive polymeric hydrogel through which a drug is delivered by contacting biological tissue. The recognitive polymeric hydrogel is formed by using a bio-template, which is a drug or is structurally similar to the drug, functionalized monomers, preferably having... Agent: Auburn University
20130195954 - Films and particles: Described herein are compounds and processes that can be used to prepare polymer-based films, particles, gels and related compositions, and processes for delivery of agents, and other uses.... Agent: The Brigham And Women's Hospital
20130195955 - Implants containing bmp-7: Osoteogenic implants, and related compositions, methods and kits. The implants comprise a biodegradable scaffold comprising a polycaprolactone matrix and tricalcium phosphate particles within the matrix. The implants further include a formulation comprising BMP-7.... Agent:
20130195953 - Methods and formulations for administration of anti-inflammatory compounds: The invention relates to resolvins and their use as anti-inflammatory compounds. The resolvins may be administered in a variety of forms, including drug depots comprising polymers or lipids. The pharmaceutical formulations of the present invention may be used to treat a variety of conditions including acute pain and chronic pain.... Agent: Warsaw Orthopedic, Inc.
20130195957 - Patch and method for enhancing adhesion force of the same: A patch comprising a support and an adhesive agent layer, wherein the adhesive agent layer comprises at least one selected from the group consisting of tolterodine acetate and salts thereof.... Agent: Hisamitsu Pharmaceutical Co., Inc.
20130195956 - Transdermal hormone delivery: Compositions and devices for transdermal hormone delivery are disclosed. The compositions and devices include desogestrel and enable delivery of effective amounts of progestin without the use of skin permeation enhancers.... Agent: Agile Therapeutics, Inc.
20130195958 - Process for the production of patches or derssings of autologous skin through cultivation of autologous keratinocytes and fibroblasts with autologous serum for the generation of skin: The process in general is based on taking a sample of skin and a sample of blood from the patient and based on these two elements skin is cultured, being placed on a collagen patch to produce a dressing which is subsequently placed on the patient requiring same.... Agent:
20130195959 - Lyophilized platelet lysates: The present disclosure is drawn to compositions and methods of making and using lyophilized platelet lysates. Specifically, a method of preparing a composition suitable for therapeutic use or as a culture medium can comprise steps of concentrating platelets from a platelet source to form a platelet rich portion of the... Agent:
20130195960 - Substituted cellulose acetates and uses thereof: The present invention relates to substituted cellulose acetates and methods of use thereof. One embodiment of the present invention provides a diaper having an inner layer having an absorbent core having a substituted cellulose acetate having a polar substituent that has an oxygen atom covalently bonded to a nonmetal selected... Agent: Celanese Acetate LLC
20130195964 - Compositions and methods for the treatment of cancer: The present invention provides compositions and methods for the treatment of cancer are provided.... Agent: Board Of Regents Of The University Of Nebraska
20130195966 - Double-stranded rna oligonucleotides which inhibit tyrosinase expression: Novel double-stranded RNA oligonucleotides are useful for decreasing tyrosinase expression, have cosmetic and/or pharmaceutical applications, for example are useful skin depigmenting or anti-browning agents, and can be associated with cationic particles less than or equal to 1 μm in size, having a zeta potential of from 10 to 80 mV.... Agent: L'oreal
20130195962 - Lipid membrane structure: A lipid membrane structure for delivering a substance to a target cell having satisfactory cell permeability, selectivity for target cell, and in vivo stability, wherein lipid membrane is modified with (a) a polyalkylene glycol bound with a target cell-selective ligand; and (b) a polypeptide comprising a plurality of arginine residues.... Agent: National University Corporation Hokkaido University
20130195967 - Liver specific delivery of messenger rna: Disclosed herein are compositions and methods of modulating the expression of gene or the production of a protein by transfecting target cells with nucleic acids. The compositions disclosed herein demonstrate a high transfection efficacy and are capable of ameliorating diseases associated with protein or enzyme deficiencies.... Agent: Shire Human Genetic Therapies, Inc.
20130195963 - Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity: Disclosed are mesoporous silicon multi-stage vehicles that comprise liposomal-based second-stage particles, as well as pharmaceutical compositions and formulations including such vectors for use in a variety of diagnostic and therapeutic indications. In particular embodiments, MSV comprising ligand decorated second-stage particles are provided for therapeutic methods including, for example, treatment of... Agent: The Methodist Hospital Research Institute
20130195965 - Method for formulating large diameter synthetic membrane vesicles: The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment... Agent: Pacira Pharmaceuticals, Inc.
20130195961 - Novel mucosal vaccination approach for herpes simplex virus type-2: Methods and kits for immunizing animals (e.g. mammals) against viral antigens, including herpes-simplex virus type 2 are provided. The protective immune response elicited by the methods and kits is characterized by robust humoral, cellular, and mucosal immunity. In particular, a heterologous immunization method comprising a priming DNA vaccine encoding an... Agent:
20130195969 - Small liposomes for delivery of immunogen encoding rna: Nucleic acid immunisation is achieved by delivering RNA encapsulated within a liposome. The RNA encodes an immunogen of interest, and the liposome has a diameter in the range of 60-180 nm, and ideally in the range 80-160 nm. Thus the invention provides a liposome having a lipid bilayer encapsulating an... Agent: Novartis Ag
20130195968 - Virion-like delivery particles for self-replicating rna molecules: Nucleic acid immunisation is achieved by delivering a self-replicating RNA encapsulated within a small particle. The RNA encodes an immunogen of interest, and the particle may deliver this RNA by mimicking the delivery function of a natural RNA virus. Thus the invention provides a non-virion particle for in vivo delivery... Agent: Novartis Ag
20130195971 - Pharmaceutical composition 271: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.... Agent: Astrazeneca Ab
20130195972 - Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same: The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same.... Agent: Amarin Pharmaceuticals Ireland Limited
20130195970 - Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other... Agent: Rani Therapeutics, LLC
20130195973 - Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof: The present invention relates to an extended-release pharmaceutical dosage form of carbidopa and levodopa comprising (i) an immediate-release unit of carbidopa and levodopa; (ii) an extended-release unit of carbidopa and levodopa; and (iii) an immediate or extended-release unit of a carboxylate salt. The present invention further provides a process of... Agent: Ranbaxy Laboratories Limited
20130195974 - Ph-dependent gradual release pharmaceutical composition: The invention concerns a pH-dependent gradual sustained release composition for increasing the pH in the upper part of the small intestines. Particles of the composition are provided with a multilayer polymer coating of specific structure which ensures the gradual release of the active agent in the range of pH 4.5... Agent:
20130195975 - In vivo use of water absorbent polymers: The subject invention is a method and material for removing fluid from the intestinal tract of a host and may be useful in treating animals or human patients suffering from fluid overload states. In one embodiment, the subject method involves ingesting an enterically coated non-systemic, non-toxic, non-digestible, water absorbing polymer... Agent: Sorbent Therapeutics, Inc.
20130195977 - Low concentration meloxicam tablets: A solid tablet formed through direct compression of powder, the powder comprising meloxicam as an active ingredient and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the meloxicam.... Agent: Boehringer Ingelheim Vetmedica Gmbh
20130195976 - Pharmaceutical composition for the treatment of acute disorders: A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active... Agent: Orexo Ab
20130195978 - Darunavir compositions: The present invention relates to an oral pharmaceutical composition of amorphous darunavir.... Agent: Hetero Research Foundation
20130195979 - Core-excited nanoparticles and methods of their use in the diagnosis and treatment of disease: Core-excited nanoparticle thermotherapy (CENT) represents a new paradigm in thermotherapy. The CENT method employs core-shell nanoparticles. The core of the nanoparticles is formed from one or more core-exciting, energy absorbing materials which absorbs core-exciting energy, either from an external energy source or from an energy source within the nanoparticle core... Agent:
20130195980 - Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and crohn's disease: The present invention concerns a new method of preparing granules comprising 5-aminosalicylic acid and a new method of preparing a pharmaceutical composition for the treatment of ulcerative colitis or Crohn's disease by oral administration comprising as active ingredient 5-aminosalicylic acid.... Agent: Ferring B.v.
20130195981 - Non-abusable pharmaceutical composition comprising opioids: There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are... Agent: Orexo Ab
20130195982 - Non-abusable pharmaceutical composition comprising opioids: There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are... Agent: Orexo Ab
20130195984 - Combinations and modes of administration of therapeutic agents and combination therapy: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as... Agent: Abraxis Bioscience, LLC
20130195985 - Composition comprising sod, lutein and zeaxanthin: The invention relates to a composition comprising an enzyme selected from the group comprising superoxide dismutase (SOD) and SOD mimics and the like, in association with lutein and at least one stereoisomer of zeaxanthin; the invention also includes a kit of parts comprising such composition, wherein the kit comprises a... Agent: Visiotact Pharma
20130195983 - Nanoparticle formulations and uses thereof: The present invention provides compositions comprising nanoparticles comprising: 1) a drug, such as a hydrophobic drug derivative; and 2) a carrier protein. Also provided are methods of treating diseases (such as cancer) using the compositions, as well as kits and unit dosages.... Agent:
20130195986 - New particles of tetracyclines and protecting agent: Particles containing a tetracycline or one of its pharmaceutically acceptable salts and an antioxidant, formulations containing the same and their use in the treatment of infectious diseases are described. Methods of encapsulation of a tetracycline or one of its pharmaceutically acceptable salts and an antioxidant are also disclosed.... Agent: Hovione Inter Ltd
20130195987 - Polymeric micelles for drug delivery: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.... Agent: Intezyne Technologies, Inc.
20130195988 - Vascular embolization gelling agent for sustained release of drugs for treating tumors and method for preparing the same: A vascular embolization gelling agent for sustained release of drugs for treating tumors having a drug and a drug carrier. The drugs are antitumor drugs. The drug carrier includes poloxamer polymer and polyvinylpyrrolidone or gel made of the combination, and may be purified before use. The drug carrier accounts for... Agent: Shanghai Cancer Institute
20130195989 - Compositions of human lipids and methods of making and using same: The disclosure features methods of making compositions that include a human lipid. The methods can include: obtaining whole human milk; separating the milk into a cream portion and a skim portion; processing the cream portion; and pasteurizing the processed cream portion.... Agent: Prolacta Bioscience, Inc.
20130195990 - Composition of whey growth factor extract for reducing muscle inflammation: The invention relates to the production of compositions containing milk products for use as a nutritional supplement. More specifically, it relates to compositions containing whey growth factor extract, as well as their use in methods for reducing muscle inflammation in individuals undertaking resistance exercise training. According to one aspect of... Agent: Murray Goulburn Co-operative Co Limited
20130195991 - Composition for treatment of damaged part: The present invention provides a damaged part treatment composition for repairing a damaged part of a target tissue that includes a stem cell-conditioned medium obtained by culturing stem cells; a damaged part treatment method for repairing or restoring a damaged part of a target tissue that includes administering the damaged... Agent: National University Corporation Nagoya University
20130195992 - Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from... Agent: Tissuetech, Inc.
20130195994 - Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from... Agent: Tissuetech, Inc.
20130195993 - Purified amniotic membrane compositions and methods of use: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from... Agent: Tissuetech, Inc.
20130195995 - Synergistic antimicrobial preparations containing chlorite and hydrogen peroxide: An anti-microbial preservative for use in ophthalmic and dermatologic products. The preservative includes from about 0.005 wt. % to about 0.20 wt. % chlorite compound and from about 0.005 wt. % to about 0.05 wt. % peroxy compound. Additionally, the preservative does not generate chlorine dioxide within the pH range... Agent: S.k. Pharmaceuticals, Inc.
20130195996 - Method of producing pleurodesis: The present invention provides methods of producing pleurodesis in a mammalian subject, comprising administration of a low dosage of a sclerosing agent such as silver or a salt of silver.... Agent: Carefusion 2200, Inc.
20130195997 - Fungicidal mixtures: The invention relates to a method of controlling fungi and spores and to compositions suitable for this purpose and their use. The compositions according to the invention comprise trifloxystrobin, formate and optionally at least one further fungicide.... Agent: Lanxess Distribution Gmbh
20130195998 - Therapeutic compositions: The present invention discloses a non-irritating tea tree oil (TTO)-based topical therapeutic composition useful for both veterinary and human dermatology. The composition comprises a homogeneous mixture of TTO, 0.05 to 1.0% (wt/wt); at least one hypertonic composition providing the said TTO-based composition to 1700 to 2500 mOsm/L, 10 to 60%... Agent:
20130195999 - Wound dressing compostion and method of use: The present invention provides a non-irritating, sprayable wound dressing composition and a non-irritating, non-sprayable ointment for treating wounds in mammals such as horses or dogs. The composition of the present invention is made of an acceptable carrier and an active ingredient made of organic salts of naturally occurring cations having... Agent:
20130196000 - Combination therapy including isophosphoramide mustard, analogs, or salts thereof: In one aspect, a method for treating a subject having a hyperproliferative disorder is disclosed, including administering to the subject a composition including: IPM, an IPM analog, or a pharmaceutically acceptable salt thereof in the dosage from about 70 mg/m2/day to about 160 mg/m2/day; etoposide in the dosage up to... Agent: Ziopharm Oncology, Inc.
20130196001 - Salt replacement compositions and methods of using same: Presented are salt replacement compositions and methods which are useful for replacing dietary sodium and for preventing and treating diseases associated with sodium overconsumption, including diabetes-Type 2.... Agent: Health & Science, LLC
20130196002 - Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders: The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of... Agent:
20130196003 - Class of anti-adhesion hydrogels with healing aspects: Disclosed are hydrogels polymerized with a biofunctional moiety, biodegradable and permanent, designed to be implantable in a mammalian body and intended to block or mitigate the formation of tissue adhesions. The hydrogels of the present invention are characterized by comprising four structural elements: a) a polymeric backbone which defines the... Agent: Bvw Holding Ag
20130196004 - Natural soap using herbal medicine mature decoction, and method of preparing the same: A natural soap is provided. The natural soap is made using a herbal medicine mature decoction which is obtained by putting herbs including lotus roots, lotus leaves, red ginseng, Hippophae rhamnoides leaves and trunk, persimmon leaves, thuja orientalis, ginger, rosemary, black beans, black sesame, aloe, mulberry leaves, Orostachys japonicus, Angelica... Agent:
20130196005 - Use of salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease: Provided is the use of a Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease, and particularly the use of the Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of stable angina type coronary heart disease and the reduction of serious vascular events.... Agent: Tasly Pharmaceutical Group Co., Ltd.
20130196006 - Ph modified insect repellent/insecticide composed of plant essential oils: An insect repellent/insecticide starts with a main composition that is composed of the three primary essential oils of eucalyptus, citronella, and pine. A number of secondary essential oils can be added that provide additional beneficial characteristics, depending upon the application. A safe embedded tick “remove and kill” product includes a... Agent:
20130196007 - Alcohol extract of dehulled adlay seeds for treating breast cancer: The present invention provides a method for treating breast cancer in a subject, which comprises administering to said subject an effective amount of an alcohol extract of dehulled adlay seeds. Preferably, an ethyl acetate sub-fraction of the alcohol extract of dehulled adlay seeds has a better effect in treating breast... Agent:
20130196008 - Products containing highly unsaturated fatty acids for use by women and their children during stages of preconception, pregnancy and lactation/post-partum: A method and product for improving maternal and child health through nutrition. Omega-6 fatty acid and/or omega-3 fatty acid are provided to a woman and/or child prior to, during and/or after pregnancy to improve the health of the woman and her child. The ratios of the omega-6 and omega-3 fatty... Agent: DsmIPAssets B.v.
20130196009 - Anti-inflammatory and antioxidant composition and related method of use: A composition having at least one of a high antioxidant capacity, an anti-inflammatory effect and/or a DNA protection function is provided. The composition includes an extract from plants of the genus Caesalpinia, for example, Caesalpinia spinosa, also known as Tara. The Tara extract can be included in a nutritional supplement... Agent: Access Business Group International LLC
20130196010 - Use of extracts of capraria biflora in the prevention and/or treatment of senile cataracts: The invention provides methods for treating and/or preventing the recurrence of a senile cataract, and/or for inhibiting the development of a senile cataract and/or an incipient senile cataract, in a human or animal subject. The invention further provides nutraceutical compositions suited for the same, derived from an extract of the... Agent: Burrows Enterprises, LLC
20130196011 - Antimicrobial bacteria strains and uses thereof: The present invention provides novel antimicrobial bacteria strains and uses thereof to prepare novel antimicrobial agents. Also provided are the novel antimicrobial agents.... Agent: Fraunhofer Usa Inc.
20130196013 - Chemical and biological agents for the control of molluscs: Compositions and methods for controlling molluscs, members of the Gastropoda and Bivalvia classes which includes but is not limited to lactones, lactams, carbamates, amides, and/or carboxylic acid containing compounds as active ingredients and/or compounds derived from Pseudomonas and/or Erwinia. Also provided are methods and compositions for increasing the efficacy of... Agent: Marrone Bio Innovations, Inc.
20130196012 - Extended-release formulation for reducing the frequency of urination and method of use thereof: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount... Agent: Wellesley Pharmaceuticals, LLCPrevious industry: Chemistry of inorganic compounds
Next industry: Plastic article or earthenware shaping or treating: apparatus
RSS FEED for 20131128:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.
FreshPatents.com Support - Terms & Conditions
Results in 4.98103 seconds